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The tumour suppressor p53 has evolved a MDM2-dependent feedback loop that has a 
dual role as either a stimulator of p53 protein translation through mRNA binding or a 
stimulator of p53 protein degradation through the ubiquitin-proteasome system. A 
unique pseudo-substrate motif or “lid” in MDM2 is adjacent to its N-terminal 
hydrophobic drug-binding pocket and we have evaluated whether the lid of MDM2 is a 
physiological regulator of this dual function of MDM2. Deletion of this flexible pseudo-
substrate motif inhibits MDM2 indicating that this peptide stretch can function as a 
positive regulatory motif. Phospho-mimetic mutation in the pseudo-substrate motif at 
codon 17 (MDM2S17D) stabilizes the binding of MDM2 towards p53. Molecular 
modeling orientates the pseudo-substrate motif over a charged surface patch on the 
MDM2 surface at Arg97/Lys98 and mutation of these residues to the MDM4 equivalent 
reverses the activating effect of the phosphomimetic mutation. Transient or inducible 
low level expression of MDM2WT can promote an increase in p53 protein steady-state 
levels whilst the expression of MDM2S17D in cells results in p53 protein de-stabilization. 
Phospho-specific antibodies to the MDM2 lid demonstrate two physiological conditions 
that alter lid phosphorylation: (i) lid hypo-phosphorylation occurs after DNA damage 
where p53 protein is stabilized and (ii) lid hyper-phosphorylation occurs at high cell 
density under conditions where p53 protein is de-stabilized. Expression of MDM2S17D in 
cells also de-stabilizes hyperubiquitinated mutant p53 under conditions where MDM2WT 
has no effect on mutant p53 protein degradation. The lid functions as a flexible 
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regulatory motif whose phosphorylation switches MDM2 from a synthesis mode to a 
degradation mode with implications for defining the physiological signals that control 

























AD(Ac)  Acid domain 
AH    Azaserine-Hypoxanthine 
AI   Arabinose inducible 
APBS Adaptive Poisson-Boltzmann Solver (Calculating electrostatic 
properties) 
ARF   Alternate reading frame 
Arg (R)  Arginine 
Asp (D)  Aspartic acid 
ATM   Ataxia telangiectesia mutated protein 
ATP   Adenosine tri-phosphate 
ATR   ATM-Rad3-related protein 
BALB/C            Albino strain of laboratory mouse 
BAX   BCL2-associated X protein 
BCR-ABL An oncogene fusion protein consisting of BCR and ABL 
BSA Bovine serum albumin 
CaCl2 Calcium chloride 
C-Abl   Nonreceptor tyrosine kinase 
CD   Circular dichroism 
CHIP   C-terminus of Hsc70-interacting protein (E3 ligase) 
CHK1   Checkpoint kinase 1 
CHK2   Checkpoint kinase 2 
CK1   Casein kinase 1  
COP-1   Constitutive photo-morphogenic 1 (E3 ligase) 
CREB   cAMP response element binding 
C-terminal  Carboxy-terminal 
Cul1   E3 ligases cullin family 
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Cys (C)  Cysteine 
dH2O   distilled H2O 
DMEM  Dulbecco’s modified eagle’s medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DNA-PK  DNA-activated protein kinase 
dNTP   Deoxynucleotide triphosphate 
DOC    Deoxycholate  
DP   E2F dimerisation partner 
DTT   Dithiothreitol 
E2   Ubiquitin-conjugating enzyme 
E2F   A family of activating transcription factors 
E3 A ligase which transfers ubiquitin from E2 to substrate 
EDTA Ethylenediaminetetraacetic acid 
ESI-MS  Electrospray ionization mass spectrometry 
FBS Fetal Bovine Serum 
FL Full length 
ELISA Enzyme-linked ImmunoSorbent assay 
GFAP    Glial fibrillary acidic protein  
Gln (Q) Glutamine 
Glu (E) Glutamic acid 
Gly (G) Glycine 
GST   Glutathione-S-transferase 
HATS   Histone acetyltransferases 
HCl Hydrochloric acid 
HECT Homologous to E6-associated protein (E6-AP) C-terminus (E3 
ligase 
His (H) Histidine 
HRP   Horseradish peroxidase  
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HSP90   Heat shock protein 90  
Hy   Hydrophobic pocket 
IB   Immunoblot 
IC50 Concentration of drug that is required for 50% inhibition in vitro 
Ile (I) Isoleucine 
IPTG   Isopropyl--D-1-thiogalactopyranoside 
IR   Ionising radiation 
IRF-1   Interferon regulatory factor 1 
IRF-2   Interferon regulatory factor 2 
JNK   c-Jun N-terminal kinase 
kDa   kilo-Dalton 
KLH    Keyhole limpet hemocyanin 
KOH   Potassium hydroxide 
LB   Luria-Bertani 
Leu (L)  Leucine 
Lys (K)  Lysine 
MCS   Multiple cloning site 
MEF   Mouse embryonic fibroblast 
MDM2  Murine double minute 2 protein (E3 ubiquitin ligase) 
MDM4  Murine double minute 4 protein  
MDM-ES  MDM2 binding domain encoding sequence 
MgCl2   Magnesium chloride 
MOPS 3-(N-morpholino)propanesulfonic acid 
N-terminal Amino-terminal 
NaCl Sodium chloride 
NaF Sodium fluoride 
NaOH Sodium hydroxide 
NEDD8 Neural precursor cell expressed, developmentally down-regulated 
8 (UBL) 
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NLS Nuclear localisation sequence 
NMR Nuclear magnetic resonance 
Ni-NTA Nickel-nitrilotriacetic acid 
NoLS   Nucleolar localisation sequence 
ORF   Open reading frame 
p21 Cyclin-dependent kinase inhibitor 
p53 Tumour suppressor p53 
PARP1 Poly (ADP-ribose) polymerase family, member 1 
PBS Phosphate buffered saline 
P/CAF   p300/CREB-binding protein associated factor 
PCR Polymerase chain reaction 
PDB ID Protein database identification 
Phe (F) Phenylalanine 
PIAS1 Protein inhibitor of activated STAT-1  
Pirh2   p53 induced protein with a RING-H2 domain (E3 ligase) 
Pro (P)   Proline 
PTM   Post translational modification 
Pu   Purine 
Py   Pyrimidine 
PKB/Akt Protein kinase B/RAC-serine/threonine protein kinase 
RAM   Rabbit anti-mouse 
Rb   Retinoblastoma protein 
RbCl   Rubidium chloride 
Rbx1 Ring box protein 1 
RING   Really interesting new gene 
RLU   Relative light units 
RNA   Ribonucleic acid 
RPMI 1640  Roswell park memorial institute 
rpm   Revolutions per minute 
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SB   Sample buffer 
SCF   Skp, Cullin, F-box containing complex 
SCFSkp2 Mammalian SCF complex, composed of Rbx1, Skp1, Cullin and 
Skp2 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser (S)   Serine 
siRNA   Small interference RNA 
Skp1   S-phase kinase-associated protein 1A (p19A) 
Skp2   S-phase kinase-associated protein 2 (p45) 
SNP   Single nucleotide polymorphism 
STAT-1  Signal transducer and activator of transcription-1 
SUMO   Small Ubiquitin-like Modifier 
Syc-7   Small molecule which binds the MDM2 hydrophobic pocket  
TAE   Tris-Acetate-EDTA 
TBE   Tris-Borate-EDTA 
TCA    Trichloroacetic acid 
Thr (T)  Threonine 
Trp (W)  Tryptophan 
Tyr (Y)  Tyrosine 
Ub   Ubiquitination   
UBC   Ubiquitin conjugating enzyme E2 domain 
UBL   Ubiquitin-like molecule 
UPS   Ubiquitin proteasome system 
UV   Ultraviolet 
WT   Wild type 
WW Protein-protein interaction site characterised by two conserved 
trypophans 
YY1   Ying Yang 1 
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1.1 Oncogenes and tumor suppressors in cancer 
 
Cancer arises as a result of a change in the activity or expression of oncogenes or tumor 
suppressors.  These changes generally occur at the somatic level but can also occur 
through germ-line mutations, leaving offspring predisposed to some cancers.  Cancer 
arises from a series of mutations within both oncogenes and tumor suppressors.  
Oncogenes are a group of genes that, when mutated, are highly expressed or overactive 
and as a consequence act to initiate carcinogenesis.  Genes encoding proteins that 
control cell proliferation, apoptosis or both are generally regarded as having the potential 
to become oncogenes.  These genes encode proteins that can be categorized into 6 
groups: transcription factors, chromatin remodelers, growth factors, growth factor 
receptors, signal transducers, and apoptosis regulators.  They are generally activated by 
point mutations, which can alter protein activity, or by gene amplification.  For example 
the RAS oncogene, when mutated at codon 12, 13 or 61, becomes constitutively active 
resulting in a constant signal transduction cascade which promotes cell survival.  
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Mutations in RAS are common in lung, colon and pancreatic carcinomas (Rodenhuis, 
1992).    
 The discovery of oncogenes provided a simple and powerful explanation for how 
cell proliferation is driven and how mutation of these genes can result in uncontrolled 
cell growth.  For any process that drives cell proliferation forward there needs to be a 
process which can slow it down or stall it.  Such genes are termed tumor suppressors and 
they function as anti-growth genes.  The p53 gene is a tumor suppressor gene, and, its 
activity stops the formation of tumors by activating the transcription of the cyclin 
dependent kinase inhibitor p21 and preventing cell division.  If a person inherits only 
one functional copy of the p53 gene from their parents, they are predisposed to cancer 
and usually develop several independent tumors in a variety of tissues in early adulthood 
as a result of mutation of the remaining allele. This condition is rare, and is known as Li-
Fraumeni syndrome.  
 
1.2 Ubiquitination overview 
 
Ubiquitin is a 76 amino acid protein which can be covalently attached to target lysines 
on proteins through the carboxyl group of its C-terminal residue (Gly76). Ubiquitin was 
the first protein shown to modify other proteins (Pickart, 2001).  First thought to just be 
a way of ridding the cell of misfolded proteins it has become apparent that ubiquitination 
has a much larger role to play in cellular signalling mechanisms to a similar extent as 
other post-translational modifications (PTMs) such as phosphorylation (Pickart, 2001).    
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Ubiquitin can form poly-ubiquitin chains through attachment of other ubiquitin moieties 
at lysine 48 or lysine 63.  Ubiquitin attached through lysine 48 generally marks a protein 
for degradation via the proteasome, while mono-ubiquitination or lysine 63 linked 
ubiquitin chains can have other effects such as influencing cellular localisation and 
protein function (Hicke 2001).  Ubiquitin is attached onto the target protein through the 
sequential actions of activating (E1), conjugating (E2) and ligase (E3) enzymes.  The C-
terminal lysine residue of ubiquitin is activated in an ATP-dependent step via an E1 
enzyme, of which there is only one in humans (Figure 1.1A).  The activated ubiquitin is 
then transferred to a cysteine residue within the ubiquitin carrier protein, E2 (Figure 
1.1B).  The final step involves an E3 ligase which attaches the ubiquitin moiety via its 
C-terminus in an amide isopeptide linkage to the ε-amino group of a specific lysine 
within the target protein (Hershko and Ciechanover, 1998) (Figure 1.1C).  In addition to 
the E1, E2, and E3 cascade there is also evidence of the involvement of an E4 enzyme 
which can help catalyze multi-ubiquitin chain formation along with E1, E2 and E3 


























Figure 1.1 Ubiquitin transfer cascade.  Ubiquitin (Ub) is activated by covalent attachment to E1 enzyme 
in an ATP-dependent reaction and is subsequently transferred to an E2 (ubiquitin-conjugating) enzyme. 
Ubiquitin is transferred from E2 to target substrate with or without the assistance of an E3 (ubiquitin 
ligase) enzyme. E3s control the specificity and timing of ubiquitination reactions. After several cycles of 
ubiquitination, the multiubiquitin chain-bearing substrate is recognized by the 26S proteasome and 
degraded. 
 
1.2.1 E1 and E2 enzymes 
 
There is only one E1 to begin the cascade off in mammals, yet there are around 60 
mammalian genes encoding for E2’s.  This is the first step in substrate specificity in the 
ubiquitin proteasome system.  Within the E2 enzyme is a 150 amino acid stretch which 
is highly conserved among E2’s, called the ubiquitin conjugating enzyme E2 (UBC) 
domain and located within this the cysteine residue required for the E2’s activity 
(Sullivan and Vierstra, 1991).  E2’s can range from being very small, consisting only of 
the core UBC domain, to very large with C or N terminus extensions, which can be 
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responsible for providing substrate specificity.  E2’s can either attach ubiquitin to the 
lysine on the target protein itself with the support of an E3, or it can attach the ubiquitin 
to the E3 before attachment to the target lysine (Mani and Gelmann, 2005).   
 




A second level of substrate specificity within the ubiquitin cascade is exerted by the E3 
enzymes of which there are around 600 known enzymes.  E3’s work via many different 
mechanism, many of which are poorly understood, however they work either, through 
direct contact with ubiquitin or by helping the E2 transfer of ubiquitin to the substrate 
(Hershko et al., 1986) (Reiss et al., 1989).  E3 ligases can be subcategorized into two 
classes, those which are: Homologous to E6-associated protein (E6-AP) C-Terminus 
(HECT) E3 ligase or: Really Interesting New Gene (RING) E3 ligases (Mani and 
Gelmann, 2005).   
  
1.2.3 HECT E3 ligases 
 
HECT E3 ligases work by covalently attaching the ubiquitin moiety from an E2 via 
thioester linkages before it is transferred to the substrate lysines.  All HECT domain E3 
ligases have a conserved 350 amino acid C-terminal HECT domain with a conserved 
cysteine residue.  This cysteine is required for the conjugation of ubiquitin via a 
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transthiolation reaction which catalyzed by the E3 from the E2 (Scheffner et al., 1995).   
The N-terminal region of HECT E3 ligases provide the substrate specificity of the ligase 
and some forms contain a WW domain, characterised by two conserved tryptophan 
residues which form a pocket (Sudol et al., 1995b).  This pocket can bind phospho-
serine or phospho-threonine residues on the target protein suggesting that some kinds of 
phosphorylation may be a marker for ubiquitination by HECT E3 ligases. (Sudol et al., 
1995a).   
  
1.2.4 RING E3 ligases 
 
RING E3 ligases are characterised by the presence of conserved cysteine and histidine 
residues orientated around two Zn+ ions (Joazeiro and Weissman, 2000).  Rather than 
covalently binding ubiquitin before its transfer to the substrate, RING ligases provide a 
scaffold onto which the E2 and the substrate can bind, allowing transfer of ubiquitin 
directly from the E2 to the substrate.  The RING E3 ligase’s can be further sub-
categorized into single or multi protein complexes.  A good example of a single subunit 
E3 ligase is MDM2, which catalyzes the ubiquitination of the tumor suppressor p53 
(Wallace et al., 2006), and CBL which is the E3 ligase for receptor tyrosine kinases 
(Joazeiro et al., 1999).  The Skp1-cullin1-F-BOX (SCF) family represents the multi-
subunit E3 ligase’s (Deshaies, 1999).  In the SCF enzyme complex, functions are 
divided between subunits with substrate recognition and E2 transfer being performed by 
different proteins within the complex.   In the case of the mammalian SCFSkp2 complex, 
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the E2 is recruited through Rbx1 protein while cullin1 acts as a scaffold holding Rbx1 
and Skp1, which recruits the F-BOX protein Skp2 for substrate recognition, in the 
correct positions (Jackson and Eldridge, 2002)    
 
1.3 The Proteasome 
 
Ubiquitination often leads to proteasomal degradation via the 26S proteasome.  The 26S 
proteasome is a proteolytic multi-subunit complex whose main function is to unfold, 
breakdown and recycle proteins marked by ubiquitin chains (Kisselev and Goldberg, 
2001).  It consists of three main subunits, a 20S proteolytic core particle sandwiched 
between two 19S ‘cap’ regulatory complexes (Voges et al., 1999) (Figure 1.2).  The 20S 
subunit is composed of four stacked rings with a core through the centre.  Each outer 
ring is composed up of 7 α-subunits and each inner ring is composed of 7 β-subunits 
which posses the core proteolytic activity (Baumeister et al., 1998).  The 19S subunits 
control substrate access into the proteolytic core through ubiquitin chain recognition.  It 
is composed of a base and a lid and the lid is believed to be responsible for the 
recognition and cleavage of poly-ubiquitin chains. The base associates with the 20S 
subunit and contains 6 ATPases which are responsible for the ATP dependent opening 
of the α-ring of the 20S subunit allowing substrate access to the proteolytic region 
(Kohler et al., 2001).     
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 The proteasome cleaves peptides multiple times before they are released, unlike 
conventional proteolytic enzymes which cleave peptides only once before they are 
released.  This results in the release of peptides anywhere from 3-22 amino acids in 




Figure 1.2 Proteasome Structure.  Three dimensional image representing the 26S proteasome composed 
of a 20S complex consisting of two α and two β subunits and two 19S complexes at either end of the 20S 
complex, which act as lids.  The 19S lids are responsible for ubiquitin recognition and catalyze entry into 
the 20S complex in an ATP dependent manner. (Adapted from (Adams, 2004).  
 





Figure 1.3 The UPS. Schematic representation of the ubiquitin proteasome system. The main UPS 




The growing understanding of the ubiquitin proteasome systems (UPS) involvement in 
human disease has led to the interest in developing small molecules that can inactivate 
specific components of the pathway (Figure 1.3).  There are multiple steps within the 
UPS which can be targeted by such drugs; the earliest being the E1 enzyme and the 
latest being the proteasome.  The ubiquitin activation step performed by the E1 is ATP 
dependent and provides a good starting point for drug design.   The drug Gleevec, 
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developed by Novartis is a potent inhibitor of the oncogenic BCR-ABL fusion kinase by 
targeting its ATP pocket (Ren, 2005).  Gleevec has since been shown to be less specific 
than originally thought and can bind a variety of ATP pockets with non-specific side 
effects.   
 The next step in the UPS is the transfer of ubiquitin from the E1 to the E2 
enzyme.  This step involves the E1 and E2 coming into contact with each other and thus 
providing the next possible druggable target.  There is a growing realization that many 
protein-protein interactions occur through short linear peptide motifs and not through 
deep pocket interfaces.  While these short linear peptide motifs may prove to be harder 
to inhibit, blocking these interactions may be a potential therapeutic target.  The result of 
inhibiting the UPS at the E1, E2 stage is the global inhibition of the system.  
 
1.3.2 Targeting E3 ligases 
 
Targeting the E3 class of enzymes in the UPS provides a way of specifically controlling 
the activity of the E3’s target protein.  The targeting of one specific E3 ligase would 
allow the regulation of a distinct pathway, resulting in the stabilization of a subset of 
ubiquitinated proteins.   For example, targeting and inhibiting the E3 ligase MDM2 
would cause in the stabilization of its target p53, resulting in cell cycle arrest.  The 
potential for such therapy could reduce any unwanted side effects of broad UPS 
inhibitors.  There are three main classes of E3 ligases, RING, HECT and SCF complexes 
and the main difference between their mechanism of action is the mode of presenting the 
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E2 and ubiquitin moiety to the substrate.  This difference obviously requires 
consideration when targeting E3 ligases.   
 For the RING class E3 ligases, there are two potential approaches for blocking 
their activity.  Firstly it would be of benefit to disrupt the interaction between the RING 
finger and the E2 enzyme and secondly to disrupt the interaction of the E3 with the 
substrate.  The latter strategy has yielded drugs such as Nutlin which inhibit the 
interaction between MDM2 and p53, but in this case it does not block p53 ubiquitination 
(Vassilev, 2004; Wallace et al., 2006).   There are many potential druggable targets 
within the SCF ubiquitin ligases which due to their multi domain nature, possess 
numerous protein-protein interactions which could be targeted and disrupted.  HECT 
domain E3 ligases bind the E2 as well as covalently binding ubiquitin. This provides 
three potential druggable interfaces, 1) blocking the interaction of the E2 with the E3, 1) 
blocking the attachment of ubiquitin to the E3 and, as with RING domain ligases, 3) 
blocking the E3-substrate interaction (Nalepa et al., 2006).   
 
1.3.3 Targeting the proteasome directly 
 
The final approach in targeting the UPS is to block the proteasome directly.  The 
proteasome contains three types of active sites for proteolytic cleavage; chymotrypsin-
like which cleaves after large hydrophobic residues, trypsin like which cleaves after 
basic residues and ‘caspase-like’ which cleaves after acidic residues (Kisselev and 
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Goldberg, 2001).   The chymotrypsin-like sites were shown by genetic studies to be the 
main sites involved in protein degradation so these sites provided a target to develop 
inhibitors to.  The proteasome inhibitor MG132 and the drug Velcade are such 
inhibitors.  Velcade is an aldehyde derivative of three leucine residues with a blocked N-
terminus.  It had been predicted that inhibiting the proteasome would have a catastrophic 
effect on the cellular functions.  However Velcade only inhibits the chymotrypsin like 
activity and as trypsin and caspase like activity is unaffected, Velcade can only reduce 
protein degradation by 40% at most.    To inhibit peptide cleavage to a greater extent 
than this then more than one type of active sites need to be blocked within the 
proteasome and this can occur at higher concentrations of the drug Velcade (Goldberg, 
2007; Kisselev et al., 2006).  Targeting the ubiquitin proteasome pathway is an emerging 
concept in the fight against many human diseases including cancer and inflammatory 




The human p53 gene has been mapped to the short arm of chromosome 17 (17q13), and 
spans approximately 20kb of DNA.  The gene is composed of 11 exons, the first of 
which is non-coding and is localized 8-10kb away from exons 2-11 (Benchimol et al., 
1985).  Phylogenetic mapping elucidated five highly conserved regions within the p53 
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protein termed BOX-I (13-23), BOX-II (117-142), BOX-III (171-181), BOX-IV (234-
250) and BOX-V (270-286) (Soussi and May, 1996).   
The p53 protein consists of three functional domains; the N-terminal 
transactivation domain and proline rich region (amino acids 1-92); the central DNA 
binding domain (102-292); and the C-terminal negative regulatory domain and 
tetramerization domain (TD) (360-393) (May and May, 1999) (Figure 1.4). 
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Figure 1.4 p53 Domain Structure.  The N-terminus (green) contains the transactivation domain (TAD) 
and the proline-rich domain (PRD). The central region (red) contains the DNA-binding domain (DBD). 
The C-terminus (blue) contains the tetramerisation domain (TET) and the negative regulatory domain 
(REG). The corresponding amino acid residues are shown below each domain. The lower panel represents 
the highly conserved regions termed BOX-I, -II, -III, -IV, and -V with corresponding amino acids shown 
below each region.      
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1.4.1 The N-terminus of p53 
 
The N-terminus of p53 is formed by two contiguous transcriptional activation 
subdomains (amino acids 1-42 and 43-63).  Adjacent to these and completing the N-
terminus is a proline rich domain (amino acids 62-91) with five repeats of the sequence 
PXXP which contribute to p53s apoptotic function.  p53 interacts with components of 
the transcriptional machinery through the highly conserved BOX-I region within the 
transactivation domain.  The N-terminus of p53 is also heavily phosphorylated in 
response to stress signals by a number of protein kinases.   These include c-Jun N-
terminal kinases (Oliner et al., 1993), the DNA activated protein kinase (DNA-PK) 
(Kamijo et al., 1998), casein kinase 1 (CK1) (Maclaine et al., 2008), ataxia-
telangiectasia mutated kinase (ATM)  and ataxia-telangiectasia related kinase (ATR) 
(Saito et al., 2002).  C-terminal acetylation requires the binding of CBP/p300 to the N-
terminus which can be stimulated by phosphorylation of p53 at ser15.  Acetylation 
activates p53’s function as a transcription factor. Phosphorylation within the N-terminus 
also leads to decreased interaction between p53 and its negative regulator MDM2 (Moll 
and Petrenko, 2003; Schon et al., 2002).   
 
1.4.2 The Core-Domain of p53 
 
The core region (102-292) forms a sequence specific DNA-binding domain consisting of 
the remaining four highly conserved regions BOX-II-BOX-V.  p53 binds DNA through 
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a consensus DNA binding site which composed of two copies of the 10bp motif 5’-
PuPuPuCWWWGPyPyPy-3’ (Pu = purine base, Py = pyrimidine base, W = A/T) 
separated by up to 13 base pairs. (el-Deiry et al., 1992)  The closer the sequence is to the 
consensus the higher the affinity for p53 binding.  High affinity binding sites can be 
found in promoters of genes involved in cell cycle arrest whereas lower affinity sites are 
found in promoters of genes involved in apoptosis (Weinberg et al., 2005).  With the 
advancement of crystallographic techniques came the structure of the core domain of 
p53.  The structure revealed the presence of a large β-sandwich which forms a scaffold 
for DNA binding.  The surface is formed by two large loops, L2 and L3, which are 
stabilized through a zinc ion and a loop-sheet-helix motif (Cho et al., 1994).  The zinc 
ion is essential for p53 structure function as its removal drastically de-stabilizes the 
protein (Butler and Loh, 2003).   The L3 is anchored to the minor groove of DNA via 
Arg248 while other conserved amino acids within the loop-sheet-helix motif make 
additional contacts with the major groove (Cho et al., 1994).   Over 80% of p53 
mutations are found within the core DNA binding domain highlighting the importance 
of the core domain in p53.   
 
1.4.3 The C-terminus of p53 
 
The C-terminus of p53 can also bind DNA, however this interaction is less sequence 
specific than the core region.  The C-terminus can bind with high affinity to a variety of 
DNA structures including short single strands, X-irradiated DNA, and 
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insertion/deletions (Ahn and Prives, 2001).  The C-terminus is thought to play a crucial 
role in determining the conformation of p53 and can switch p53 from latent to an active 
sequence specific DNA binding form.  Allosteric regulation between the C-terminus and 
the core DNA binding domain is responsible for this interchange between the two states 
(Hupp and Lane, 1994a; Hupp et al., 1992).  p53 can exist as a tetramer although under 
non stressed conditions it is usually present as a monomer (Sakaguchi et al., 1997). 
Upon binding to DNA consensus recognition elements, p53 forms tetramers through the 
tetramerization domain, and this is required for p53 to exert its activity as a transcription 
factor (Friedman et al., 1993; Kitayner et al., 2006). The tetramerization domain 
contains a -strand linked to an -helix by a single residue. Two monomers come 
together through their TDs to form a dimer. The p53 dimers then associate across a 
hydrophobic interface to form the tetramer (Jeffrey et al., 1995). Mutation within the TD 
decreases p53’s ability to bind DNA.  The formation of a tetramer is therefore integral to 




The murine double minute 2 (MDM2) gene was first identified in the 1980’s and was 
found to be amplified in the spontaneously transformed 3T3-DM mouse cell line.  Soon 
after this discovery, MDM2 was shown to be amplified in several human tumors and 
could bind to and inhibit p53 (Toledo and Wahl, 2007).  A single nucleotide 
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polymorphism (SNP309) in the promoter of MDM2 can lead to its heightened 
expression by the increased binding of the transcriptional activator Sp1.  This increase in 
MDM2 expression leads to the direct inhibition of p53, releasing the cell from p53 
tumor suppression (Bond et al., 2004).  
MDM2 is composed of a ‘Lid’ or pseudo-substrate domain, which at present has 
no known function, a hydrophobic pocket into which p53 binds, an acid domain which is 
involved in many protein interactions, a zinc finger which also has as yet no known 
function and a RING domain which is responsible for its ligase activity (Figure 1.5). 
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Figure 1.5  MDM2 Domain Structure.  The N-terminus contains the Lid domain (yellow), the 
hydrophobic pocket responsible for binding p53 (blue) and the nuclear localization and export sequences 
(purple).  The central region contains the acid domain (red) and the zinc finger (turquoise).  The C-
terminus consists of the RING finger (green) and embedded within the RING finger, an ATP binding site. 
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1.5.1 The MDM2 Lid 
 
The N-terminus of MDM2 contains a flexible lid consisting of residues 10-25.  This 
region is thought to compete with p53 for binding to the hydrophobic pocket of MDM2.  
The fact that the lid is not resolved in x-ray crystallography highlights its flexibility 
(McCoy et al., 2003).  The lid peptide has a significant degree of homology to the p53-
activation domain, suggesting that it might compete in cis for binding with p53 and act 
like a pseudo-substrate domain.  Embedded within the lid sequence is a classic DNA-PK 
or ATM consensus (SQ-motif) whose phosphorylation is thought to disrupt the MDM2-
p53 complex (Mayo et al., 1997).   
 
1.5.2 The Hydrophobic Pocket of MDM2 
 
MDM2 contains a hydrophobic pocket adjacent to the lid which consists of two globular 
repeats related by an approximate dyad axis of symmetry (Kussie et al., 1996).  The two 
repeats come together via their hydrophobic faces and form the binding cleft for the p53 
peptide (Uhrinova et al., 2005).  This cleft or groove is 25  in length and begins as a 
very narrow and shallow cleft, then opens into a wider and deeper cleft.  Crystal analysis 
shows the p53 peptide (18-26) adopts an amphipathic α-helical structure and binds into 
the wider deeper portion of the cleft.  The remainder of the p53 peptide (27-29) is 
extended and associate with the shallow end of the cleft (Uhrinova et al., 2005).  Three 
highly conserved amino acids, which are integral in p53s transactivation domain (Phe19, 
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Trp23 and Leu26), form a structure which fits tightly into the hydrophobic pocket of 
MDM2 (Lin et al., 1994; Picksley et al., 1994). The hydrophobic pocket has been shown 
to be highly flexible in terms of the peptides it can accommodate, in general the greater 
the helical structure of the peptide the higher its affinity for the pocket (Dastidar et al., 
2008).  Formation of a tight protein-protein interaction through a binding pocket makes 
this specific point of contact a very good site for drug development, with the aim of 
disrupting this interaction with small molecules.   
   
1.5.3 The Acid Domain of MDM2 
 
 
The acid domain of MDM2 is a site of many protein-protein interactions including 
p14ARF, L5, L11, L23, p300 and YY1 (Bothner et al., 2001; Dai and Lu, 2004; 
Marechal et al., 1994; Sui et al., 2004; Zhang et al., 2003).  A second site for MDM2 to 
interact with p53 has also been discovered in the acid domain, and this interaction is 
essential for p53 ubiquitination (Wallace et al., 2006).  This second site was first 
highlighted by the ability of peptides derived from the acid domain to interact with the 
core region of p53 (Yu et al., 2006b).  Soon after this discovery, Wallace et al (2006) 
showed the direct interaction with MDM2 acid domain and the p53 BOX-V peptide 
(This study).   It also showed that the acid domain of MDM2 and BOX-V region of p53 
are essential for MDM2 catalyzed ubiquitination of p53.  Structural data indicates that 
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the acid domain is mainly unstructured but can form β-strand structures upon ligand 
binding (Bothner et al., 2001). 
 p14/ARF activates p53 in response to mitogenic stimulus through binding to 
MDM2 via its acid domain, inhibiting its E3 ligase activity (Sherr, 1998; Zhang and 
Xiong, 2001), and sequestering it to the nucleolus (Weber et al., 1999).  It has been 
proposed that binding of p14/ARF to MDM2 via the acid domain induces 
conformational changes within MDM2, exposing a cryptic nucleolar localization 
sequence (NoLS) in its C-terminus (Lohrum et al., 2001; Weber et al., 2000).  ARF is 
also reported to stimulate MDM2 mediated p53 sumoylation through an unknown 
mechanism (Xirodimas et al., 2002).   What is known is that the level of p53 
sumoylation is regulated by MDM2 and ARF through a mechanism which requires the 
formation of a p53-MDM2-ARF complex (Chen and Chen, 2003). 
 In a mechanism similar to ARFs, several ribosomal proteins, L5, L11 and L23 
have been shown to inhibit MDM2s E3 ligase function through binding to the acid 
domain (Bhat et al., 2004; Dai and Lu, 2004; Dai et al., 2004; Jin et al., 2004).   
 YY1 is a transcription factor that plays a crucial role in development however its 
full role and actions remain to be elucidated.  YY1 knockdown by siRNA was shown to 
result in the accumulation of p53 in DT40 cells as a result of reduced ubiquitination.  
Conversely over expression of YY1 in DT40 cells resulted in increased p53 
ubiquitination.  It is thought that YY1 promotes the interaction between p53 and MDM2 
which is essential for ubiquitination (Sui et al., 2004).  
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1.5.4 The RING finger domain of MDM2 
 
The MDM2 RING finger is essential for its function as an E3 ligase and mutation of any 
of the Zn+ co-ordinating residues renders the protein inactive (Fang et al., 2000). The 
MDM2 RING domain is atypical when compared to conventional RING motifs with 
respect to the Zn+ coordinating cysteines and its multi-functions in the body 
(Poyurovsky et al., 2007).   The C-terminal RING co-ordinates the dual activity of 
MDM2 in E2-mediated ubiquitin transfer (Linke et al., 2008) and in promotion of the 
MDM2-dependent stimulation of p53 protein synthesis (Candeias et al., 2008). 
Imbedded within the RING domain is an ATP-binding motif that regulates the 
chaperone functions of MDM2 (Stevens et al., 2008; Wawrzynow et al., 2007).  At the 
extreme C-terminal is a peptide tail that also helps maintain RING domain conformation 
(Poyurovsky et al., 2007) (Uldrijan et al., 2007). 
 
1.6 The MDM2:p53 interaction as a therapeutic target  
 
The biological importance of p53 has been apparent for some time now.  The myriad of 
roles MDM2 and p53 play within the cell and the elucidation of the structure of the 
MDM2:p53 interface has led to the realization that the MDM2:p53 interaction is a 
“druggable” target (Kussie et al., 1996).  As previously discussed p53 is a transcription 
factor which controls the cellular response to stress through the induction of the cyclin 
dependent kinase inhibitor p21 (Xiong et al., 1993).  MDM2 down regulates p53 activity 
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via a negative feedback loop through binding to the a-helical transactivation domain of 
p53 (Wu et al., 1993).  In addition to inhibiting transactivation function of p53, MDM2 
also exports p53 from the nucleus and targets it for proteasomal degradation via 
ubiquitination (Roth Levine 1998), (Pickart, 2001; Tao and Levine, 1999).   
p53 is phosphorylated on specific serine residues in its transactivation domain in 
response to stress. This abrogates p53’s interaction with MDM2 and activates its 
function as a transcription factor (Jimenez et al., 1999).  Overexpression of MDM2 leads 
to inhibition of the p53 pathway and uncontrolled cell proliferation due to expression of 
the cyclin dependent kinase (CDK) inhibitor p21, and release from the inhibitory effects 
of the cell cycle.  Amplification of the Mdm2 gene is observed in around 7% of human 
tumors and is most commonly found in soft tissue tumors (20%), osteosarcomas (16%) 
and oesophageal carcinomas (13%) (Momand et al., 1998).  As a result of this 
amplification and suppression of p53 signalling, tumors become less susceptible to 
chemotherapeutic agents and do not undergo programmed cell death, or apoptosis.  
Treating cells that overproduce MDM2 with inhibitors which block the MDM2:p53 
interaction should therefore result in the stabilization and accumulation of p53, increase 
MDM2 levels, and the activation of p53 target genes such as p21 and BAX.  This in turn 
would cause cell cycle arrest in G1 and G2 phases and/or apoptosis (Vassilev, 2005).   
These factors put the disruption of the MDM2:p53 interaction at the forefront of 
therapeutic targeting for the treatment of cancer (Chene, 2003).   A series of MDM2:p53 
antagonists have been developed with varying success which includes antibodies and 
RNAi as proof of principle.  Three other classes of inhibitors have been developed so 
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far, and they are peptide aptamers, naturally occurring compounds and small molecule 
inhibitors.   
 
1.6.1 Antibodies and RNAi 
 
Antibodies and RNAi targeting of the p53 pathway showed that by inhibiting MDM2 it 
is possible to stabilize and activate p53 signaling.  Injecting the MDM2 N-terminal 
antibody 3G5 into cells resulted in the accumulation and stabilization of p53 (Blaydes 
and Wynford-Thomas, 1998).  To date, antibodies are by far the most successful class of 
protein-protein interaction inhibitors available to target and disrupt the MDM2/p53 
pathway but the difficulty in their administration (injection) and production has favoured 
the use of small molecules which can be administered orally ((Puppo et al., 2005).  
RNAi has also show that targeted knock down of MDM2 leads to the accumulation and 
activation of p53 (Tortora et al., 2000).  Despite vast alteration of the oligonucleotide 
backbone of RNA to improve its stability in vivo, the problem still exists as to delivery 
of antibodies and RNAi across both cellular and nuclear membranes (Elmen et al., 
2005).   
  




MDM2 can bind with high affinity to 15 amino acid peptides derived from the 
transactivation domain of p53 (Fig 1.6).   Further studies have developed more potent 
versions of this p53 peptide which inhibit the interaction between MDM2 and p53 to a 
higher degree (Bottger et al., 1997).  When these peptides are directly applied to cells or 
expressed as peptide fusion proteins, p53 accumulation and activation can be observed.  
Crystal analysis of the structure of the MDM2 hydrophobic pocket in complex with the 
p53 peptide showed that only three amino acid side chains from the p53 peptide were 
buried within the deep pocket (Chene et al., 2000).       
 
 
Figure 1.6. The MDM2 N-terminus with the BOX-I peptide of p53 bound within the hydrophobic 




1.6.3 Natural inhibitors of the MDM2:p53 interaction 
 
Of the drugs available for cancer treatment today, around 60% have arisen from natural 




























to be effective in inhibiting MDM2:p53 interactions (Newman et al., 2003),  these are 
chalcone based inhibitors, chlorofusin, and hexylitaconic acid.   
Chalcones were proposed to bind to MDM2 within its canonical p53 binding 
pocket and inhibit MDM2:p53 interaction (Stoll et al., 2001).  Although p53 levels 
accumulate after treatment with chalcones free p53 cannot bind to DNA and so is 
inactive (Murray and Gellman, 2007).  This observation led a reduction into research on 
the chalcones so there mode of action still remains elusive.       
Chlorofusin was identified as a MDM2:p53 inhibitor by screening 54,000 
products generated from the fermentations of a wide range of microorganisms.  
Chlorofusin is a cyclic peptide and was shown to bind to the N-terminus of MDM2 with 
the ability to inhibit the MDM2:p53 interaction (Duncan et al., 2003).   Chlorofusin is 
being used today to model potential analogues to elucidate the structure/activity 
relationship of this class of inhibitors so as to better understand there role and 
mechanism of action. 
Hexylitaconic acid is a recently discovered inhibitor of the MDM2:p53 
interaction, and is derived from a marine fungus (Tsukamoto et al., 2006).  This inhibitor 
is structurally distinct from other inhibitors and more work is needed to characterize its 
mechanism of action. 
 
1.6.4 Small molecule inhibitors of MDM2:p53 interaction 
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Small molecule inhibitors of the MDM2:p53 binding interface have also been 
developed.  Drugs such as Syc-7, Nutlins and Benzodiazepinediones have been modeled 
to fit within the MDM2 hydrophobic pocket.   
 Syc-7 was the first non-peptidic small molecule inhibitor of the MDM2:p53 
interaction (Zhao et al., 2002).  It was designed in silico using knowledge of co-
crystalised MDM2 and p53 peptide to mimic the orientation of Phe19 and Trp23 of the 
p53 BOX-I peptide which bind tightly into the binding cleft.  Although the potency of 
syc-7 is very low, it provides a platform for the development of other drugs using a 
similar approach. 
 Nutlins were discovered through a high throughput screen of potential lead 
structures generated by Roche.  They were the first small molecules shown to have high 
potency both in vivo and in vitro.  Crystal structures of Nutlin bound to MDM2 revealed 
that Nutlin binding mimics the interactions of the p53 peptide, with a bromophenyl ring 
sitting deep in the tryptophan binding pocket of MDM2 and another bromophenyl ring 
occupying the leucine site while an ethyl ether side chain is directed towards the 
phenylalanine binding pocket.  The imidazoline scaffold of Nutlin substitutes for the α-
helical backbone and directs the side chains into their respective pockets (Figure 1.7).  
Nutlin was shown to activate p53 in vivo and arrest cells in G1 and G2 phases, 
preventing mitosis.  Oral Nutlin treatment of nude mice, with established tumor 
xenografts resulted in a 90% reduction in tumor growth (Vassilev et al., 2004).  Due to 
its potential Nutlin is already being screened for treatment of acute myeloid leukemia 
and multiple myeloma (Kojima et al., 2005; Stuhmer et al., 2005).  Nutlin can only 
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activate p53 in tumors with wild type (WT) p53, however, as 50% of tumors are 
reported to have mutant p53, Roche devised a way to still use Nutlin in the treatment of 
these cancers.  The process works as follows; pre-treatment with Nutlin induces cell 
cycle arrest in normal proliferating cells but does not affect cells with mutant p53.  
Subsequent treatment with a mitotic inhibitor, such as paclitaxel, causes mitotic arrest 
and apoptosis in cancer cells, but does not cause cytotoxic effects in normal cells 
(Carvajal et al., 2005).   
 
 
Figure 1.7.  The MDM2 N-terminus with the drug Nutlin occupying the hydrophobic pocket.  Nutlin 
fits within the binding pockets for F19, W23 and L26 of the p53 peptide.  Figures made using Pymol. 
 
 
Benzodiazepinediones were developed using high throughput screens to identify 
MDM2:p53 inhibitors by Johnson and Johnson Pharmaceuticals.  Once again the 
compound was found to occupy the Trp23, Leu26 and Phe19 pockets of MDM2 
(Grasberger et al., 2005).  The drug was 375 times less potent in cells than in vitro and 
so was optimized to make it more permeable to cells and applied as a sensitizing agent 
90o
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in conjunction with doxorubicin (Koblish et al., 2006).  It was found that when used in 
conjunction with doxorubicin the level of doxorubicin required was vastly reduced in 
order to have the same effect.  This synergism results in a reduction in side affects seen 
with doxorubicin alone (Koblish et al., 2006).    
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Figure 1.8 MDM2 Functions.  MDM2 has three potential roles in regulating the activity of p53. Firstly it 
can promote p53 translation via binding to its mRNA, secondly it can chaperone p53 onto its 
transcriptional target promoters and thirdly, it functions as an E3 ligase to ubiquitinate p53.  Mutations 
within p53 favour the ubiquitination route. 
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1.7.1 Ubiquitination and transrepression 
 
Perhaps MDM2’s most famous role is as a negative regulator of p53.  This is achieved in 
two ways, either by MDM2 binding via its N-terminus to the p53 BOX-I domain, thus 
preventing p53 interactions with the basal transcription machinery such as p300 (Arva et 
al., 2005), or by targeting p53 for degradation via the proteasome (Figure 1.8) (Michael 
and Oren, 2003; Toledo and Wahl, 2007).  The importance of MDM2 in p53 regulation 
is highlighted by the rescue of embryonic lethal MDM2 knockout mice by knockout of 
p53 (Jones et al., 1995).  After cellular stress, such as exposure to UV or ionizing 
radiation (IR), both of which cause DNA damage, p53 becomes phosphorylated at 
specific serine and threonine residues in its transactivation domain.  These 
phosphorylations impair the ability of MDM2 to bind to p53 through the TAD and as 
such MDM2 is unable to inhibit or degrade p53.  This results in the accumulation and 
stabilization of p53 as a result of MDM2 not being able to inhibit or degrade it.  
Together with p53 modifications, MDM2 can also be modified by phosphorylation and 
this can result in reduced ubiquitination of p53.  Following ionizing radiation, ATM 
rapidly phosphorylates MDM2 at serine 395 and this lowers its E3 ligase potential 
towards p53 (Maya et al., 2001).  MDM2 can also interact with TAFII250, which 
promotes the phosphorylation of the acid domain of MDM2 by CK2. This results in 
increased p53 turnover.  In contrast, phosphorylation of MDM2 at tyrosine 276 by c-Abl 
promotes its interaction with ARF, thus increasing its localisation to the nucleolus and 
decreasing p53 turnover (Allende-Vega et al., 2008; Dias et al., 2006).  Multiple 
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phosphorylation sites are present within the acid domain of MDM2 and these been 
shown to be phosphorylated by a wide range of kinases (Hay and Meek, 2000).  This 
region could provide an important role in regulating MDM2s function as an E3 ligase 
towards p53.           
 
1.7.1.1 MDM4  
 
MDM4 is a close relation and paralogue of MDM2.  MDM4 shares much structural 
similarity to MDM2, including the presence of a RING but with one important 
difference in that it lacks its E3 ligase activity (Shvarts et al., 1996).  From knockout 
studies in mice, it was discovered that MDM4 knockout mice die in the uterus, from p53 
dependent cell proliferation arrest (Jackson and Berberich, 2000).  It was hypothesised 
that MDM2 and MDM4 work closely together, with MDM4 stabilizing MDM2 and 
MDM2 facilitating nuclear import of MDM4 (Jackson and Berberich, 2000).   One 
important feature of MDM4 is that its expression is not stimulated by p53 and its 
promoter does not contain p53 recognition elements (Marine and Jochemsen, 2005).   A 
model incorporating the roles of MDM2 and MDM4 exists which suggested that under 
normal non-stressed conditions, p53 is ubiquitinated by MDM2 and kept inactive by 
MDM4 binding to its transactivation domain.  Following cellular stress, MDM2 
degrades MDM4, and perhaps to some extent itself, leading to the accumulation and 
activation of p53.  As p53 transactivates the MDM2, increased MDM2 leads to elevated 
levels of MDM4 degradation and consequently further activated p53.  After the cellular 
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stress has passed, MDM2 targets p53 for degradation and thus lowering p53 levels and 
as MDM4 levels increase, p53 activity returns to pre stress levels (Toledo et al., 2006).   
 
1.7.1.2 Ubiquitination mechanism 
 
While much is known about MDM2s function as an E3 ligase and how its activity is 
regulated, be it via post translational modifications, or protein-protein interactions, very 
little is known about the mechanism behind MDM2 catalyzed ubiquitination of p53.  
The E3 ligase catalyzed reaction involves at least two distinct steps, firstly the 
recognition of the substrates ‘ubiquitination signal’ and secondly the covalent 
attachment of one or more ubiquitin moieties to the substrate (Pickart, 2001).  The 
accepted view, based upon evidence at that time, was that MDM2 mediated 
ubiquitination of p53 proceeded through the binding of the MDM2 N-terminus to the 
BOX-I site within the transactivation domain of p53.  This was supported by evidence 
that mutation of single residue (Phe19) within the BOX-I domain of p53 prevented 
MDM2 catalyzed ubiquitination and that BOX-I mimetics could inhibit stable MDM2-
p53 complex formation (Bottger et al., 1997; Lin et al., 1994; Liu et al., 2001).  Previous 
studies have highlighted that MDM2 can still bind to p53 lacking the conventional N-
terminal binding domain in the presence of RNA and that this site has the ability to 
regulate p53 ubiquitination in cells (Burch et al., 2000; Shimizu et al., 2002).  Evidence 
was therefore beginning to emerge that suggested that ubiquitination of p53 was not 
solely controlled by the N-terminal interactions.   Before the emergence of a second 
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possible binding site in p53, it was shown that the acid domain of MDM2 was essential 
for p53 ubiquitination (Meulmeester et al., 2003).    
 
1.7.2 MDM2 as a chaperone 
 
As well as its ubiquitination function, MDM2 has also been shown to be an effective 
chaperone of p53 and E2F1 (Stevens et al., 2008; Wawrzynow et al., 2007).  It has 
previously been reported that the transient interaction of HSP90 with p53 is required for 
the correct assembly of the p53 tetramer on DNA, and that this occurs in an ATP 
dependent manner (Walerych et al., 2004).  HSP90 can cooperate with MDM2 and 
CHIP (C-terminus of HSP70 Interacting Protein) to stimulate the unfolding of the native 
p53 tetramer (Burch et al., 2004).   MDM2 can substitute for HSP90 in the ATP 
dependent folding of p53 onto the p21 promoter sequence (Figure 1.8) (Wawrzynow et 
al., 2007).  This leads to the proposed model whereby MDM2 can bind p53 and partially 
unfold it acting as a molecular chaperone.  Following cellular stress and activation of 
p53, MDM2 dissociates from the p53 protein resulting in spontaneous refolding of the 
p53 tetramer.  This repeated binding, dissociation and refolding event could lead to p53 
being in the correct conformation to bind DNA (Wawrzynow et al., 2007).  MDM2 
localises with latent p53 at the promoter sequences before but not after stress such as 
UV, supporting the idea of dissociation of MDM2 from p53 following cellular stress 
(White et al., 2006).  This dual function of MDM2 is thought to regulate the equilibrium 
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of whether p53 should be folded correctly onto its promoter elements in cooperation 
with HSP90 or whether MDM2 should function as an E3 ligase and degrade p53.    
There is also evidence of additional E3 ligases functioning as molecular chaperones, 
such as CHIP, which can specifically recognise unfolded proteins after stress such as 
heat shock (Rosser et al., 2007).  
 Unlike p53, MDM2 appears to have the opposite effect on E2F1 with regards to 
its chaperone functions.  E2F1 is misfolded in an ATP dependent manner and prevented 
from binding to its promoter elements.  Thus the ATP binding motif within the MDM2 
RING domain has clearly evolved to manipulate MDM2 protein-protein interactions in a 
substrate specific manner.       
 
1.7.3 MDM2 in p53 mRNA binding 
 
MDM2 has been shown to bind to p53 mRNA and stimulate p53 and its isoform lacking 
the N-terminus TAD, p53/47,  translation in a manner which is independent of MDM2-
p53 protein interactions.  MDM2 can bind p53 mRNA through p53s MDM2 binding 
domain encoding sequence (MDM-ES) via the MDM2 RING domain, and this regulates 
the rate of p53 mRNA translation.  Silent mutations introduced within the MDM-ES of 
p53 reduce the binding of MDM2 to p53 mRNA presumably by disrupting the RNA 
structure.  Mutation of codon 446 in the MDM2 RING domain, which has previously 
been shown to be responsible for MDM2 binding to RNA, reduces the p53 mRNA 
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binding ability of MDM2 (Elenbaas et al., 1996).  Experimental data also confirms that 
MDM2 is present at the polysomes in situations where MDM2 has high binding affinity 
for p53 mRNA, and that this allows increased p53 translation and reduced p53 
ubiquitination (Candeias et al., 2008).   The physiological factors that regulate the ability 
of MDM2 to promote the synthesis of p53 on one hand or its degradation on the other 
are not clear; indeed p53 synthesis, elevated specific activity, and enhanced rates 
degradation might even be coupled (Liu et al., 2001)    
   
1.8 Post translational modifications of MDM2 
 
As previously described, MDM2 contains several conserved functional regions, a 
flexible lid, an N-terminal hydrophobic pocket, an acid domain and a RING domain, all 
of which are required for MDM2 to function correctly as an E3 ligase, a chaperone or in 
mRNA binding.  MDM2s activity is regulated by multiple post translational 
modifications (PTMs) depending on the cellular signals.  Such PTM’s include self 
ubiquitination, sumoylation, neddylation, acetylation and phosphorylation.   
 
1.8.1 MDM2 auto-ubiquitination 
 
MDM2’s activity as an E3 ligase can mediate auto-ubiquitination as well as substrate 
ubiquitination (Fang et al., 2000).   However this finding has recently been challenged 
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by in vivo mouse models whereby mutant MDM2 lacking its E3 ligase function is 
degraded in the same way as MDM2 WT.  This study came to this conclusion by a 
number of observations; first MDM2 wild type and RING mutant constructs have the 
same half life, both are stabilised by the addition of the proteasome inhibitor MG132 and 
both yield identical ubiquitin modified bands following MG132 treatment.  They felt it 
was unlikely that another E3 ligase would be able to target and ubiquitinate the MDM2 
RING mutant with exactly the same kinetics as wild type MDM2 autoubiquitinates itself 
(Clegg et al., 2008).  As such they proposed that both wild-type and mutant MDM2 are 
ubiquitinated by an as yet unknown E3 ligase.  In support of this it has recently been 
reported that the histone acetyl transferase, PCAF, can both ubiquitinate and degrade 
MDM2 (Linares et al., 2007).  The observation that MDM2 can autoubiquitinated is 
thought to come about by over expression of the protein within the cell via transfection.  
When MDM2 WT or MDM2 RING mutant are over expressed in cells, the MDM2 WT 
can be autoubiquitinated whereas the RING mutant tends to accumulate.  It is thought 
that the endogenous E3 ligase cannot keep up with ubiquitination of exogenous MDM2 
and that at these high levels, MDM2 gains the ability to auto-ubiquitinate, thus MDM2 
WT can degrade itself and the RING mutant which lacks the ability to ubiquitinate isn’t 
degraded and therefore accumulates (Clegg et al., 2008).  
 
1.8.2 MDM2 can be Neddylated 
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Ubiquitin is the founding member of the ubiquitin like family of proteins (UBL).  Like 
ubiquitin, ubiquitin like proteins are small proteins that are covalently ligated to target 
protein via an iso-peptide linkage between the C-terminal carboxyl group of ubiquitin 
like proteins and the ε-amino group of a lysine residue in the target protein 
(Ciechanover, 1998).  Two of these ubiquitin like proteins include SUMO and NEDD8, 
and their effects on protein regulatory functions differ to that of ubiquitination 
(Weissman, 2001).    
 Amongst the myriad of UBL family members, NEDD8 is the most homologous 
to ubiquitin.  The mechanism of NEDD8 conjugation to its target protein is analogous to 
that of ubiquitination.  E1 and E2 enzymes are required for NEDD8 activation and 
conjugation to target proteins.  A role for NEDD8 conjugation has been highlighted in 
plant, fungal and animal systems and is thought to be involved with cell proliferation, 
viability and development (Cernac et al., 1997; Osaka et al., 2000; Tateishi et al., 2001). 
 MDM2 has been shown to neddylate p53 both in vivo and in vitro and this 
neddylation inhibits p53’s transcriptional activity but does not target it for degradation.   
MDM2 is also a target for neddylation and a functional RING finger is required to 
achieve this.  MDM2 controls neddylation of bothp53 and itself, thus the NEDD8 
conjugation pathway inhibits both the transcriptional activity of p53 and the suppressive 




1.8.3 MDM2 can be Sumoylated 
    
The reversible modification of proteins involved in gene expression by the small 
ubiquitin like modifier (SUMO) can regulate protein stability, localization, protein-
protein interactions and DNA binding.  Like that of NEDD8 and ubiquitin conjugation, 
sumoylation is mechanistically similar, with the activation and transfer achieved by E1 
and E2 enzymes.  Sumoylation is thought to play a major role in proteins involved with 
gene expression (Gill, 2003).   
 MDM2 can be sumoylated in vivo and in vitro by the E2 enzyme Ubc9, and the 
E3 ligases PIAS1 and PIASxβ (Buschmann et al., 2001; Miyauchi et al., 2002).  
Sumoylation is thought to regulate MDM2s localization within the cell, facilitating 
SUMO-mediated nuclear entry which can be regulated by ARF (Miyauchi et al., 2002).  
ARF inhibits MDM2 catalyzed p53 ubiquitination but promotes MDM2 sumoylation 
(Xirodimas et al., 2002).  This supports the idea that SUMO and ubiquitin modifications 
can be mutually exclusive and/or antagonistic (Meek and Knippschild, 2003).  Using a 
mutant Ubc9 to act as a dominant negative and down regulate sumoylation in cells it was 
found that sumoylation of MDM2 was reduced and this was accompanied by an increase 
in ubiquitination of MDM2 and the concomitant decrease in p53 ubiquitination 
(Buschmann et al., 2001).   Thus sumoylation provides a mechanism in which to 
regulate the activity of MDM2’s ligase function.   
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1.8.4 MDM2 can be Acetylated 
 
Sequence specific transcription factors can be activated by the cofactors histone acetyl-
transferases (HATS) such as p300, CREB binding protein (CBP) or p300/CPB-
associated factor (P/CAF).  HAT-mediated facilitation of gene expression usually 
involves acetylation by HATS of core histones at the target gene promoters, generating a 
more accessible chromatin conformation for the transcriptional machinery to access 
(Jenuwein and Allis, 2001).  As well as acetylating histones, transcription factors can 
also be acetylated directly (Kouzarides, 2000).  p53 is such a transcription factor which 
is targeted for acetylation by p300, and thus activates transcriptional activity.  MDM2 
can negatively regulate this acetylation by binding to p53 transactivating domain 
masking the p300 binding site (Gu et al., 1997).     
 MDM2 can interact with p300 and CBP and can lead to an increase in p53 
ubiquitination (Grossman et al., 2003; Grossman et al., 1998).  Further studies identified 
MDM2 a target for acetylation by CBP and p300 (Wang et al., 2004).  Although the 
interaction between p300 and CBP can lead to an increase in p53 ubiquitination, the 
acetylation of MDM2 reduces its activity as an E3 ligase towards p53 and can increase 
its own degradation (Wang et al., 2004).  Thus p300/CBP may play a dual role in 




1.8.5 MDM2 can be Phosphorylated 
 
 
As briefly eluded to earlier MDM2 is subject to control by phosphorylation at multiple 
residues.  Nearly 20% of the amino acid sequence of MDM2 is serine or threonine 
residues, many of which have been shown to be phosphorylated in vivo (Meek and 
Knippschild, 2003).  The N-terminus and the acid domain contain the two main clusters 
of phosphorylation residues within the MDM2 protein (Hay and Meek, 2000).   
 MDM2 is phosphorylated by ATM at ser395 in response to genotoxic stress and 
this modification can be observed via western blot by the loss of the 2A10 epitope via 
epitope masking.  Direct phosphorylation of MDM2 by ATM inhibits MDM2’s ability 
to turnover p53 (Maya et al., 2001).  Tyr394 of MDM2 can be phosphorylated by the 
protein-tyrosine kinase c-Abl in a DNA damage-dependent manner, blocking the ability 
of MDM2 to down regulate p53 activity (Sionov et al., 2001).  C-Abl is also a target of 
ATM, which raises the question of a two hit phosphorylation mechanism with ATM 
phosphorylating a kinase which in turn can phosphorylate MDM2 but also 
phosphorylating MDM2 itself at residues adjacent to each other (Meek and Knippschild, 
2003).   
Akt is thought to regulate MDM2’s translocation to the nucleus via 
phosphorylation of residues 166 and 186 which lie in close proximity to the nuclear 
export and nuclear localization sequences of MDM2 (Mayo and Donner, 2001).  This 
phosphorylation stimulates p53 ubiquitination and reduces MDM2’s interaction with 
ARF (Ogawara et al., 2002; Zhou and Elledge, 2000).. 
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A cluster of amino acids in the acid domain of MDM2 have been shown to be 
phosphorylated (Blattner et al., 2002; Hay and Meek, 2000).  This cluster of amino acids 
are thought to be phosphorylated under normal cellular conditions and play a role in 
MDM2 catalyzed p53 degradation, so as to maintain low p53 levels in the absence of 
stress (Blattner et al., 2002). 
 There are many more phosphorylation sites in the MDM2 protein, and very little 
is known about some of these.  Like many other PTM’s, phosphorylation can regulate 
MDM2’s sub-cellular localization, its stability and its activity as an E3 ligase towards 
p53.  Figure 1.9 summarizes MDM2 phosphorylations. 
 
Figure 1.9  Schematic diagram showing the sites of phosphorylation within the MDM2 protein.  
Where possible potential kinases are indicated.  The effects of phosphorylation on p53s activity are also 
shown.  (Adapted from (Meek and Knippschild, 2003) 
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1.9 p53 post translational modifications 
 
As with MDM2, p53 is targeted for a multiple array of PTMs including ubiquitination, 
neddylation, sumoylation, acetylation and phosphorylation.  Many of these PTM’s can 
act in concert to elicit a desired effect, highlighting the deep complexity of p53 function 
and regulation (Figure 1.10). 
 
1.9.1 Ubiquitination, Neddylation and Sumoylation of p53 
 
p53 is targeted for degradation by MDM2 via ubiquitination of specific lysine residues 
contained within its C-terminus.  These lysine’s are also subject to modification by the 
ubiquitin like proteins, NEDD8, and SUMO which regulates the MDM2:p53 interaction 
and protein stability. 
As well as being modified by ubiquitin, which targets p53 for degradation, p53 
can be modified by NEDD8 and SUMO however these modifications do not target p53 
for degradation but instead effect p53 activity.  Lysines 370, 372 and 373 of p53 have 
been implicated in NEDD8 conjugation (Xirodimas et al., 2004).  It is interesting to note 
that these residues are also targeted for ubiquitination.  Neddylation results in reduced 
p53 transcriptional activity (Xirodimas et al., 2004).   
 p53 can be sumoylated at lysine 386 which results in the activation of p53’s 
transcriptional activity independent of p53 ubiquitination  (Gostissa et al., 1999). 
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1.9.2 Acetylation of p53 
 
p300/CBP serves as a co-activator for p53 by mediating histone acetylation as well as 
targeting p53 for acetylation within its C-terminus.  Acetylation also occurs on residues 
used for ubiquitination thus acetylation results in p53 stabilization as a consequence of 
blocking MDM2 catalyzed ubiquitination (Gu and Roeder, 1997).  Not only is p53 
activated by blocking MDM2 ubiquitination, but acetylation causes conformational 
changes within p53 which enhances its specific DNA binding activity  (Friedler et al., 
2005; Gu and Roeder, 1997). 
 
1.9.3 Phosphorylation of p53 
 
In response to stress, phosphorylation of p53 occurs on numerous sites within its N-
terminal transactivation domain, the core DNA binding domain and the C-terminal 
domain. These phosphorylation events are mediated by many different protein kinases 
that respond to different stresses including, ATM, ATR, CHK1, CHK2, JNK and p38. 
Significant redundancies are observed in that the same p53 site is often phosphorylated 
by different protein kinases (Appella and Anderson, 2001; Bode and Dong, 2004) 
Generally, phosphorylation of p53 is associated with protein stabilisation and 
transcriptional activation (Craig et al., 1999; Hupp and Lane, 1994b). Due to the 
magnitude of p53 post-translational modifications, it has been proposed that a distinctive 
combination of phosphorylated residues may be required for additional modifications, 
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leading to maximal activation of p53 (Bode and Dong, 2004). For example, 
phosphorylation of p53 at Ser15 occurs rapidly in response to DNA damage and 
prepares the protein for subsequent modifications, including phosphorylation at 
threonine-18 and serine-20 by additional kinases (Saito et al., 2003). Phosphorylation at 
serine-15, threonine-18 and serine-20 stimulate the recruitment of transcriptional co-
activators such as p300/CBP, while blocking the interaction with MDM2, and enhance 
p53 transcriptional activity (Craig et al., 1999; Saito et al., 2003).  Similarly, 
phosphorylation of p53 at serine-33, threonine-81, and serine-315 promotes its 
interaction with the propyl isomerase, PIN1. PIN1 mediates a conformational change in 
p53 and augments p53 activity (Zacchi et al., 2002; Zheng et al., 2002).  Figure 1.10 





Figure 1.10  p53 Phosphorylation.  Schematic diagram indicating the potential phosphorylation sites 
within p53 and where possible the kinase responsible.  The effect on p53 function is indicated. Adapted 
from http://www.dundee.ac.uk/biomedres/meek.htm.  
 
1.10  The aim of this thesis 
 
As discussed the ubiquitin proteasome system (UPS) is an attractive target for cancer 
therapy, thus new ways need to be developed to target it.  The components of the UPS 
are now well known, starting from the E1 through to the proteasome itself.  With much 
specificity brought about by the different E2s and even more E3s the ability to switch off 
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one particular ubiquitination pathway is of great interest.  If it was possible to protect 
one protein from degradation then many unwanted side effects caused by general UBS 
inhibition would be a thing of the past.  One such protein is p53.  Stabilizing p53 would 
result in cell cycle arrest followed by DNA repair and/or apoptosis.  p53 is targeted for 
degradation by the E3 ligase MDM2.  MDM2 is overexpressed in up to 7% of human 
cancers resulting in the inactivation of p53.  There have been many attempts to target the 
MDM2:p53 interaction in the hope of stabilizing and blocking p53 ubiquitination with 
varying degrees of success.  However before drugs can be successfully modelled a better 
understanding of the mechanism of MDM2 catalyzed p53 ubiquitination is needed.  
Given the time MDM2 and p53 have been known and the extensive research into them, 
it is surprising that very little is know about how MDM2 transfers the ubiquitin moiety 
form the E2 to p53.  The aim of this thesis was to use biochemical and cellular analysis 









MATERIALS AND METHODS 
 
2.1 General Reagents 
 
Chemicals and reagents were supplied by Sigma unless otherwise stated. Tissue culture 
reagents including Dulbecco’s modified eagle’s medium (DMEM), RPMI 1640, 
penicillin/streptomycin solution, trypsin-EDTA solution and Lipofectamine™2000 were 
supplied by Invitrogen unless otherwise stated, while fetal bovine serum (FBS) was 




Faxitron® cabinet X-ray system, 43855D (Faxitron X-ray Corporation) was used to carry 
out X-irradiation treatment. A Fluroskan (Ascent FL), PowerwaveXSTM microplate 
reader (Bio-Tek), and an Envision fluorescence detector (Perkin Elmer) were used to 
read 96-well plates. DNA concentrations were measured using a NanoDrop® 
spectrophotometer. SDS PAGE was carried out using Biorad Protean II mini-gel system.  
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X-ray films were developed using a Mediphot 937 developer. Sorvall RC-5C plus and 
Eppendorf 5415R were used for all centrifugations.  
 
2.3 Cell Culture 
 
2.3.1  ell lines and Media 
 
All cells were kept in a humidified incubator at 37oC. Media were supplemented with 10 
% (v/v) fetal bovine serum (FBS). DMEM and RPMI-1640 were further supplemented 






Table 2.1 List of cell lines used in this study. 
 
2.3.2 Subculturing, storage and recovery of cells 
 
Freezing media 
50 % (v/v) Fetal bovine serum 
Cell Line Source Medium % CO2 
A375 













10 % (v/v) DMSO 
40 % (v/v) Tissue culture media (depending on cell line)  
 
Cells were subcultured 2-3 times per week in 10 cm diameter culture dishes in sterile 
conditions and split to a maximal dilution of 1/10. The media was discarded and the 
cells were washed with sterile phosphate buffered saline (PBS). 1x Trypsin-EDTA 
solution (0.5 ml/ 10 cm diameter culture dishes) was added and the cells were placed in 
the incubator until the cells started to detach from the culture dish. The cells were taken 
up into media (9.5 ml/ 10 cm diameter culture dishes) and then split 1:10 into new 
culture dishes with fresh media (10 ml/ 10 cm diameter culture dishes).  
Cells were kept in liquid nitrogen for long-term storage. To prepare cells for 
storage a 10 cm diameter culture dish with confluent cells was trypsinised and the cells 
collected by centrifugation (1000 rpm, 5 min, 4 ºC). The cell pellet was gently 
resuspended in 4 ml freezing media and transferred to cryotubes (Nunc) at 1 ml/ tube. 
The cells were frozen down slowly in NalgeneTM Cryo 1 ºC freezing containers and then 
transferred to liquid nitrogen.  
To recover the cells the tubes were thawed quickly at 37 ºC and the cells 
transferred to a culture dish containing fresh media. The media was changed the 
following day and the cells were left to grow until they were confluent before being 
subcultured for the first time 
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2.3.3 Transient transfections  
 
Cells were seeded out onto 6-, 24well plates or 10 cm2 plates 24 h prior to transfection 
without antibiotics and grown to 80-90 % confluency. The cells were transfected with 
plasmid DNA (pcDNA3.1; pDEST vectors, Invitrogen) using LipofectmineTM 2000 
(Invitrogen) according to manufacturer’s handbook. DNA was transfected at a ration of 
1:1 using LipofectamineTM 2000. Cells were then incubated at 37oC overnight before 
they were harvested or subjected to chemical treatment or stress. 
 
2.4 Microbiological Techniques 
 
All microbiological techniques were carried out under aseptic conditions. 
 
2.4.1 Growing bacterial cultures 
 
Luria-Bertani  (LB) broth  
 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaCl 
Sterilised by autoclaving at 121 °C for 20 min 
 
Selective antibiotics used 
Ampicillin (Sigma) at 50 g/ml 
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Kanamycin at 100mg/ml  
 
5 ml LB media (containing a selective antibiotic if required) was inoculated with a 
colony of bacteria from a stock plate or from a glycerol stock and incubated for several 
hours overnight at 37 °C (225 rpm). This starter culture was then transferred to 200 ml 
LB media (containing antibiotics if appropriate) and incubated under the same 
conditions overnight. Culture flask capacities were at least 5x the volume of the culture 
being grown to allow for aeration. 
 
2.4.2 Glycerol stocks 
 
Glycerol stocks of bacterial cells were prepared by adding 0.15 ml of sterile glycerol to 
0.85 ml of liquid bacterial culture in a cryovial (Nunc) and snap frozen. The cells were 
stored at –70 °C. 
 
2.4.3 Agar bacterial culture dishes 
 
LB agar 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaCl  
1.5 % (w/v) Agar, granulated 
Sterilised by autoclaving at 121 °C for 20 min. 
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LB agar was liquefied by heating in a microwave oven. When the agar was hand warm it 
was poured into 90 mm diameter Petri dishes (Sterilin) and left to cool. If antibiotic 
selection was required, the antibiotic was added to the agar immediately before pouring. 
The culture dishes were stored at 4 °C for no longer than one month. Prior to use the 
plates were dried at 37 °C for 1 h.   
 
2.4.4 Preparation of competent cells  
 
Heat shock method 
Transforming buffer 1 (TFBI) 
30 mM Potassium acetate 
100 mM RbCl 
10 mM CaCl2 
50 mM MnCl2 
15 % (v/v) Glycerol 
Adjust to pH 5.8 with acetic acid and 
sterilise by filtration. 
Transforming buffer 2 (TFBII) 
10 mM MOPS 
75 mM CaCl2 
10 mM RbCl2 
15 % (v/v) Glycerol 
Adjust to pH 6.5 with KOH and sterilise 
by filtration.  
 
 
A starter culture of DH5α cells was set up by transferring a colony of bacteria from a 
stockplate to 2 ml of LB in a 15 ml sterile tube. The culture was incubated overnight at 
37 °C and with agitation at 225 rpm. This culture was diluted 1/100 in 200 ml of LB and 
incubated at 37 °C at 225 rpm until the OD600nm lay within 0.3-0.5. The cells were 
collected by centrifugation (10 min, 8000 rpm, 4 °C) and resuspended in ice-cold 80 ml 
of TFBI buffer at 2/5 of the original 200 ml culture volume. After 10 min of incubation 
on ice the cells were again centrifuged (5 min, 2500 rpm, 4 °C) and gently resuspended 
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in 8 ml of TFBII buffer at 1/25 of the original 200 ml culture volume. The cells were 
incubated on ice for 15 min and 200 l aliquots were added to pre-chilled 
microcentrifuge tubes. The aliquots were snap frozen on dry ice and stored at –70 °C.  
 
2.4.5 Transformation of bacteria 
 
2.4.5.1  Heat shock method 
 
100 µl of DH5α competent cells were defrosted on ice and mixed with 0.1-0.5 µg of 
plasmid DNA. The cells were incubated on ice for 45 min and heat-shocked at 42°C for 
2 min. Following another 2 min incubation on ice, 1 ml LB media was added and the 
culture was incubated at 37 °C at 225 rpm for 30 min in a 15 ml sterile tube. Cells were 
then plated onto LB agar bacterial culture dishes containing selective antibiotic where 
appropriate and incubated overnight at 37 °C.  
 
2.5 Molecular Biology Methods 
 
2.5.1 Plasmid DNA 
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Amplification of plasmid DNA – A single colony of bacteria containing the plasmid 
required was used to inoculate a starter culture of 5 ml of LB containing selective 
antibiotic and incubated at 37 °C at 225 rpm for 4-8 h in a 50 ml sterile tube. The starter 
culture was then transferred to a larger 100 ml liquid bacterial culture and incubated 
overnight at 37 °C at 225 rpm in a 500 ml flask.  
Purification of plasmid DNA – Cells from the culture grown for amplification of 
plasmid DNA were collected by centrifugation at 6000 rpm for 20 min at 4 °C. Plasmid 
DNA was isolated using Qiagen MaxiTM and MiniTM prep kits according to 
manufacturer’s instructions. The DNA was resuspended in nuclease-free dH2O and 
stored at -20 °C.   
Quantification of plasmid DNA – The concentration of plasmid DNA was 
determined by spectrophotometry at 260 nm using the PowerwaveXSTM Microplate 
Spectrophotometer (Bio-Tek). Plasmid DNA was diluted 1/100 and 100 l volumes 
were added to wells of a 96-well UV-StarTM Plate (Greiner), using 100 l dH2O as a 
blank control. 50 g/ml DNA gives an OD260nm of 1 A thus DNA concentrations could 






2.5.2.1 Preparation of cell lysates 
 
Cell lysis  
0.1 % or 1 % Triton X-100 lysis buffer 
50 mM HEPES pH 7.6 
0.1 mM EDTA 
150 mM NaCl 
1x protease inhibitor mix* 
0.1 % or 1 % (v/v) Triton X-100 
10 mM NaF 
Stored at -20 ºC in aliquots. 
2 mM DTT (add prior to use) 
 
Urea lysis (Denaturing) buffer 
7 M Urea 
0.1 M DTT 
0.05 % (v/v) Triton X-100 
25 mM NaCl 
25 mM HEPES pH 7.6 
Buffer prepared just prior to use. 
 
*10x Protease inhibitor mix 
10 µg/ml Leupeptin 
4 µg/ml Aprotinin 
2 µg/ml Pepstatin 
1.2 mM Benzamidine 
10 µg/ml Soya bean trypsin inhibitor 
400 µg/ml Pefabloc 
1 mM EDTA 
Stored at -20 ºC in aliquots.  
SDS sample buffer (SB) 
5 % (w/v) SDS 
25 % (v/v) Glycerol 
125 mM Tris pH 6.8 
0.02 % (w/v) Bromophenol blue 
DTT (1 M) added to buffer (1 DTT : 4 
SB) prior to use 
 
Cells were washed with cold PBS, scraped with 150 l of PBS into microcentrifuge 
tubes and then centrifuged at 5000 rpm for 5 min at 4 ºC. The supernatant was removed 
and cell lysis buffer was added in excess of the cell pellet (50-100 l per well in a 6-well 
plate). The cells were resuspended by pipeting the cell lysis buffer up and down several 
times. Samples were then incubated on ice for 20 min. The cell lysate was centrifuged at 
13000 rpm for 2 min and the supernatant was recovered. The cell pellet was recovered 
and lysed further by resuspending it in 200 l of SDS sample buffer and heated at 70 ºC 
for 10 min. Samples were then sonicated (Soniprep150TM, MSE) twice for 10 sec (Level 
2-3). Samples were snap-frozen in liquid nitrogen and stored at -70 ºC. 
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2.5.2.2 Protein precipitation 
 
Trichloroacetic acid (TCA) was used to precipitant protein and concentrate protein 
samples using the following method. 2 % deoxycholate (DOC) was added to the samples 
to a final concentration of 0.02 % and incubated at room temperature for 15 min. 24 % 
TCA was added to a final concentration of 8 % and incubated on ice for 1 hr. The 
precipitated proteins were pelleted by centrifugation at 13,000 g for 10 min at 4 oC. The 
supernatant was removed and the pellet washed with 200 µl ice cold acetone to remove 
residual TCA. The protein pellet was air dried for 1 – 2 min before resuspending in 
either urea lysis buffer or 4 x SDS sample buffer (4 % SDS, 250 mM Tris-HCl pH 6.8, 
10 mM EDTA, 0.2 M DTT, 1% Bromophenol blue). 
 
2.5.2.3 Protein quantification  
 
Protein concentrations were determined using the BCATM Assay kit (Pierce, Perbio 
Science) in a 96-well plate measuring absorbance at 562 nm with the PowerwaveXSTM 
Microplate Spectrophotometer (Bio-Tek). Read-outs were converted to concentrations 
using the standard curve generated from the BSA standards and adjusted by the dilution 
factor.  
 Biorad protein assay dye reagent concentrate was diluted 1 in 5 in distilled water. 
1 µl diluted protein sample was added to 200 µl of this solution in a clear 96-well plate 
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and mixed. The absorbance at 595 nm was measured and the protein concentration was 
determined from a standard curve generated from known concentrations of BSA.  
 
2.5.3 Preparation of gels and separation of proteins by SDS-PAGE 
 
Running buffer  
192 mM Glycine 
25 mM Tris 
0.1 % (w/v) SDS 
Separating gel – 10%  (per 5 ml) 
30 % Acrylamide mix*  1.7 ml 
1.5 M Tris (pH 8.8)  1.3 ml 
10 % SDS  0.05 ml 
10 % Ammonium peroxidisulphate  0.05 ml 
TEMED (Sigma)  0.002 ml 
dH2O  1.9 ml 
 
Separating gel – 15 %  (per 5 ml) 
30 % Acrylamide mix*  2.5 ml 
1.5 M Tris (pH 8.8)  1.3 ml 
10 % SDS  0.05 ml 
10 % Ammonium peroxidisulphate  0.05 ml 
TEMED (Sigma) 0.002 ml 
dH2O  1.1 ml 
Stacking gel – 5 %  (per 1 ml) 
30 % Acrylamide mix*  0.17 ml 
1.5 M Tris (pH 6.8)  0.13 ml 
10 % SDS  0.01 ml 
10 % Ammonium peroxidisulphate  0.01 ml 
TEMED (Sigma)  0.001 ml 
dH2O  0.68 ml 
* Acrylamide mix (National Diagnostics; Ultrapure Protogel) consists of 30 % (w/v) 
acrylamide and 0.8 % (w/v) bis-acrylamide. 
 
SDS-polyacrylamide gels at polyacrylamide concentrations of 10 % or 15 % were 
prepared [described by Laemlli et al (1970)] using a MiniProtean3TM (Bio-Rad) blot. 
The separating gel was left to polymerise and overlaid with water to straighten the top of 
the gel. The water was then removed and the stacking gel with a polyacrylamide 
concentration of 5 % was added together with a 10- or 15-well comb, which was also 
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left to polymerise. The combs were removed and the wells were washed out with 
Running buffer.  
SDS sample buffer was added to the cell lysates containing between 25-50 g of 
protein in a ratio of 1:1 (v/v) and samples were heated at 95 ºC for 5 min prior to 
loading. 5 l of pre-stained protein standards (Bio-Rad) were loaded in the first well as 
size markers. Proteins were separated by electrophoresis in Running buffer at 100-170 V 
until the Bromophenol blue dye front reached the bottom of the gel.  
 
2.5.4 Detection of fractionated protein  
 
Gels were removed from the glass plates and the stacking gel was discarded. 
Coomassie brilliant blue staining 
Destain 1 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
 
Destain 2 
7.5 % (v/v) Methanol 
10 % (v/v) Acetic acid 
Coomassie brilliant blue stain 
50 % (v/v) Methanol 
10 % (v/v) Acetic acid 
0.2 % (w/v) Coomassie Blue R-250 
 
 
Gels were transferred to a dish containing Destain 1 for >5 min and then placed into 
another dish containing Coomassie Blue Stain. The duration of the staining procedure 
depended on the strength of the staining required (5 min to 12 h) and in some cases the 
stain was preheated to 45 ºC to increase staining even further. Gels were then placed in a 
dish containing Destain 2. A folded tissue was used to absorb excess dye and Destain 2 
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was renewed as needed. Destaining was performed until the bands became visible and 
the background staining was removed. Gels were air-dried in between DryEase 




10x PBS (Phosphate-Buffered Saline) 
1.37 M NaCl 
0.1 M Na2HPO4 
0.027 M KCl 
0.018 M KH2PO4 
Adjust pH to 7.4 with HCl 
 
PBS+Tween (PBST) 
1x PBS + 0.1 % (v/v) Tween 20 
 
ECL Solution 1 
100 mM Tris pH 8.5 
2.5 mM Luminol stock 
0.4 mM p-Coumaric acid 
 
ECL Solution 2 
100 mM Tris pH 8.5 
0.02 % (v/v) H2O2 
Solutions stored at 4 ºC in the dark.  
Transfer buffer 
192 mM Glycine 
25 mM Tris 




The separated proteins were transferred electrophoretically to PROTRANTM 
nitrocellulose transfer membranes (Schleicher & Schuell Biosciences) in tanks with 
agitated Transfer buffer and an ice block to control the temperature. Electroblotting was 
carried out at 100 V for 1 h or at 20 mA overnight. After transfer of proteins the 
membranes were washed in PBST and stained with black ink (Pelikan) diluted in PBST 
(1/100) for 10-15 min. Membranes were washed again in PBST to remove the excess 
stain and non-specific antibody binding was blocked by a 1 h incubation in PBST + 5 % 
 77 
(w/v) dried skimmed milk (PBST5M; Marvel). The membranes were then incubated 
with the primary antibody in PBST5M for 1 h at RT (or overnight at 4 ºC). Following 
three 5x 5 min washes in PBST, the appropriate secondary antibody (conjugated to horse 
radish peroxidase; DAKO) diluted 1/1000 – 1/2000 in PBST5M was added to the 
membrane and incubated for 1 h at RT. Membranes were again washed for 5x 5 min 
with PBST and specific bands were detected by enhanced chemiluminescence (ECL). 
Membranes were overlaid with ECL solution 1 and 2 (mixed 1:1) for 1 min, blotted dry 




2.5.6.1 Primary antibodies 
Table 2.2 List of primary antibodies used in this study. 
Target kDa Clonality Supplier Dilution 
 - actin 42 Mouse Monoclonal Abcam 1:5000 
E2F-1  60 Rabbit Polyclonal Santa Cruz 1:1000 
IRF-1 (C-20) 48 Mouse Monoclonal BD 1:1000 
MDM2 (2A9) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
MDM2 (2A10) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:2000 
MDM2 (4B2) 90 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 
p21 (Ab-1) 21 Mouse Monoclonal Oncogene 1:1000 
p53 (DO1) 53 Mouse Monoclonal 
Moravian 
Biotechnology 1:5000 
p53 (DO12) 53 Mouse Monoclonal 
Moravian 
Biotechnology 1:1000 








2.5.6.2 Secondary antibodies 
 
Secondary antibodies were sourced from Dako and HRP-conjugated forms of Rabbit -
Mouse IgG; Swine -Rabbit IgG; Rabbit -goat IgG; Rabbit -sheep IgG were used. 
 
2.5.7 Stripping Membranes 
 
Stripping buffer 
50 mM Tris pH 6.8 
2 % (w/v) SDS 
100 mM -mercaptoethanol 
 
Antibodies bound to membranes were removed by stripping when the blots needed to be 
re-probed. The stripping buffer was heated to 50 ºC in a water bath and added to the 
membrane. The blot was kept at 50 ºC in the water bath for 15-30 min with occasional 
agitation. The membrane was rinsed multiple times with PBS and was then 
immunoblotted as described above.  
 





Hot-start Taq polymerase amplification  
 
PCR Master mix/reaction  Cycling conditions  
1xPCR buffer (Qiagen)  
1m dNTPs (Promega)  
0.1M forward and reverse primers  
1g DNA template  
HotstarTaqTM DNA polymerase 5units/reaction 
(Qiagen)  
ddH2O up to a final volume of 50 l  




Annealing: 53.6°C for 
30sec,  
Elongation:72°C for 1min  
Cycle to step 2 x30 times,  
72°C x 5min.  
4 °C for t  
 
In order to ensure maximum yield of amplification for each product, different annealing 
times, varying from 50-70°C, along with elongation times between 30sec-3min, were 
tried. 100ng of DNA template were used as initial concentration.  
 
PFU polymerase reaction  
 
PFU® Turbo amplification was used instead of Taq polymerase for site directed 
mutagenesis because of it is a highly thermostable Pfu DNA polymerase and possesses 
3' to 5' exonuclease proof-reading activity that enables the polymerase to correct 
nucleotide-misincorporation errors. This means that Pfu DNA polymerase-generated 
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PCR fragments will have fewer errors than Taq-generated PCR inserts. All reactions 
performed in a DNA Engine DyadTM machine.  
 
2.6.2 Agarose gel electrophoresis  
 
50x TAE (Tris-Acetate EDTA)  6x DNA loading buffer  
2M Tris pH 6.8,  
0.1M Na2EDTA.2H2O  
4% Acetic acid (v/v)  
Adjust pH to 8.5  
0.25% Bromophenol blue (w/v)  
0.25% Xylene cyanol (w/v)  
15% Ficoll 400 (w/v)  
 
TAE buffer was diluted (50x) to 1x and 1% (w/v) ultrapure agarose was added. The 
solution was heated in a microwave oven until the agarose is completely dissolved and 
left to cool down to handwarm under the hood. Ethidium Bromide EtBr was added to a 
PCR Master mix/reaction  
 
Cycling conditions  
1x cloned PFU® buffer (Stratagene)  
1m dNTPs (Promega)  
0.5mM MgCl2 (Qiagen)  
0.1M forward and reverse primers  
5% (v/v) DMSO  
1g DNA template  
PFU® Turbo DNA polymerase 2.5 units/reaction 
(Stratagene)  
ddH2O up to a final volume of 50 l  




Annealing: 53.6°C for 
30sec,  
Elongation:72°C for 1min  
Cycle to step 2 x30 times,  
72°C x 5min.  
4 °C for t  
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final concentration of 5% (w/v). The solution was then poured into a horizontal 
electrophoresis gel tray with a 10-well or bigger comb inserter and left to solidify. When 
solid, the agarose gel was submerged in a horizontal electrophoresis tank filled in 
1xTAE buffer. DNA loading buffer (6x) was added to the samples (3l of site-directed 
mutagenesis DNA or 10l of PCR amplified DNA) to 1x and then loaded onto the gel. 
1kb DNA ladder was also loaded at 5l volume. Electrophoresis at 100V at room 
temperature followed till adequate separation was achieved and then the bands were 
visualized by UV light using a CHEMI Genius2 BioImaging SystemTM (Syngene) and 
the GenesnapTM tool with an ethidium bromide filter and transilluminator. The images 
were captured with a Sony UP-D895MD. 
 For cloning the DNA was extracted from the gel using a DNA gel purification kit 
from Qiagen. 
 
2.6.3 Restriction enzyme digestion and Ligation of DNA in the appropriate vector 
 
Restriction enzyme digestion of the vector and the DNA-insert is required after PCR 
amplification. The restriction endonucleases recognize specific sequences to digest. As 
far as the insert is concerned the adequate restriction enzymes were chosen according to 
the Multiple Cloning Site (MCS) of the vector to be inserted in.  Restriction digests were 
performed to manufacturers protocol (New England Bio-labs). 
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Ligation reaction  Formula for the vector:insert ratio  
1x Ligation Buffer (10x Promega)  
10-100ng vector DNA  
xng insert  
10units of T4 ligase (10u/ l , Promega) 
ddH2O up to 10  
g of vector x size of insert (Kb) x ratio insert  
size pf vector (Kb) vector  
 
After digestion the vector plasmid and the DNA-insert were ready to be ligated. The 
above reaction was incubated at 4 °C in Eppendorf tubes, overnight. For each ligation 
different ratios insert:vector were applied each time, varying between 1:1 and 5:1, 
according to the size of the insert when compared to the vector.  
 
2.6.4 Site-directed mutagenesis and Cloning 
 
2.6.4.1  Primer design  
 
Cloning primers were designed with a length of around 20-30 bp spaced over the 
beginning or end of the MDM2 open reading frame with restriction sites or a 
homologous recombination site incorporated into them.  
Oligonucleotides were purchased from Sigma-Aldrich, de-salt purified for 
cloning and were reconstituted in nuclease-free ddH2O. 














































































2.6.4.2 Site-directed mutagenesis 
 
Primers containing the desired mutations were designed according to the guidelines in 
the QuikChangeTM Site-Directed Mutagenesis Kit Manual (Stratagene). 
Oligonucleotides were purchased from Sigma-Aldrich de-salt purified and were 
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reconstituted in nuclease-free ddH2O. Site-directed mutagenesis was carried using the 
QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene) according to manufacturer’s 
instructions. After mutant strand synthesis reaction, 1 l of DpnI restriction enzyme 
(10U/l) was added to the amplification reaction and mixed. The reaction mixture was 
microcentrifuged for 1 minutes and incubated at 37oC for up to 4 hours to digest the 
parental (nonmutated) dsDNA. After incubation, 2 l of DpnI-treated DNA was used to 
transform 25 l of DH5 competent cells using heat-shock method. 
 
Table 2.4:  Site Directed Mutagenesis Primers 
 





Arginine 97 to 
Serine 







Arginine 97 to 
Serine 










































































































2.6.5 Sequence analysis of plasmid DNA 
 
All sequence analysis was performed by the Sequencing Unit at the MRC Human 
Genetics Unit, Edinburgh. Ten l of sequencing reaction containing 2 l of BigDye® 
Terminator 3.1 (Applied Biosystems), 3.2 pmol of primer, 1x BigDye Sequencing buffer 
(Applied Biosystems), 250 ng of DNA template and nuclease-free ddH2O was 
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assembled. The sequencing reaction was thermal-cycled using cycling parameters 
according to the manufacturer’s instructions.  
The sequenced DNA was then precipitated by mixing the reaction with 2.5 l of 
125 mM EDTA and 30 l of 100 % (v/v) ethanol. After vortexing, the reaction was 
incubated at room temperature for 15 minutes. After centrifuging at 13000 rpm for 20 
minutes, the solution was removed and precipitated DNA was microcentrifuged for 20 
seconds. Residual ethanol was removed before 30 l of 70 % (v/v) ethanol was added to 
the precipitated DNA and centrifuged at 13000 rpm for 5 minutes. The ethanol was 
removed before the precipitated DNA was microcentrifuged for 20 seconds. Residual 
ethanol was removed and the precipitated DNA was left to air-dry before sequence-
analysed. 
 




BL21 cells were transformed with pDEST-15 full length MDM2 or acid domain MDM2  
for GST-tagged expression and a single colony was picked to make a starter culture.  
The starter culture was diluted to 1:100 in half a litre of LB and grown at 37oC until 
OD600nm was about 0.6-0.9.  The culture was then induced with 0.2% arabinose 4 hours 
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at room temperature with shaking (225 rpm).  Following induction cells were pelleted 
and resuspended in 10ml of 50mM Tris-ph8 and snap frozen. 
The suspension was slowly allowed to defrost before adding 0.3M KCl, 10X 
protease inhibitor mix and 0.5% NP40.  Cells were then sonicated twice for 10 seconds 
and left on ice for 20 minutes.  Cells were again pelleted and supernatant was incubated 
with 0.25ml GST-beads (Qiagen) for 3 hours.  Beads were then washed 3 times in 
50mM Tris-pH8 before 500µl elution buffer (0.1M HEPES, 10xprotease inhibitor mix, 
50mM Glutathione, pH 7.5 with NaOH) was added and left overnight at 4oC rotating.  




Cultures were grown and induced as for GST-purification.  After induction the cells 
were pelleted and resuspended in 10ml of lysis buffer (20mM Tris pH8, 150mM NaCl, 
0.1% NP-40, 10% glycerol, 10mM MgCl2) and sonicated as before and spun down.  The 
supernatant was added to 250ul of Ni-NTA agarose beads (Qiagen) washed in PBS, and 
incubated for 1 hour at 4oC.  Supernatant was removed, leaving enough to transfer beads 
to a small column and washed 6x with lysis buffer + 40mM imidazole.  Protein was then 
eluted in 14 fractions of 0.5 ml using lysis buffer plus 250mM imidazole.  All fractions 
were run out on an 18% gel.  Peak fractions were then pooled and loaded onto an 
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equilibrated fast flow Q-column (GE Healthcare) and eluted off with a high salt 
concentration. 
 
2.7.3 Native protein Purification 
 
pDEST14-MDM2 constructs were overexpressed in BL21 arabinose inducible (AI) 
E.coli for 3 hours at room temperature.  Cells were harvested by centrifugation at 6 000g 
for 10 minutes and frozen in liquid nitrogen.  Bacterial pellet was lysed in 10% sucrose, 
50mM Tris-HCl (pH8), 150mM NaCl and 150ug/ml lysozyme and left on ice for 45 
minutes before sonication.  After sonication 2mM Pefabloc, 5mM DTT and 1mM 
benzamidine was added to lysate before centrifugation at 30 000g for 20 minutes.  
Lysate was loaded onto a fast flow SP column (GE Healthcare) equilibrated with buffer 
A (25mM Hepes, pH7.5, 10% glycerol, 1mM benzamidine, 5mM DTT, 50mM KCl and 
2mM Pefabloc).  Bound protein was eluted with increasing salt concentration using 
buffer B (same as buffer A but 1M KCl).   
 
Lysis Buffer  Wash Buffer  Elution Buffer 
20mM Tris pH 8,  
150mM NaCl  
0.1% NP40  
10mM MgCl2 
 
+ 40mM Imidazole  + 250mM Imidazole 







A 96-well microtiter plate (Corning Inc.) was coated with purified p53 (50ng per well) 
diluted in 0.1 M Na2HCO3, pH 7.6,
 and incubated overnight at 4 °C. Each well was 
washed 6x with PBS containing 0.1% Tween 20 (PBS-T) followed by incubation for 1 h 
at room temperature with gentle agitation in PBS-T supplemented with 3% bovine serum 
albumin. The wells were washed 6x with PBS-T prior to incubation with appropriate 
amounts of purified MDM2WT, MDM2∆lid, or MDM2S17D mutants diluted in PBS-T 3% 
bovine serum albumin for 1 h at room temperature.  For competition ELISA’s a fixed 
concentration of 25ng MDM2 was used with a titration of appropriate inhibitor added at 
the same time.  After 1 h incubation the plate was washed again 6x with PBS-T and 
incubated with MDM2 specific antibody 2A10 (1:1000 in PBS-T 3% BSA) for 1 h at 
room temperature.  For peptide ELISA’s plate was coated with streptavidin overnight, 
washed 6x with PBS-T and biotinylated peptides were added for 1 hour followed by 
addition of MDM2.   Following a further 6x washes with PBS-T wells were incubated 
with secondary rabbit anti mouse horseradish peroxidase antibodies followed by further 
washing and ECL. The results were quantified using Fluoroskan Ascent FL equipment 
(Labsystems) and analyzed with Ascent Software version 2.4.1 (Labsystems).    
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Peptides BOXIa, BOXIb, BOXVa, and BOXVb were from Chiron Mimetopes and 
Nutlin3a from Alexis Biochemicals 
BOXIa Biotin-SGSGPPLSQETFSDLWKLLP  
BOXIb (12.1) Biotin-SGSGMPRFMDYWEGLN  
BOXVa Biotin-SGSGRNSFEVRVCACPGRD  
BOXVb (Rb1) Biotin-SGSGDQIMMCSMYGICKVKNIDLK  
 
2.8.2 In Vitro Ubiquitination Assay 
 
Reactions contained 25 mM HEPES (pH 8.0); 10 mM MgCl2; 4 mM ATP; 0.5 mM 
DTT; 0.05% (v/v) Triton X-100; 0.25 mM benzamidine; 10 mM creatine phosphate; 3.5 
units/ml creatine kinase; ubiquitin (2 g); E1 (100 nM), E2 (1 M), and pure p53(0.5 
g). Reactions were started with purified MDM2WT, MDM2∆lid or MDM2 S17D at various 
concentrations (50-200ng), incubated for 15 min at 30°C, and analyzed with 4%–12% 
NuPAGE gels in a MOPS buffer system (Invitrogen) followed by immunoblot.  For 
temperature gradient MDM2 was subjected to heat shock for 5 minutes prior to addition 
to ubiquitination reaction. 
 
Master Mix: 
366µl H2O  
10µl 1M HEPES (pH8) 
2.4µl 1M MgCl2 
2µl    10% Triton X-100 
 91 
0.2µl 1M DTT 
6µl     0.2M ATP 
0.4µl 1M Benzamidine 
3.2µl 10mg/ml Ubiquitin 
 
2.8.3 In vivo ubiquitination assay 
 
The H1299 cells were transfected with 0.5 g p53 and 0.5 g His-Ubiquitin (His-Ub) , 
in a 6-well plate.  4 hours prior to harvesting, the cells were treated with the proteasome 
inhibitor MG132 (50 M; Sigma). 24 hours post transfection, the cells were harvested in 
1 ml ice-cold PBS. Prior to centrifuging, this 1 ml was divided into two parts: 800 l for 
analysis by His-pulldown, and 200 l for analysis by direct lysis. Both parts were then 
centrifuged at 5,000 rpm for 5 min at 4ºC, the supernatant was discarded, and the cell 




Buffer A: 6 M Guanidium-HCl, 95 mM Na2HPO4, 5.3 mM NaH2PO4, 10 mM Tris-HCl    
(pH 8.0),  0.01 M -mercaptoethanol 
   Adjust pH to 8.0 
 
Buffer B: 8 M Urea, 95 mM Na2HPO4, 5.3 mM NaH2PO4, 10 mM Tris-HCl (pH 8.0),    
 0.01 M -mercaptoethanol 
 Adjust pH to 8.0 
 
Buffer C: 8 M Urea, 22.5 mM Na2HPO4, 77.5 mM NaH2PO4, 10 mM Tris-HCl (pH                 
8.0),    
 0.01 M -mercaptoethanol 
   Adjust pH to 6.3 
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Buffer D: Buffer C + 0.2% Triton X-100 
 
Buffer E: Buffer C + 0.1% Triton X-100 
 
Lysis Buffer: Buffer A + 5 mM Imidazole 
 
Elution Buffer: 0.2 M Imidazole, 5% SDS, 0.15 M Tris-HCl (pH 6.7), 10% glycerol,  
            0.72 M -mercaptoethanol 
 
 
The thawed pellet (800 l) was lysed in 1 ml freshly prepared ubiquitination lysis buffer 
by pipetting up and down using a liquipette (Elkay). The lysate was transferred to a 15 
ml falcon tube containing a further 4 ml of lysis buffer. 75 l of Ni2+-NTA Agarose 
beads (GeHealthcare) was added to each tube, following which the tube was placed on a 
rotating table overnight at 4ºC. 
The beads were collected by centrifugation at 2000 rpm for 3 min at 4ºC and the 
supernatant was carefully removed. The beads were washed in 750 l Buffer A, and 
transferred to microfuge tubes. The tubes were then placed on a rotating table for 15 min 
at RT, following which the beads were collected by centrifugation at 2000 rpm for 4 
min. The supernatant was discarded. In a similar manner, the beads were washed with 
buffers B-E. 
Following the wash with buffer E, 75 l of elution buffer was added to the beads, 
and the tubes were incubated on a rotating table for 30 min at RT. The beads were 
collected by centrifugation at 13,200 rpm for 5 min at 4ºC. The supernatant was mixed 
with an equal volume of sample buffer. 
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 50 l of each sample was loaded on a pre-cat Novex 4012% gel (Invitrogen), 
which was subsequently run in 1X MOPS buffer (Invitrogen) at 200 V for about 1 hour. 
The separated proteins were then transferred to a nitrocellulose membrane and analysed 




AlphaScreen (amplified luminescent proximity homogeneous assay), the donor bead is 
streptavidin labeled and linked to the relevant biotin linked peptide. The acceptor bead 
contains protein A, an appropriate antibody and its target protein.  The AlphaScreen relies 
on the conjugation of proteins to the functional groups of hydrogel coated donor and 
acceptor beads. Excitation (680 nm) of photosensitizers present on the donor bead results in 
the production of singlet oxygen. If the acceptor bead is brought into close proximity (within 
~ 200 nm) to the donor by the formation of a protein-peptide complex the singlet oxygen 
will react with thioxene derivatives on the acceptor bead generating chemiluminescence at 
370 nm. Energy transfer to fluorescent acceptors in the same bead shifts the emission to 
520-620 nm.  
 5µl of protein A beads were added to 0.6ml of envision buffer + 1.25ml of GST-
mAb and wrapped in foil.  In another Eppendorf 5ml of streptavidin coated beads were 
added to 0.6ml of envision buffer and foil wrapped.  A 96 well plate (Cornstar) was 
blocked with 3% BSA.   
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 Peptides were prepared in 10µl of envision buffer as such that when diluted to 
50µl they will be at desired concentration.  20µl of streptavidin coated beads prepared as 
described were added to each tube and left to incubate for 1 hr in the dark.  20µl of 
protein A coated beads + GST-Ab was added to tubes and transferred to the 96 well 
plate (which was washed 3x in PBST).  The plate was covered and allowed to incubate 
for 1 hr with gentle agitation in the dark.  The plate was then read on an Envision 
fluorescence detector (Perkin Elmer).        
 
2.8.5 Dual Luciferase Reporter Assay  
 
Human Lung Carcinoma H1299 cell line was seeded onto 24 well plates. Upon reaching 
80-90% confluency the cells were transfected by means of lipofectamine™ 2000 
(Invitrogen) reagent with the total amount of DNA for all wells kept constant at 0.8 µg.  
In all experiments focusing on transcriptional potential of desired proteins an optimised 
ratio between the ‘experimental’ reporter and the ‘control’ reporter has been set up in 
order to minimize unspecific in trans effects between promoters of cotransfected 
plasmids. Thus (30ng) pGL4.10[luc2] bearing a 44base stretch of the p21 promoter 
(‘experimental’ reporter) was mixed with 70ng of the phRL-CMV (‘control’ reporter). 
To this mixture 150ng of the pcDNA3.1 p53wt or pcDNA3.1 p53F19A, 7.5-550ng 
pDEST-3.2 MDM2S17D or MDM2D17S, MDM2S17N, MDM2S17A, MDM2S17N, 
MDM2R97S:K98P, MDM2S237F, or MDM2F240K were added.  The DNA mixtures, with 
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appropriate controls were made up accordingly for each well to be transfected with the 
addition of pcDNA3.1 empty vector  the make up the 0.8µg total DNA  were necessary.  
Twenty four hours post transfection, the cells were washed once in ice-cold PBS 
and passively lysed with 1x Passive Lysis Buffer (supplied with the Dual-Luciferase® 
Reporter Assay System from Promega) Afterwards the Dual-Luciferase® Reporter Assay 
System supplied by Promega, was performed in accordance to the technical manual 
supplied with the kit.  The assay was carried out on 96 well black polypropylene plates 
and the luminescent signals were measured with the Thermo Scientific Fluoroskan 
Ascent Multimode Reader.   
 
2.8.6 Immunoprecipitation protocol 
 
Lysis Buffer 
50mM HEPES pH 7.2 
150mM NaCl 
0.5%Tween20 
Protease Inhibitor mix (10x) 
 
Cell pellets were resuspended in 200ml of ice cold lysis buffer mixed well and incubated 
on ice for 15 minutes.  Cell debris was spun down at 10000 rpm for 20 minutes at 4oC.  
Lysate was pre-cleared with 100µl of sephadex CL-4B beads (Sigma-Aldrich).  Beads 
were washed 3x in cold lysis buffer.   The beads were added to the cell lysate in a 1.7ml 
Eppendorf and incubated for 40 minutes at 4oC with rotation. The beads were spun down 
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at 5000 rpm and supernatant transferred to a new Eppendorf and protein concentration 
was calculated by bradford. 
 2µg of 2A10 antibody was added to lysate (200-800 µg) and incubated for 2 hrs 
at 4oC with rotation.  15µl of protein G beads (GE healthcare) were added to Eppendorf 
and left to incubate for an hour.  The beads were spun down at 5000rpm at 4oC for 2 
minutes.  Beads were washed 4x with ice cold PBS.   
 The antibody-antigen complex was removed by the addition of 50µl of sample 
buffer followed by incubation at 95oC for 5 minutes.  Beads were spun at 10000 rpm for 




ProtoArrays® were performed to manufacturers guidelines.  Briefly, 500 nM of MDM2 
was diluted in probing buffer (PBS, 5mM MgCl2, 0.5mM DTT, 0.05%Triton X-100, 5% 
glycerol, 1% BSA) for 2 hrs.  The array was washed 3x 10 mins in probing buffer before 
adding the primary antibody 2A10 for 1 hr. Array was then washed a further 3x in 
probing buffer followed by AlexaFluor-rabbit anti-mouse secondary antibody was added 
for 1 hr.  Array was washed 3x with probing buffer followed by analysis. 
Imaging of the protoarrays are carried out using Scan Array Express from Perkin 
Elmer. Scan array settings for imaging Alexa647 arrays: Laser 633nm, Alexa647 filter 
sets, Laser power 75%, PMT 45, Resolution 10 µm. The pmt gain and laser power is 
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specific to each fluorophore.  Data processing was carried out using BlueFuse software. 
The Bluefuse software (originally developed for 2 channel or two colour DNA arrays) is 
adapted for data processing of protoarrays.    
Data processing on the bluefuse involves grid alignment of array to the GAL file 
(to locate each protein position to its subsequent reference number. Quantitation is then 
carried out, with each spot being assigned a FLAG confidence score. The flag score is a 
measure of confidence in interaction depending on the spot intensity, shape and 
integrity. Bluefuse uses an "advanced statistical modelling technology".  Bluefuse then 
generates an output file with each spot matched to its reference number. Next, simple 
perl script written by Dr. Karl Burgess (Strathclyde University) is then used to for data 
sorting. The perl script matches the protein reference number to its full protein name to 
allow easy identification of  protein spots with its corresponding score to the protein ID.  
 
2.9 Antibody Production 
 
2.9.1 Immunisation protocol 
 
Four BALB/C mice were used for immunization.  On day one an  intraperitoneal 
injection of 10-50 µg of phospho peptide coupled to KLH in complete Freunds adjuvant 
was carried out.  This is repeated on day 21 but this time in incomplete Freunds 
adjuvant.  At this point tail bleeds are collected and screened  against the peptide in a 
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dot-blot.  Another intraperitoneal injection is carried out at day 42 also in incomplete 
Freunds adjuvant.  Tail bleeds were once again collected and screened against the 
peptide in a dot-blot.  On days 45 and 46 two intraperitoneal injections of KLH coupled 




Culture Media  
DEM Media 1000mg/ L glucose      400 mL 
Penicillin & Streptomycin   1%               5 mL 
FBS        10%                   50 mL 
200nM Glutamine    1%          5 mL 
 
Fusion Media (w/o FBS)         
DEM Media 1000mg/ L glucose      450 mL 
Penicillin & Streptomycin  1%                  5.5 mL 
 
AH Media (SIGMA A9666) 
DEM Media 1000mg/ L glucose      400 mL 
Penicillin & Streptomycin  1%                                 5 mL 
FBS        20%      100 mL 
200nM Glutamine    1%          5 mL 
Lyophilized AH (Azaserine-Hypoxanthine, 50x, -irradiated, Sigma A9666) 1x 1 vial 
 
 
The spleens were remove from the mice into a sterile petri dish and cleaned of all fats.  
The spleen was then washed with fusion media outside then fusion media was injected 
into the spleen multiple times to wash out the splenocytes.  The splenocytes were then 
transferred to a 50ml falcon and left to settle to the bottom.  The Petri dish was washed 
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with more fusion media and transferred to a 50ml falcon tube.  Six dishes of 60% 
confluent myeloma cells were then resuspended in 4 falcon tubes each containing 40ml 
of media.  The splenocytes were spun down for 10min at 1000rpm at room temperature.  
The media was then removed leaving a small volume to loosen the pellet.  35ml of fresh 
fusion media was added to one tube and the splenocytes were resuspended before 
pooling it with the second tube of splenocytes.  These were spun down as before and the 
media removed leaving a small volume to resuspend the cells in. The myeloma cells and 
splenocytes were mixed in ratio 5 splenocytes : 1 myeloma SP2 cells in 40 ml of Fusion 
media in falcon tubes.  The cells were then spun down for 7 minutes at room 
temperature and each falcon tube was resuspended in 50ml of AH media.  50µl of fusion 
cells was added to each well in 15 96 well plates.  After three days 50 ml fresh AH 
media was added to the wells and after seven days 200ml of AH media was added.  
Screening begun after day 11, hybridomas that were growing well were picked for 
screening.  Hybridomas were check and screened daily for two weeks.      
 
2.9.3 Dot Blot 
 
20 µg of either rabbit anti mouse Ig (RAM) or phospho peptide (coupled to BSA) in 
PBS were bound to nitrocellulose membrane for 2 hrs at 37oC.  The membranes are 
blocked with 10% fetal calf serum (FBS) in DMEM for 2 hrs at room temperature.  For 
screening 2ml of supernatant from each tested hybridoma or tail bleed was added onto a 
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labeled spot on the both membranes, Ig and peptide, followed by a 2 hr incubation.  
Membranes were washed 3x in PBS for 5 minutes and incubated with rabbit anti mouse 
secondary antibody diluted 1:100 in DMEM plus 10% FBS.  The membranes were then 
washed 3x in PBS for 5 minutes before developing with 1, 4-chloronapthol (Sigma-















THE ROLE OF THE ACID DOMAIN IN MDM2 CATALYZED 




p53 is a sequence specific DNA binding protein that functions as a transcription factor 
activating target genes involved in DNA repair or apoptosis after cellular stress or insult 
(Harris and Levine, 2005).  Four distinct E3-ligases negatively regulate p53 activity: 
MDM2, Pirh2, COP-1, and CHIP (Brooks and Gu, 2006), by ubiquitination and 
degradation via the proteasome.  p53 can also be positively regulated via the 
transcriptional co-activator p300, thus the p53 pathway is controlled by the fine balance 
between p300-stimulated acetylation and E3-ligase catalyzed ubiquitination (Shimizu 
and Hupp, 2003). 
 MDM2 exerts its negative effect on p53 in two distinct ways, firstly by 
competing with p300 for binding to the N-terminal transactivating domain and secondly 
by repressing p53-dependent gene transcription (Arva et al., 2005).  Mutations within 
the p53 transactivation domain can lead to p53 mutants which can escape MDM2 
mediated transrepression (Lin et al., 1994).  Alternatively MDM2 acts as an E3-ubiquitin 
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ligase and facilitates the ubiquitination and subsequent degradation of p53 (Michael and 
Oren, 2003).  Nuclear magnetic resonance (NMR) studies have highlighted the 
flexibility of the MDM2 hydrophobic pocket and substantial conformational changes are 
observed upon ligand binding (Schon et al., 2004).  The drug Nutlin, which was 
designed to mimic the p53 activation domain, can disrupt MDM2-p53 interactions in 
cells leaving large pools of active p53 (Vassilev et al., 2004). 
The mechanism of MDM2-catalyzed ubiquitination of p53 is largely undefined, 
but there is an intrinsic conformational restraint to ubiquitination of the native p53 
tetramer which is relieved when the tetrameric structure is distorted upon MDM2 
binding.   The binding site on protein targets required for ubiquitination is often referred 
to as the ‘ubiquitination signal’ and can be composed of a simple linear stretch of amino 
acids or a more complex signal comprising a conformational sensitive motif (Laney and 
Hochstrasser, 1999).  In many cases, the ubiquitination signal for a given E3-ligase is 
poorly or incompletely defined as is the case with p53.   
The conventional point of contact between MDM2 and p53 is through the 
transactivation domain in p53 and the hydrophobic pocket of MDM2.  This chapter 
looks at a second contact site within MDM2 and p53 and its role in the ubiquitination of 
p53.  The results presented are focused on the role of the MDM2 acid domain and p53-
BOX-V interactions and were studied using AlphaScreen, circular dichroism and mass 
spectroscopy.  They form part of a larger piece of research that identified the mechanism 
whereby MDM2 catalyzes the ubiquitination of p53 and this will eluded to further in the 





3.2.1 Cloning and purification of GST-tagged full length MDM2 and acid domain 
MDM2 
 
In order to investigate the importance of the acid domain in MDM2 mediated 
ubiquitination of p53, we generated mutant forms of MDM2 to study the biochemistry it.  
These included full length (FL) MDM2, delta N-terminus (∆N) MDM2, delta acid 
domain (∆AD) MDM2 and acid domain only MDM2 (AD).  
Full length GST-MDM2 and GST-Acid Domain were cloned into pDEST15 as 
described in materials and methods.  PCR of full length MDM2 generated a product with 
an approx size of 1500 bp which corresponds to the actual size of the MDM2 open 
reading frame (ORF) (1473 bp) (Fig 3.1 lanes 2 and 3).  PCR amplification of the acid 
domain  of MDM2 generated a product of around 200 bp in size which  corresponds to 
size of acidic domain (Fig 3.1 lanes 5 and 6).  PCR Fragments were ligated into 
pENTR11 as described in materials and methods, then using homologous recombination 
were inserted into the pDEST15 vector for GST-tagged expression of protein in 
Esherichia coli. 
GST-tagged AD, FL, ∆AD (gift from Aart Jochebson) and ∆N were cloned as 
described in materials and methods.   MDM2 constructs were all expressed in BL21 AI 
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cells, and purified using glutathione sepharose 4B beads.  Analysis of purified GST-
MDM2 AD by coomassie staining showed a strong band with an approx molecular mass 
of 31 KDa and immunoblot of the same fraction using an MDM2 specific antibody 
(2A10) confirmed this band to be MDM2 AD (Fig 3.2A lanes 1-4).  Full length MDM2 
purified to a lesser extent as shown in figure 3.2B lanes 1 and 2 by a faint band at 125 
kDa by coomassie stain but more evident when imunoblotted with 2A10 (Fig 3.2B lanes 
3 and 4).  Purification of ∆AD resulted in a band around 90 kDa which was confirmed as 
∆AD (Fig 3.2C, lanes 1-4).  Finally ∆N MDM2 was purified giving just one band 
around 97 KDa in size (Fig 3.2D, lanes 1 and 2). 
 
3.2.2 Classic MDM2 binding ligands do not block ubiquitination of p53 
 
Many proteins targeted for ubiquitination contain a ubiquitination signal which promotes 
the target proteins ubiquitination through contact with the E3 ligase.  In p53 it was 
thought to involve the N-terminus.  In order to study the interactions we used peptides 
from the N-terminus and the BOX-V region of p53.  These peptides were added to a 
ubiquitination reaction containing p53, MDM2, E1, E2, and ATP and the ability of 
MDM2 to ubiquitinate p53 was analysed by western blot.  Ubiquitination of p53 is 
observed as a ladder of high molecular weight forms of p53. 
Peptide aptamers targeting the N-terminal hydrophobic pocket of MDM2 such as 
BOX-I, 12.1 (an optimized BOX-I) and the drug Nutlin are incapable of inhibiting 
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MDM2 mediated p53 ubiquitination (Figure 3.3 A,B lanes 1-12, and C,  lanes 1-7).  
Titrations of increasing concentrations of BOX-I, 12.1 and Nutlin (3-50µM) showed 
little change in MDM2 ubiquitination towards p53 Figure 3.3 A, B lanes 1-12, and C,  
lanes 1-7).  The results presented above suggest that the BOX-I domain of p53 alone is 
not sufficient to form the ubiquitination signal for p53 as blocking this interaction with 
peptide aptamers or drugs is insufficient to inhibit p53 ubiquitination by MDM2.  Thus, 
alternative interaction sites out with the N-terminal activation domain of p53 most likely 
comprise the ubiquitination signal for MDM2 targeting.  It is surprising that Nutlin 
failed to inhibit MDM2 E3-ligase activity in vitro as it has previously been shown that 
Nutlin-treated cells accumulate transcriptionally active p53 protein (Vassilev et al., 
2004).   We also show an increase in p53 ubiquitination after treatment of A375 with 
Nutlin, highlighting that blocking the N-terminal interactions between MDM2 and p53 
is insufficient to inhibit p53 ubiquitination, and actually stimulates p53 ubiquitination 
(Fig 3.3D).  
Peptides from the core domain of p53, which are contiguous with the S9-S10 
linker motif previously shown to control p53-MDM2 binding (Shimizu et al., 2002), 
capable of inhibiting the ubiquitination of p53 were identified by a chemical genetics 
screen (Wallace et al., 2006).  These peptides mapped to the BOX-V region which is 
within the core DNA binding domain of p53.  A separate study identified a peptide from 
the RB-MDM2 interface, Rb1, which showed homology to the S9-S10linker/BOX-V 
region of p53.  Further investigation showed both peptides were able to inhibit 
ubiquitination of p53 yet with very different potencies.  The BOX-V peptide inhibits 
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MDM2 E3-ligase activity with an I0.5 in the range of 20–30 M (Fig 3.4, lanes 9-13) 
whilst  Rb1 titrations showed that it had a 100-fold lower I0.5 than the BOX-V peptide 
(Fig 3.4, lanes 4-8).  Ubiquitination assays were performed at three different time points 
in order to elucidate any subtle differences in ability of peptides to interfere with 
ubiquitination which might indicate differences in binding properties (Fig 3.3A, B, and 
C).  At 7 minutes incubation, both peptides were able to inhibit p53 ubiquitination to the 
same extent (Fig 3.4A Rb1: lanes 4-8, BOX-V: lanes 9-13 compared to lane 3).  
However after 10 minutes, the BOX-V peptide can be seen to have reduced inhibitory 
effect at 10 and 20 µM concentrations against equivalent 0.25 and 0.5 µM of Rb1 (Fig 
3.4B, Rb1: lanes 4-8, BOX-V: lanes 9-13 compared to lane 3).  Finally, after 15 minutes 
incubation, strong ubiquitinated forms of p53 are observed in the presence of the BOX-
V peptide whereas the Rb1 peptide still maintains a substantial inhibition of p53 
ubiquitination as observed by the lack of high molecular weight ladder. (Fig 3.4C  Rb1: 
lanes 4-8, BOX-V: lanes 9-13 compared to lane 3).   
This data provides evidence for two interesting aspects.  Firstly that the Rb1 
peptide is a more potent inhibitor of MDM2 mediated p53 ubiquitination than the BOX-
V peptide and secondly that the BOX-V seems to bind with a lower affinity to MDM2 or 
has a higher rate of dissociation from MDM2 than Rb1 and as such is less potent and so 




3.2.3 Rb1 and BOXV peptides bind the acidic domain of MDM2 by AlphaScreen 
 
The interaction between Rb1 and MDM2 was mapped using multiple mutant protein 
forms by ELISA and AlphaScreen (Wallace et al 2006).  This data identified the acid 
domain as a possible site of contact within MDM2 as only recombinant protein 
containing the acid domain showed any binding to the peptide.  Given that Rb1 was 
identified by showing homology to S9-S10linker/BOX-V region it was hypothesized 
that the BOX-V peptide may also bind to the acid domain of MDM2.   
To complement the above experiments, an MDM2 acid domain deletion mutant 
protein (AD) was expressed and purified from E. coli (Fig 3.2C).  When binding of the 
AD to Rb1, BOX-V or BOX-I was compared with binding of the isolated acid domain, 
the results were complementary. BOX-V and Rb1 bound to the acid domain of MDM2 
with high affinity but not to the AD protein where binding was no greater than the 
control peptide (Fig 3.5A and C), whereas BOX-I did not bind to the acid domain but 
bound to the AD protein (Fig 3.5B) 
This data highlights the acid domain as being the site of contact for the BOX-V 
peptide of p53 as well as confirming that the Rb1 peptide bound the acid domain.  
Although previous studies had identified a second interaction within MDM2 and p53 




3.2.4 Purification of cleavable 6xHis tagged acid domain for biophysical studies 
 
  Untagged acid domain MDM2 was required to perform circular dichroism and 
mass spectroscopy.  GST is known to form dimers so in order to draw any conclusions 
from CD and Mass spectroscopy the tag needed to be removed from MDM2.   To 
achieve this, the acid domain of MDM2 was cloned into the pET-15b vector to express it 
as a His-fusion protein.  This vector contains a thrombin cleavage site between the tag 
and the protein which permits the cleavage of the tag from the recombinant protein 
following expression and purification.   
To begin with the construct was expressed in E.coli and purified using Nickel 
agarose affinity chromatography (Fig 3.6A).  A high degree of protein purity is needed 
for biophysical studies so the purified His tagged MDM2 was further purified using Ion 
exchange chromatography to achieve this high degree of purity.  The peak fractions 
from nickel agarose purification (4-9) were loaded onto a HiTrap FF-monoQ column 
and bound proteins were eluted using a salt gradient from 0-1M.  Samples were 
collected and resolved by SDS PAGE and analysed by coomassie staining (Fig 3.6B). 
His-AD showed a long elution profile from fractions 6-21.  Peak fractions (15-22) were 
pooled and concentrated using Centricon centrifugal filter devices with a molecular 
weight cut off of 3 KDa.  The His tag was then cleaved from the concentrated AD using  
RECOMT Sigma Thrombin CleanCleaveTM kit (Fig 3.6C).  Comparing cleaved and 
uncleaved his-AD shows cleavage was 100% successful (Fig 3.6C, lanes 1 and 2).  The 
free His tag was then removed from the prep by passing the mix over nickel agarose 
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beads to bind the His tag.  The flow through contained pure untagged AD and this was 
used in further biophysical studies (Fig 3.6C lane 3). 
 
3.2.5 Far-UV  circular dichroism (CD) analysis of human MDM2 acidic domain 
interaction with BOX-V peptide 
 
The BOX-V peptide has been previously shown to bind to the acidic domain of MDM2 
using AlphaScreen, but this technique can not be used to examine effects of peptide 
binding on induced structural changes.  Circular dichroism (CD) in the far-UV range 
however, can be used to estimate the secondary structure content of a sample of MDM2.  
Far-UV CD was used to investigate the hypothesis that changes within the secondary 
structure of MDM2 accompany peptide binding to the acidic domain of human MDM2. 
CD spectra in the far UV range (190 - 250 nm) of recombinant AD protein only, BOX-V 
peptide only and AD plus BOX-V were measured. 
CD spectra are additive, so changes in secondary structure caused by protein 
interaction can be by assessed by calculating a difference spectra [(Protein + peptide) - 
peptide] and comparing it to protein alone.   AD alone has a spectra characteristic of a 
random-coil (disordered) conformation, dominated by large negative band at 200 nm 
(Fig 3.7 Yellow). Analysis of the data with CDSSTR, an algorithm for deconvoluting 
the CD spectra into its contributing secondary structures, predicts a protein with 
approximately 10 % helix, 30 % sheet, 25 % turn and 35 % disordered. 
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The BOX-V and BOX-V + AD spectra also are characteristic of a random-coil. 
The difference spectra [(AD + BOX-V) – BOX-V] and protein spectra are super-
imposable suggesting no coupled binding-folding event (Fig 3.7 Green). 
 
3.2.6 Mass-Spectrometry confirms BOX-V and Rb1 bind the acidic domain 
 
To further characterize the interactions between the AD and BOX-V and Rb1 peptides, 
MDM2 acid domain – peptide mass spectrometry was performed to determine whether 
stable protein/peptide complexes could be detected. Direct infusion electrospray 
ionization mass spectrometry (ESI-MS) was performed to analyse the native AD. 
 Ionization conditions were optimized to retain any solution formed complexes. MDM2 
acid domain showed a small peak which indicated the acid domain could form a dimer 
(Fig 3.8A).  When acid domain was analyzed in presence of the BOX-V peptide the 
overall charge state of the acid domain shifted from 5+ to 4+ states with complex 
formation between a dimer of peptide and monomer of acid domain being observed (Fig 
3.8B-upper spectra compared to lower spectra).   
Analysis of the ESI-MS spectra of AD in the presence of Rb1 peptide showed 
similar binding characteristics to AD/BOX-V, with a reduction in charge state of 
predominantly 5+ to 4+ (Fig 3.8C-upper spectra compared to lower spectra) and a small 
complex formation between a dimer of Rb1 and monomer of MDM2 acid domain (Fig 
3.8D).   
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During the course of the ESI-MS analysis it was found that BOX-V or Rb1 
multimers were present in solution (data not shown) and so the resulting peptide dimer-
MDM2 complexes are not thought to result from non-specific binding or binding formed 
during the desolvation process. The fact that peptide-MDM2 complexes are still 
observed in the presence of such dimers suggests the peptide dimerization does not 
affect the protein interface but binding it is weak so little is retained. 
  
3.2.7 The N-terminus and acidic domain of MDM2 are required for 
ubiquitination of p53 
 
After verifying that the BOX-I peptide bound to the N-terminus of MDM2 and the 
inhibitory peptides, Rb1 and BOX-V bound to the acid domain of MDM2 we went on to 
examine whether these two domains within MDM2 are essential for ubiquitination of its 
substrates.    GST-MDM2 is fully functional in catalyzing the ubiquitination of p53 in 
vitro (Fig 3.9A, lanes 1-5).  When the first 120 amino acids of MDM2 encompassing the 
hydrophobic pocket, are removed its ability to target and ubiquitinate p53 is lost (Fig 
3.9A, lanes 6-10).    The acid domain also proved crucial to MDM2s’ E3-ligase 
properties as ∆AD could no longer catalyze p53 ubiquitination (Fig 3.9B lanes 5-7 
compared to lanes 2-4).  
 These studies show that the N-terminus and the acid domain are crucial 
components of MDM2 for it to function as an E3 ligase. 
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3.2.8 The BOX-V region of p53 is required for ubiquitination 
 
Having identified the BOX-V region of p53 as a second contact site for the MDM2 acid 
domain, the requirement of the BOX-V site was analyzed.  A naturally occurring 
isoform of p53 which lacks the BOX-V region, called ∆BOX-Vp53, was expressed and 
purified as a GST fusion protein in insect cells and was purified using GST affinity 
chromatography (Fig 3.10A lanes 6-10).  As a control for ubiquitination experiments, 
GST-wtp53 was also expressed and purified in the same way (Fig 3.10 lanes 1-5).  The 
concentration of p53 protein forms were normalized by western and Bradford and 
equivalent concentrations of p53 were mixed with purified MDM2 in an in vitro 
ubiquitination reaction.  While MDM2 can still catalyze ubiquitination of GST-wtp53, it 
was unable to ubiquitinate the p53 form lacking the BOX-V region, highlighting the 
requirement of this site for efficient ubiquitination of p53 by MDM2.  This isoform is 
still transcriptionally active, suggesting it may have evolved to avoid proteasomal 




The oncoprotein MDM2 is a key negative regulator of the p53 tumor-suppressor protein 
and can regulate the activity of p53 by two distinct mechanisms.  First, MDM2 can 
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function as a transcriptional repressor of p53 that inhibits p53’s activity by preventing 
recruitment of transcriptional co-factors (Arva et al., 2005).  However, it is the second 
function of MDM2 as a regulator of p53 protein degradation that has excited the most 
interest in recent years.  MDM2 acts as an E3-ubiquitin ligase for p53, promoting its 
nuclear export and proteasome-dependent degradation (Brooks and Gu, 2006). 
In contrast to the mechanism of ubiquitin transfer, defined by the classic E1-E2 
conjugation reactions, the mechanism of MDM2-catalyzed ubiquitination of p53 and the 
mechanism of action of RING E3-ligases in general is largely undefined. The E3-ligase-
catalyzed reaction involves at least two distinct steps: E3 recognition of the substrates' 
“ubiquitination signal” and covalent ligation of one or more ubiquitin moieties to the 
substrate (Pickart, 2001).  The accepted view, based on available evidence, was that 
MDM2-mediated ubiquitination of p53 proceeded through binding of the MDM2 N-
terminal domain to a BOX-I ubiquitination signal in p53.  This view was supported by 
the finding that mutation of a single phenylalanine residue in the BOX-I domain of p53 
prevented MDM2-mediated stabilization of p53 and that a BOX-I mimetic could inhibit 
formation of a stable p53-MDM2 complex (Bottger et al., 1997; Lin et al., 1994; Liu et 
al., 2001; Vassilev et al., 2004). However, this finding is complicated by the observation 
that BOX-I mimetics, including Nutlin, do not inhibit MDM2 E3-ligase activity and 
efficient ubiquitination of p53 still occurs in their presence (Fig 3.3A, B and C).  If, as 
previously assumed, the BOX-I domain of p53 contained the primary ubiquitination 
signal for MDM2 targeting, molecules like Nutlin and the 12.1 peptide would be 
expected to block its ubiquitination by MDM2.  Nutlin was identified in a screen for 
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MDM2 agonists that fit into MDM2s hydrophobic pocket (Vassilev et al., 2004) and 
therefore competes with the p53-BOX-I domain for binding to MDM2.  During this 
work it was shown that although Nutlin is able to disrupt the interaction between the N-
terminal domain of MDM2 and the BOX-I transactivation domain of p53 (Wallace et al., 
2006), it does not inhibit MDM2-dependent ubiquitination of p53 (Fig 3.3C). In 
addition, when the status of endogenous p53 was examined in A375 cells treated with 
Nutlin, we found that the accumulation of transcriptionally active p53 protein was 
associated with an increase in modified forms of the p53 protein (Fig3.3D). 
 The concept that an MDM2 docking site other than the BOX-I motif of p53 
could be involved in p53 ubiquitination was originally suggested by studies showing that 
ribonucleic acid can induce binding of MDM2 to p53 lacking the BOX-I domain (Burch 
et al., 2000).  A motif within the BOX-V domain is a candidate for this p53 
ubiquitination signal, as a peptide from this region can inhibit ubiquitination with an I0.5 
of between 20 and 30 M (Fig 3.4A, B and C).  These data are consistent with a 
previous report identifying the BOX-V region as a conformationally flexible docking 
site for MDM2 that could control p53 ubiquitination in cells (Shimizu et al., 2002).  The 
data presented here goes further and highlights a secondary contact site between the acid 
domain of MDM2 and the BOX-V peptide of p53 (Fig 3.5A, B and C).   Furthermore, 
deletion of the N-terminus or the acid domain of MDM2 abolishes its ability to function 
as an E3-ligase, demonstrating that both of these contact sites are required for MDM2 to 
catalyze ubiquitination of p53 (Fig 3.8A and B).  In support of this conclusion, removal 
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of the BOX-V region of p53 results in a p53 protein refractory to ubiquitination by 
MDM2 (Fig 3.9A and B). 
 Biophysical techniques, such as circular dichroism (CD), failed to detect any 
ligand binding induced changes in the structure to the acid domain of MDM2.  In fact 
binding between the acid domain and the BOX-V peptide was not detected.  One 
conclusion that can be drawn from the spectra is that the MDM2 acid domain shows a 
random-coil (disordered) conformation.  This data supports previous work which 
suggests that the acid domain is unstructured (Bothner et al., 2001).  In fact this same 
work showed structural changes in the acidic domain occur upon ligand binding, 
focusing in particular on the interaction between MDM2 acid domain and ARF.  Using 
ARF peptides they demonstrated induced structural changes within MDM2 upon ligand 
binding, from disordered, random conformations to β-strand secondary structures 
(Bothner et al., 2001).  These β-strand structures have been predicted to occur within the 
acid domain using secondary structure prediction programmes.   
One possible explanation for our lack of observed change in MDM2 structure in 
the presence of BOX-V may be due to the poor solubility of the BOX-V peptide in 
water, required for CD analysis.  Further detailed investigations using peptides with 
higher affinity for MDM2 may reveal certain induced conformational changes within the 
E3 ligase, but as this was not the main focus of my project, this work was put to one 
side.   
 Mass spectrometry analysis of MDM2 acid domain/ BOX-V and Rb1 
interactions supported the findings obtained from AlphaScreen and confirmed  the 
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interaction between the BOX-V and Rb1 peptides with MDM2 acid domain.   The 
observation that the acid domain dimers diminish in the presence of peptide could have 
some relevance to acid domain function.  It is widely believed that MDM2 functions as a 
homodimer, or heterodimer with MDM4, dimerizing through their ring finger domains 
(Linke et al., 2008; Tanimura et al., 1999; Uldrijan et al., 2007). This dimerization could 
bring the acid domains into contact which each other, and this contact could become 
distorted upon ligand binding.  
The discovery that the BOX-V domain of p53 forms part of the ubiquitination 
signal within p53 and its regulation by the acid domain of MDM2 formed a major part 
of a piece of research published in Molecular Cell in 2006 entitled Dual-Site regulation 
of MDM2 E3-ubiquitin ligase activity (Wallace et al., 2006).  This paper proposed a 
model where by the binding of the N-terminus of p53 to the hydrophobic pocket of 
MDM2 induces a conformational change within MDM2 allowing binding to occur 
between the acid domain of MDM2 and the ubiquitination signal (BOX-V) of p53,  thus 
facilitating the MDM2 catalyzed ubiquitination of p53 (Fig 3.11).  This model was 
tested by the use of a mutant form of p53 called p53F19A that is normally refractory to 
ubiquitination by MDM2 due to the fact that it can no longer bind the N-terminus of 
MDM2.  If this model were true, addition of peptides or drugs that occupy the 
hydrophobic pocket should ‘prime’ MDM2, allowing the acid domain to form a contact 
with the BOX-V region of p53 and facilitate its ubiquitination. This proved to be the 
case as adding in trans BOX-I, 12.1 or Nutlin in trans induces the ubiquitination of this 
mutant p53 (Wallace et al., 2006).      
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At least one ubiquitination signal is therefore located within the DNA binding 
domain of p53, and access to this signal sequence is regulated through p53-BOX-I 
interactions with MDM2.   NMR analysis has also shown that the acid domain of 
MDM2 can bind directly to the DNA binding domain of p53 (Yu et al., 2006b). The 
acid-domain fragment of MDM2 induced significant chemical shifts within DNA-
contact residues within the p53 BOX-V region.   Together, these data suggest that 
MDM2 has an allosteric pocket in the N terminus that requires to be occupied in order to  
dock onto the ubiquitination signal in the BOX-V domain of p53.  This docking may 
then distort the overall conformation of the DNA binding domain of the p53 tetramer 
and permit E2-catalyzed ubiquitin transfer.   
A vast majority of drugs designed to stabilize p53 in cells are modeled to fit 
within the MDM2 hydrophobic pocket.  It may be that drugs targeting this second 
interaction may prove to be better, anti-cancer agents by inhibiting the cellular 























PHOSPHO-MIMETIC MUTATION IN THE MDM2 LID 
ACTIVATES MDM2 E3-LIGASE FUNCTION 
 
4.1  Introduction 
 
MDM2 has been dissected into multiple mini-domains with specific biochemical 
functions: an N-terminal allosteric hydrophobic pocket which interacts with specific 
linear peptide motifs in proteins such as p53 (Kussie et al., 1996); an internal acidic 
domain that binds a range of substrates (Yu et al., 2006a), a C-terminal RING domain 
that co-ordinates E2 functions in ubiquitin transfer (Linke et al., 2008) and promotes 
MDM2-dependent stimulation of p53 protein synthesis (Candeias et al., 2008), an ATP-
binding motif imbedded within the RING domain that regulates chaperonin functions of 
MDM2 (Wawrzynow et al., 2007), and a C-terminal peptide tail that maintains RING 
domain conformation (Poyurovsky et al., 2007) (Uldrijan et al., 2007). Reconstitution of 
the ubiquitin ligase function of MDM2 using purified proteins has demonstrated a two-
site docking model for ubiquitination of p53 (Wallace et al., 2006).  This involves 
occupation of the N-terminal hydrophobic pocket by a priming ligand (natural sequences 
in proteins like p53 or drug leads like Nutlin) that induces a docking event between the 
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acidic domain of MDM2 and a ubiquitin-signal in the DNA-binding domain of p53 (Yu 
et al., 2006a) (Wallace et al., 2006).  It is known that this dual-site docking catalyzes the 
ubiquitination of p53, however the details of the conformational changes that mediate 
this reaction have yet to be defined.  
One of the intriguing features of the dual-site model for MDM2 function is that 
its N-terminal hydrophobic pocket requires a ligand to prime and stimulate the E3 ligase 
function of MDM2 (Wallace et al., 2006).  Prior to these studies, it was thought that 
ligands that bind to this pocket in MDM2 would block its ubiquitination function; indeed 
such ligands do block MDM2 activity in relation to its transrepression of p53 (Vassilev, 
2004). This dual-site model for MDM2 function is also compatible with the allosteric 
nature of MDM2 as further evidenced by the flexibility of the N-terminal hydrophobic 
domain in the presence of distinct peptide-ligands (Schon et al., 2004; Uhrinova et al., 
2005).  In order to test the dual-site model of MDM2 docking to p53, the contribution of 
a flexible N-terminal peptide motif adjacent to the hydrophobic pocket of MDM2 was 
examined.  This peptide lid (aa12-25) has a significant degree of homology to the p53-
activation domain fragment (aa10-26), suggesting that it might be able to compete in cis 
for binding with p53 and act like a pseudo-substrate domain (Fig 4.1A). However, as 
ligands like Nutlin that fill the hydrophobic pocket can stimulate MDM2 E3 ubiquitin 
ligase function (Wallace et al., 2006), the role of the pseudo-substrate motif is not 
necessarily evident - would it function as a positive or negative cofactor in regulating the 
stability of the MDM2:p53 complex?  
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Multiple sequence alignment of MDM2 and MDM4 reveals the evolutionary 
divergence between MDM2 homologues and the paralogue MDM4 at the pseudo-
substrate motif (aa 16-23). (Fig 4.1B)  MDM4 has evolved without the presence of a lid 
highlighting its specific roles within MDM2. 
In this chapter, I show that the phospho-mimetic lid surprisingly stabilizes the 
MDM2:p53 complex through an allosteric model which is consistent with the pseudo-
substrate motif functioning as a positive regulatory motif.  This model is consistent with: 
(i) the dual site docking function of MDM2 (Wallace et al., 2006), (ii) the intrinsic 
flexibility of the N-terminal domain of MDM2 (Schon et al., 2004; Uhrinova et al., 
2005), and (iii) the ability of the phospho-mimetic pseudo-substrate motif to change the 
conformation of MDM2 (McCoy et al., 2003). The gain-of-function effect on MDM2 
induced by pseudo-substrate motif mutation has implications for how the MDM2:p53 
axis can be regulated post-translationally in cells and for strategies aimed at inhibiting 




4.2.1 MDM2 lid forms a positive regulatory motif 
 
In order to further evaluate the dual-site docking model of MDM2 function, the effects 
of the pseudo-substrate motif or ‘lid’ on the E3 Ubiquitin ligase function of MDM2 were 
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evaluated. Complimenting the model where a phospho-mimetic pseudo-substrate motif 
occupies the hydrophobic binding pocket of MDM2 (McCoy et al., 2003), an NMR 
study of the unliganded apo-form of the N-terminal domain of MDM2 revealed the 
pseudo-substrate motif to be largely unstructured (Uhrinova et al., 2005).  To clarify the 
role of this flexible motif, purified untagged wild-type MDM2 and MDM2 mutants were 
generated, including a mutant with an N-terminal flexible pseudo-substrate motif 
deletion (MDM2∆lid).  Proteins were purified from E.coli using HiTrapFF SP affinity 
chromatography (Fig 4.2A, B and C).   MDM2WT, MDM2∆lid and MDM2S17D eluted over 
a wide peak around fractions 1-31 with residual elution seen throughout the remaining 
fractions (Fig 4.2A, B and C).  Ubiquitination reactions were set up with p53, E1, E2, 
ATP and MDM2 to assay the proteins activity.  A titration of MDM2WT (Fig 4.3A, lanes 
1-5) or MDM2∆Lid (Fig 4.3A, lanes 6-10) in ubiquitination reactions demonstrated that 
MDM2∆lid has a lower specific activity, although it can still catalyze ubiquitination.  
Surprisingly, the phospho-mimetic mutation did not inhibit the ubiquitination function of 
MDM2 as expected; rather the Asp17 mutation increased the specific activity of MDM2 
as an E3-ubiquitin ligase (Fig 4.3B, lanes 5-7 vs 2-4).  
The lowered specific activity of MDM2∆Lid suggests the pseudo-substrate motif 
normally has an intrinsic positive regulatory effect on MDM2 function. Regulatory 
domains often alter the thermostability of an enzyme or protein (Dyson and Wright, 
2002) so we evaluated whether the pseudo-substrate motif deletion alters the 
thermostability of MDM2.  Ubiquitination reactions were set up as before but the 
MDM2 was pre-incubated at certain temperatures for 5 minutes before addition to the 
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reaction.  MDM2WT was completely unaffected by pre-incubation, even at 50oC (Fig 
4.3C, lanes 2-6 vs 1). The pre-incubation of MDM2∆Lid at any temperature completely 
inactivated the E3 ubiquitin ligase function of the protein as seen by the reduction in 
ubiquitinated p53 bands (Fig 4.3C, lanes 8-12 vs 7). By contrast, MDM2S17D behaved 
more like MDM2WT and did not show signs of thermosensitivity (Fig 4.3C lanes 13-18 
vs lanes 7-12). These data indicate that the phospho-mimetic substitution at Ser17 has an 
opposite and stimulatory effect on MDM2 stability compared to the pseudo-substrate 
motif-deletion mutant of MDM2.   
In order to test whether the loss of the lid influenced the in vivo activity/stability 
of MDM2 we transfected MDM2∆lid in to H1299 cells.  MDM2∆lid was less stable in 
cells as seen by decreased expression compared to MDM2WT and MDM2S17D in H1299 
cells and this is correlated with its decreased ability to act as an E3 ligase (Fig 4.3D).    
 These data suggest that the pseudo-substrate motif contributes positively to 
maintaining the thermostability of MDM2 protein. 
 
4.2.2 Higher specific activity of MDM2S17D towards p53 can be attributed to 
increased binding to p53 
 
Next, we analyzed whether the enhanced specific activity of MDM2S17D could be 
attributed to enhanced binding affinity for p53 protein. A titration of MDM2S17D, 
MDM2WT, or MDM2∆Lid provided a correlation between specific activity of an E3-
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ubiquitin ligase and enhanced affinity for p53 (Fig 4.4A).  Although MDM2∆Lid was 
essentially unable to form a stable contact with p53 as a result of pseudo-substrate motif-
deletion, MDM2S17D exhibited a striking increase in its binding affinity for p53 
compared to MDM2WT (Fig 4.4A).  The pre-incubation of MDM2S17D, MDM2WT, or 
MDM2∆Lid at distinct temperatures had no effect on MDM2WT protein affinity or 
MDM2S17D affinity for p53 (Fig 4.4B). This elevated affinity of MDM2 for p53 as a 
result of the Asp17 mutation contrasts with the expected ability of this substitution to de-
stabilize the MDM2:p53 complex (McCoy et al., 2003).  
 
4.2.3  Effect of phospho-mimetic mutation is only seen in low expression vectors 
 
Sets of cellular studies were carried out to determine whether the MDM2S17D protein 
exhibited increased specific activity in cells. Using MDM2 overproduced in pcDNA3.1-
based expression vectors, surprisingly we did not observe any difference in the specific 
activity of MDM2S17D compared to MDM2WT.   The promoters within vector constructs 
that drive the overproduction of genes in tissue culture cells are designed to maximally 
produce a target protein.  It is possible that such excessive over production of protein 
may not represent physiological expression levels and may swamp the normal regulatory 
machinery and this intern could mask any subtle effects caused by a phospho-mimetic 
substitute. (Clegg et al., 2008). As a result, expression vectors that produce lower and 
possibly more physiological levels of MDM2 protein (Fig 4.5A, lanes 1-3) than standard 
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expression vectors (Figure 4.5A, lanes 4-6) were used. Dual-luciferase assays to analyse 
MDM2 function revealed the difference between these two constructs with high 
expression MDM2 transrepressing p53 much better than pDEST3.2 MDM2 which 
produced only slight transrepression and even sometimes stimulation (Fig 4.5B). Under 
these conditions of more physiological levels of intracellular MDM2 protein, a striking 
effect of the S17D substitution on MDM2 function as a p53 inhibitor was observed 
compared to pcDNA 3.1 MDM2WT and pDEST 3.2 MDM2∆lid (Fig 4.6A).      In contrast 
the striking inhibitory effect of S17D on p53 expression was essentially absent when the 
S17D mutant was expressed in H1299 cells using the high expression vector pcDNA 3.1 
(Fig 4.6B). This demonstrates the importance of using vectors which give more 
physiological protein levels when studying complex pathways.   Further titrations of the 
pDEST 3.2 MDM2S17D construct revealed its striking ability to transrepress p53.  
Increasing titrations of pDEST 3.2 MDM2S17D from 15ng to 550ng resulted in 
transrepression of p53, with 15ng transrespressing p53 by around 50% (Fig 4.6C-left 
side of panel).  To try and overcome this transrepression p53 was titrated in with fixed 
MDM2S17D (Fig 4.6C-middle of panel).  This resulted in only partial rescue of 
transrepression unlike normal recovery seen with p53 only (Fig 4.6C-right side of 
panel). 
In order to confirm it was a phospho-mimic specific mutation that was having 
this effect on MDM2’s activity additional mutations were introduced at this site. An 
alanine mutation was introduced as a non polar amino acid, an asparagine was 
introduced which has neutral charge and glutamic acid was introduced as another 
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phospho-mimic amino acid.  MDM2S17A, MDM2S17N and MDM2S17E all lacked this 
striking inhibitory effect seen with MDM2S17D. (Fig 4.7A)  These mutations were only 
introduced to the pDEST 3.2 MDM2 as this was the construct which gave an over active 
MDM2.  It was surprising that the other phospho-mimic S17E did not show an increase 
in activity in a manner similar to S17D but this could be due to its longer side chain 
which is slightly bigger than aspartic acid and perhaps does not mimic phosphate as 
well.   Complimenting figure 4.3D, pcDNA3.1 MDM2∆Lid loses its transrepression 
ability which can be attributed to its thermo-sensitivity and lower expression levels (Fig 
4.7B).  To confirm that this striking effect seen was specifically due to mutation of S17D 
and not another spurious mutation missed by sequencing of the vector, the Asp17 
mutation was reversed to a Ser.  Reversal of this mutation returned MDM2s activity 
back to that of wild-type. (Fig 4.7C).  
Mutation of Ser17 of MDM2 activates MDM2 towards p53 but only when 
expressed a low levels in the pDEST 3.2 expression vector and the activating mutation 
can be reversed by restoring the Ser17.  We have shown that this activating effect is 
absent in the pcDNA 3.1 vector.  This phospho-mimetic mutation causes an increase in 
p53 binding as shown by ELISA in vitro and an increase in p53 transrepression as seen 
in vivo.          
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4.2.4 The MDM2 lid may form the switch between MDM2 promoting p53 
synthesis to degrading p53 
 
We next wanted to see the effects that MDM2WT, MDM2S17D and MDM2∆lid expressed 
in pDEST 3.2 had on p53 protein levels and down stream targets.  To do this we used 
mouse embryonic fibroblasts which lacked both MDM2 and p53, this made it easier to 
see transfected MDM2 with the low expression vector.     
Under these lower levels of MDM2WT production (pDEST 3.2), the MDM2WT 
protein enhanced the steady state synthesis of p53 and p21 protein (Fig 4.8A, lanes 3-6 
vs lane 2). Conversely, the inhibitory effect of MDM2S17D on p53 activity is attributed to 
the enhanced instability of p53 protein after transfection into cells (Fig 4.8A, lanes 11-14 
vs 3-6).  p21 protein is similarly de-stabilized upon co-transfection of p53 with 
MDM2S17D (Fig 4.8A, lanes 7-10 vs 3-6). MDM2∆lid lost some of the enhanced steady 
state synthesis of p53 and p21 seen with MDM2WT.  This stimulatory effect of MDM2WT 
on p53 protein synthesis has been reported previously (Fahraeus et al., 1999) through 
binding of MDM2 and p53 RNA (Candeias et al., 2008) and can also be attributed to the 
chaperone functions of MDM2 (Wawrzynow et al., 2007).  
As MDM4 is thought to work closely with MDM2 in regulating p53s functions 
we next evaluated whether pcDNA3.1 MDM2S17D exhibited enhanced binding to MDM4 
and whether it effected the synthesis of the p53.  The co-transfection of MDM2 or 
MDM2S17D and MDM4, followed by immuno-precipitation of the two proteins indicated 
that MDM4 was able to form a stable complex with either MDM2WT or MDM2S17D (Fig 
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4.8B). In contrast, p53 was attenuated in the formation of stable complex with MDM2 
(Figure 4.8C) presumably due to de-stabilization of the p53 protein.  Together, these 
data indicate that MDM2S17D protein can selectively de-stabilize p53, without altering 
steady-state levels of MDM4 protein.  
 
4.2.5 MDM2S17D can transrepress and inhibit p53F19A 
 
One attribute of the dual site model of MDM2 function is that when the N-terminal 
hydrophobic pocket is “occupied” by ligand, MDM2 is able to inhibit p53F19A, a p53 
mutant normally refractory to inhibition by MDM2 due to mutation of the p53 BOX-I 
docking site required for MDM2 binding. (Wallace et al., 2006) (Fig 4.9C).  In order to 
examine if MDM2S17D could transrepress p53F19A a dual luciferase assay was performed.  
Titration of pDEST 3.2 MDM2S17D with p53WT, and pDEST 3.2 MDM2S17D with 
p53F19A showed that pDEST 3.2 MDM2S17D is able to transrepress p53F19A (Fig 4.9A) 
compared to pDEST 3.2 MDM2WT (last column Fig 4.9A), which is further consistent 
with the in vitro data that this mutant form of MDM2 has a higher affinity for p53.  Like 
p53WT, pDEST 3.2 MDM2S17D can de-stabilize p53F19A protein levels in cells (Fig 4.9B).        
The data presented above showing that the phospho-mimetic S17D substitution 
of MDM2 inhibits p53, could be explained by two models which are consistent with the 
dual site docking model of MDM2 function (Wallace et al., 2006); Firstly the phospho-
mimicking pseudo-substrate motif is indeed bound in the hydrophobic binding pocket 
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(McCoy et al., 2003), but is acting like Nutlin in a positive auto-allosteric manner 
(Wallace et al., 2006) or secondly that the S17D mutation orientates the pseudo-
substrate motif in a position that stabilises the N-terminal domain of MDM2 in a 
conformation which is primed for allosteric activation. Further biochemical 
characterization of MDM2S17D was carried out in order to test these hypotheses. One 
method to examine whether the Asp17 mutation stabilizes the pseudo-substrate motif 
over the hydrophobic pocket of MDM2 would be to determine whether MDM2S17D is 
sensitive to Nutlin; it might be expected that the MDM2S17D is not able to interact with 
Nutlin (or the BOX-I domain of p53) if the Asp17 modified pseudo-substrate motif is 
stabilized over the hydrophobic pocket. However analysis of p53:MDM2 binding using 
ELISA showed that p53 binding to MDM2 was inhibited in the presence of Nutlin or 
BOX-Ia for both MDM2WT and MDM2S17D (Fig 4.10A and B).  Similarly, BOX-Va and 
BOX-Vb inhibit formation of a complex but to a lesser extent.  In a dual-luciferase assay 
MDM2 dependent transrepression of the p21 promoter can normally be rescued by 
Nutlin using the high expression vector pcDNA 3.1 MDM2 (Fig 4.10C).  Using pDEST 
3.2 MDM2S17D no rescue with Nutlin was seen suggesting that although Nutlin can 
inhibit the protein binding it is not having an effect on its cellular activity (Fig 4.10C).  
This data is not compatible with the model that the Asp17 substituted pseudo-substrate 
motif is stabilized over the hydrophobic pocket of MDM2.  Rather, the data favours a 
model where by the Asp17 substitution does change the conformation of MDM2, but 
does so by “opening” the hydrophobic pocket and sensitizing MDM2 to BOX-I like 
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ligands. One model that can be formulated to explain this would be that the pseudo-
substrate motif could contact an alternate site on MDM2 that facilitates this reaction.  
 
4.2.6 MDM2S17D binds with higher affinity to both the BOX-I and the BOX-V 
sites 
 
If the MDM2S17D protein does in fact have a more open conformation that stabilizes 
interactions with p53, it would be expected that MDM2S17D would have a higher affinity 
for the BOX-I peptides from the N-terminus of p53.  We tested this by ELISA, with the 
BOX-Ia or BOX-Ib peptides coated onto a 96 well plate.  MDM2WT, MDM2∆lid or 
MDM2S17D were incubated over the peptide before detection of complex formation with 
the MDM2 specific antibody 2A10.  In fact, as seen with the full-length p53, MDM2S17D 
binds more stably to the BOX-I peptides, when compared to MDM2WT (Fig 4.11A). The 
BOX-I peptide “a” is the naturally occurring peptide from p53, whilst BOX-I peptide 
“b” is the optimized higher affinity peptide named 12.1 identified using combinatorial 
peptide libraries (Bottger et al., 1996). Comparison of binding to BOX-Ia and BOX-Ib 
peptides by ELISA showed that this enhanced binding of MDM2S17D to the BOX-I 
peptide from p53 is not compatible with the model that the Asp17 pseudo-substrate motif 
is stabilized over the hydrophobic pocket, as if this were the case, then MDM2S17D 
should have a lower affinity for p53 (McCoy et al., 2003). MDM2∆lid was used as a 
control for BOX-I binding, MDM2∆Lid unable to form a stable complex with the BOX-I 
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peptide (Fig 4.11A), MDM2∆Lid was however able to form a stable complex with the 
ubiquitination signal in the BOX-V peptide highlighting the integrity of the acid domain 
is unaffected (Fig 4.11B). Furthermore, analysis of MDM2WT and MDM2S17D BOX-V 
binding showed that MDM2S17D is also more active in binding to the BOX-V peptide 
than MDM2WT (Fig 4.11B), which together explains in part why MDM2S17D binds better 
to p53. However, the higher affinity of MDM2S17D for Nutlin and BOX-I peptides 
cannot be explained by the current idea that the phospho-mimetic pseudo-substrate motif 
can be stabilized over the hydrophobic pocket and block the MDM2:p53 interaction.   
 
4.2.7 Analysis of MDM2WT and MDM2S17D using a ProtoArray® 
 
We wanted to see if MDM2S17D bound to a subset of proteins which was different from 
MDM2WT.  The ProtoArray® Human Protein Microarray is a high density protein 
microarray containing 8000 human proteins on its surface allowing for rapid and 
efficient detection of protein-protein interactions.  Either MDM2WT or MDM2S17D was 
incubated over the array before being washed.  Bound MDM2 was then detected using 
the MDM2 specific antibody 2A10 followed by Alexa Fluor® 647 labelled goat anti- 
mouse secondary antibody.  Spots were then scored using computer programmes and 
assigned a score from A to E with A being a strong binding protein and E showing no 
binding.  ProtoArray® revealed MDM2S17D has a higher affinity for a number of 
different proteins when compared to MDM2WT with potential to regulate many 
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pathways, specifically the ubiquitination pathway.  Figure 4.11 B highlights a few 
proteins identified in this manner.   
MDM2 can also ubiquitinate interferon regulatory factor 1 and 2 (IRF-1, IRF-2).  
They both contain potential BOX-I sites and a potential BOX-V sites (Data not shown).  
It is hypothesised that MDM2 degrades IRF-1 and IRF-2 using the same mechanism as 
for p53, the dual site mechanism.  IRF-1 encodes interferon regulatory factor 1, a 
member of the interferon regulatory transcription factor family.  IRF-1 promotes the 
expression of the toll-like receptor-3 protein (TLR-3) involved in innate immunity.  IRF-
2 negatively regulates IRF-1 and can inhibit this expression of TLR-3.  Using the IRF-1 
responsive promoter TLR-3, pDEST 3.2 MDM2S17D was shown to have similar 
transrepression effect as IRF-2 (Fig 4.13A).  This can also be reproduced using the IRF-
1 responsive TNF-related apoptosis-inducing ligand (TRAIL) derived promoter (Fig 
4.13B).  IRF-2 and pDEST 3.2 MDM2WT slightly reduces IRF-1 enhanced expression of 
TRAIL but pDEST 3.2 MDM2S17D has a marked increase in inhibition (Fig 4.13B).    
E2F1 is another protein with potential BOX-I and BOX-V motifs and transcriptional 
assays reveal it too can be repressed by pDEST 3.2 MDM2S17D (Fig 4.13C).  MDM2S17D 
also bound to E2F1 with a higher affinity than MDM2WT and MDM2∆lid in an ELISA 
assay (Fig 4.13D).    
 This data identifies other targets of MDM2 which are repressed by the 
MDM2S17D protein.  p53, IRF-1, IRF-2 and E2F1 are all transcription factors which 
function to regulate the transcription of various target genes.  MDM2S17D can negatively 
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regulate all of them to a much larger extent than MDM2WT.  This highlights the 




MDM2 is a multi-domain E3 RING-finger ubiquitin ligase and represents a model 
protein with which to define mechanisms of substrate ubiquitination. The recent dual-
site model for MDM2-mediated ubiquitination of p53 suggested an allosteric component 
to the E3 ubiquitin ligase function which invokes MDM2 docking to two distinct sites 
on p53; the BOX-I transactivation domain and a conformationally flexible motif in the 
BOX-V domain of p53. The allostery in the N-terminal domain that operates towards the 
acidic domain (Wallace et al., 2006) can be propagated presumably via the striking 
conformational flexibility of the N-terminal domain of MDM2 as defined by NMR 
(McCoy et al., 2003; Schon et al., 2004; Uhrinova et al., 2005). The unexpected feature 
of the dual site model was that the N-terminal hydrophobic pocket of MDM2 can act as 
an allosteric ligand binding site and that ligands like Nutlin can “activate” the E3 
ubiquitin ligase function of MDM2 (Wallace et al., 2006).  In order to test this model, 
the function of the poorly characterized MDM2 pseudo-substrate motif or ‘Lid’, in the 
MDM2:p53 complex interaction was evaluated, as this provides a potential 
physiological mechanism with which to regulate MDM2 conformation given the flexible 
motif proximity to the hydrophobic pocket of MDM2 (Fig 4.14). 
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These data also help to explain an apparent paradox in the MDM2:p53 regulatory 
loop. A large body of data clearly has indicated that MDM2 can function as a negative 
regulator of p53 (Toledo and Wahl, 2006). However, data has also indicated that MDM2 
can function positively as a growth suppressor (Brown et al., 1998; Zhou et al., 2005), as 
a factor that can stimulate p53 protein synthesis (Candeias et al., 2008; Yin et al., 2002), 
and as a protein that can cooperate with HSP90 to co-chaperone and stimulate p53 
function in an ATP-dependent manner (Wawrzynow et al., 2007). As suggested recently, 
more physiologically expressed levels of MDM2 protein might reveal regulation that is 
not seen by classic over-production methodologies (Clegg et al., 2008). In fact, by 
expressing very small amounts of MDM2WT, an MDM2-dependent increase in p53 
protein and p21 protein levels was observed. This can be explained by the recently 
identified model that MDM2 regulates p53 protein levels through the binding of the 
MDM2 RING to the BOX-I p53 RNA site (Candeias et al., 2008).  By contrast, the 
transfection of MDM2S17D de-stabilizes p53 protein levels completely and thus 
recapitulates the standard function of MDM2 as a p53 inhibitor. These data described in 
this chapter therefore would suggest that phosphorylation of the pseudo-substrate motif 
of MDM2 would act as a physiological switch that would convert MDM2 from a 
positively acting chaperone to a negatively regulating factor that degrades p53. Figure 
4.14 highlights the role of the lid within the Dual-site model.  Under normal non-
stressed conditions the lid is phosphorylated or in this case mutated to a phospho-mimic 
causing the lid to adopt a conformation compatible with enhance p53 binding and in tern 
enhance p53 ubiquitination , allowing p53 to be kept at low levels. (Fig 4.14A, B and C).   
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Accordingly, the kinases that activate MDM2 by this mechanism might function as 
oncogenic inhibitors of the p53 response by virtue of stimulating MDM2 function.  
Additional proteins that interact with MDM2 protein would also have the potential to 
become stabilized by such an activating phosphorylation of MDM2.  A few of these 
proteins were highlighted in the ProtoArray®.  More detailed analysis of this data and 
characterization of protein interactions are need. By contrast, de-phosphorylation of the 
pseudo-substrate motif would alter MDM2 dynamics and drive, amongst other events, 
the MDM2:HSP90-mediated folding of the native p53 tetramer and enhanced p53-
dependent transcription maintained by the chaperone machinery (Candeias et al., 2008; 
Galigniana et al., 2004; Giannakakou et al., 2000; Pratt et al., 2004; Walerych et al., 
2004; Wawrzynow et al., 2007).   
MDM2 regulation, in cis, by a pseudo-substrate motif highlights the growing 
realization that many signal transduction events are modulated by relatively small 
unstructured polypeptide motifs. Although there are many well-defined globular protein 
domains that form folded independent compact structures, these globular domains 
represent only a fraction of the cellular polypeptide sequence repertoire. The remaining 
peptide sequences are intrinsically disordered and comprise linear motifs with weaker 
binding kinetics (Neduva et al., 2005). Thus, signal transduction among many 
components interacting via linear peptide motifs with weaker binding kinetics can 
provide specific and sensitive regulation of cellular signal transduction. Perturbations in 
these linear interaction motifs, for example by covalent modifications like 
phosphorylation, has the potential to drive signaling changes that mediate changes in 
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protein-protein interactions central to signal transduction. The ability of MDM2 to be 
modulated by such a flexible peptide motif opens the door to identify the physiological 
signals that regulate this conformational switch in MDM2 as well as novel pathways that 
































AN EQUILIBRIUM MODEL FOR THE CONTROL OF MDM2 





Data from the previous chapter highlighted the activating effect that a phospho-mimetic 
mutation at S17 had on MDM2’s activity towards p53.  The current data do not fit with 
the present model in which the pseudo-substrate motif or ‘lid’, upon phosphorylation, 
binds into the hydrophobic pocket of MDM2 and blocks the interaction with p53 (Mcoy 
et al 2003).  A new mechanism was needed to explain this apparent contradiction in 
findings.  
A model to resolve this paradox invokes an equilibrium mechanism that involves 
the ability of the pseudo-substrate motif to exist in distinct conformations (Fig 5.1).  The 
pseudo-substrate motif can be positioned over the hydrophobic pocket which is not 
compatible with p53 peptide binding but can also adopt conformations directed away 
from the pocket which are compatible with p53 peptide binding (Fig 5.1).  NMR 
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analysis of the MDM2 N-terminal apo-structure revealed a narrower binding groove in 
the hydrophobic pocket of MDM2 as a result of the closer association of the two the lid 
and the hydrophobic pocket of MDM2.  (Uhrinova et al., 2005). As suggested previously 
(McCoy et al., 2003), MDM2 residues 18-24 have helical character that can partially 
occlude the shallow end of the p53 binding cleft, although this region is not highly 
structured and the remainder of the binding pocket is not occupied by the remainder of 
the pseudo-substrate motif (McCoy et al., 2003).  This conformation of the C-terminal 
region of the pseudo-substrate motif and p53 binding to the N-terminal domain of 
MDM2 are mutually exclusive (Fig 5.2A); p53 peptide binding must be preceded by the 
displacement of residues 19-25 of the lid from one end of the binding groove. The 
observation in this study that MDM2S17D induces a conformation primed for p53 peptide 
binding raises the possibility that this binding is achieved by inducing a conformational 
change within the pseudo-substrate motif which displaces it from the binding groove. In 
this model, the Asp17-pseudo-substrate motif would bind to a region of the N-terminal 
domain of MDM2 which is distinct from the binding groove, displacing the region of the 
pseudo-substrate motif occluding the end binding pocket, and facilitating p53 binding.  
Inspection of the NMR apo-MDM2 structure reveals that the conformationally 
heterogeneous pseudo-substrate motif may be in close proximity to a basic pair of amino 
acids (Arg97Lys98) which could form a complex with acidic residues (Fig 5.2B). Thus, 
the Asp17-pseudo-substrate motif might exist in equilibrium between its positioning over 
the hydrophobic pocket of MDM2 (Fig 5.2A) and with a second contact site on MDM2 
(Fig 5.2B). If the “phospho-mimetic” pseudo-substrate motif was stabilized by the 
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interaction with this arginine/lysine pair then this would suggest that the pseudo-
substrate motif can exist in equilibrium between two relatively stable states. 
In regards to this equilibrium model, it is interesting to note that the Arg97Lys98 
residues are not present in MDM4 and are replaced by serine and proline residues. (Fig 
5.3 and 5.4)(Baker et al., 2001; Gouet et al., 1999).  This is interesting as the 
surrounding region of MDM4 is highly conserved with MDM2.  This might give clues 




5.2.1 Mutating the basic region on MDM2 to MDM4 equivalent abolishes the 




To test the hypothesis that mutating the basic region on MDM2 to the MDM4 equivalent 
abolishes the activating effect of MDM2S17D we mutated the basic region of MDM2 at 
positions 97 and 98 to the equivalent residues of MDM4 and examined the effect in 
protein binding to p53 and in transcriptional assays.  This MDM2 mutant therefore 
contains the Arg97Lys98 mutated to Ser97Pro98.   MDM4 has been shown to have a 
conserved structure with MDM2 and can bind to p53 peptides in the same manner as 
MDM2 and with comparable affinities (Popowicz et al., 2007). Analysis of 
MDM2R97S:K98P binding to p53 by ELISA showed that in spite of the basic substitutions 
 169 
at positions 97 and 98, the mutant MDM4 form of MDM2 was still able to bind to p53 
and binding was the same as MDM2WT.(Fig 5.5A). By contrast, the enhanced binding of 
MDM2S17D to p53 is completely eliminated by mutation of residues 97 and 98 to MDM4 
and the MDM2S17D:R98S:K98P triple mutant was unable to bind p53 at any concentration 
tested (Fig 5.5B). We next went on to examine the impact that mutation of these residues 
had on MDM2s function in vivo using transrepression assays.  In H1299 cells the 
presence of pDEST 3.2 MDM2WT, p53 dependent transrepression is not effected (Fig 
5.5C-Red).  However as shown in chapter 4 pDEST 3.2 MDM2S17D does repress 
transcription (Fig 5.5C-Black).  Surprisingly the introduction of mutations at residues 97 
and 98 had no effect on p53 dependent transcription, however mutating these residues in 
the presence of S17D abolishes MDM2S17Ds ability to transrepress p53 dependent 
transcription and p53 transcription of the luciferase reporter in the presence of pDEST 
3.2 MDM2S17D:R97S:K98P  was comparable to pDEST 3.2 MDM2R97S:K98P (Fig 5.5C). 
These data indicate that the integrity of Arg97Lys98 residues of MDM2 are important in 
maintaining the activating effect of the Asp17 mutation and favours the equilibrium 
model of MDM2 pseudo-substrate motif function.  In spite of the difference in model 
presented, these data are consistent with the observations of McCoy and colleagues 
(McCoy et al., 2003) that the pseudo-substrate motif of the Asp17 MDM2 mutant has a 
higher affinity for MDM2, yet this increase in affinity is not due to increased binding 
within the hydrophobic pocket. 
A final prediction of this equilibrium model would be that the 
MDM2S17D:R97S:K98P triple mutant would be unable to form a stable interaction between 
 170 
the pseudo-substrate motif and the Arg97Lys98 region. This would favour the 
stabilization of the Asp17- pseudo-substrate motif over the hydrophobic pocket, perhaps 
by interacting with His73 or Lys94 residues as suggested (McCoy et al., 2003),  and this 
in turn would render the MDM2S17D:R98S:K98P triple mutant unable to bind to BOX-I like 
ligands (Fig 5.6A). To test this we examined the ability of these mutants to interact with 
the BOX-I and BOX-V peptides of p53 in an ELISA.  Comparison of MDM2WT and 
MDM2R97S:K98P showed that they were still able to bind to the BOX-I peptide (Fig 5.7A).  
Binding was however reduced by 50% maybe indicating the binding differences 
between the MDM2 and MDM4 hydrophobic pockets.  In contrast the 
MDM2S17D:R97S:K98P mutant showed that introducing mutations at residues 97 and 98 
completely abolished MDM2S17Ds ability to bind to the BOX-I peptide (Fig 5.7B)   
indicating that the Ser97Pro98 mutation overcomes the activating effect of the Asp17-
pseudo-substrate motif mutation. In order to show that the loss in binding of the 
MDM2S17D:R97S:K98P mutant was not due to global misfolding of the protein we examined 
binding to the BOX-V peptide.  If we could show that the integrity of the acid domain 
binding is still working then the loss of binding to the N-terminus is solely due to the 
mutations.  The MDM2S17D:R97S:K98P triple mutant maintains the ability to bind to the 
BOX-V peptide as well as MDM2S17D and MDM2WT (Fig 5.7C and D).  
The inability of the MDM2S17D:R98S:K98P triple mutant to form a stable complex 
with p53 in a manner similar to MDM2WT (Fig 5.5B) can be explained by the phospho-
mimetic pseudo-substrate motif contacting an alternate site and hindering access to the 
hydrophobic binding pocket (Fig 5.6A). Residues His73, Lys94 (as suggested (McCoy et 
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al., 2003)) or His96 surround the hydrophobic binding pocket could interact with Asp17. 
These data indicate that the integrity of Arg97Lys98 region is important to maintain the 
activating effect of the Asp17 mutation within the lid domain and favours the model that 
the MDM2 pseudo-substrate motif function accommodates a potentially activating effect 
in the event of lid phosphorylation.   
 
5.2.2 Activated MDM2S17D de-stabilizes mutant p53 protein in cells 
 
A recent physiological pathway has been identified, using genetic studies, whereby 
mutant forms of the p53 protein was unexpectedly ubiquitinated in murine transgenes in 
an MDM2-dependent pathway (Terzian et al., 2008). Ubiquitination of mutant p53 was 
attributed to the second MDM2 binding site in p53 in the BOX-V domain which is 
known to sensitize mutant p53 to ubiquitination in cells (Shimizu et al., 2002; Shimizu 
et al., 2006). These mutants are p53R175H and p53F270A which are hyper-ubiquitinated in 
cells. 
We thus evaluated the ability of the mutant MDM2S17D protein to degrade or de-
stabilize the mutant p53 protein under conditions where MDM2WT was not able to 
degrade the mutant p53. When pDEST 3.2 MDM2S17D was transiently transfected into 
cells co-transfected with mutant p53 isoforms containing the R175H or F270A alleles, 
the MDM2S17D was able to destabilize and deplete ubiquitinated-mutant p53 in H1299 
cells (Fig 5.8A lanes 3 and 6 vs 2 and 5 and quantified in C) as seen by the depletion of 
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p53. MDM2S17D was also able to deplete the mutant proteins in MEFs (Fig 5.7B lanes 3 
and 6 vs 2 and 5 and quantified in C). These data indicate that MDM2S17D protein can 
have dominant effects on either the more “unstable” wt-p53 or on the more “stable” 
mutant p53 with implications for how changes in phosphorylation of the MDM2 lid can 
function as dominant regulator of the p53 response.  
The alternate splice isoform of p53, p47 was also attenuated in the formation of a 
stable complex with MDM2 presumably due to de-stabilization of the p47 protein (Fig 
5.9A, B and quantified in C).  p47 lacks the conventional BOX-I binding site so this de-
stabilization due to MDM2S17D must act either through reduced protein expression due to 
the inability of MDM2S17D to bind to p53 mRNA (Candeias et al., 2008) or through the 
interaction with the acid domain. 
MDM2S17D is able to degrade both mutant p53 and p47, suggesting that the 
phosphorylation of Ser17 allows MDM2 to regulate p53 forms which are normally 
refractory to MDM2 control. 
 
5.2.3 Mutations in the β-sheet are dominant and restore p53 protein induction by 
MDM2
S17D
 acid domain mutants 
 
Studies have shown that the MDM2S17D protein has enhanced interactions with the 
BOX-V domain of p53  presumably via the acidic domain (Yu et al., 2006b). In order to 
determine whether the activating effects of the Asp17 mutation could be inhibited we 
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introduced mutations in the acid domain that have the potential to alter the flexibility of 
this region.  The MDM2 acid domain contains a putative β-strand which is thought to be 
an interface for protein-protein interactions with many proteins (Bothner et al 2001).  
Using a secondary structure prediction programme, mutations were designed to either 
stabilize or de-stabilized this β-strand, and mutations were introduced at codons 237 and 
240 which were predicted to stabilize or de-stabilize the β-strand respectively (Fig 5.10).  
Indeed, mutating codon 237 from a serine to a phenylalanine or phenylalanine 240 to a 
lysine resulted in a mutant form MDM2S17D protein which had lost the ability to inhibit 
p53 protein shown by loss of transrepression in pDEST 3.2 (Fig 5.11A).  These codon 
changes also switched the pDEST 3.2 MDM2S17D protein to a more wild-type like 
MDM2 protein resulting in enhanced steady-state levels of p53 and p21 proteins.  This 
was seen by MDM2S17D dependent decrease in p53 and p21 proteins, whereas the β-
strand mutants stimulate p53 and p21 as seen in chapter 4 with pDEST 3.2 MDM2WT 
(Fig 5.11B).  These two mutants also lost the ability to ubiquitinate p53 when co-
transfected into H1299 cells in the pcDNA 3.1 vector (Fig 5.11C). This was seen by a 
decrease in high molecular weight forms of p53 in comparison to MDM2WT.  The 
activating mutation at codon 237 resulted in a reduction in ubiquitination seen in 
MDM2WT and in MDM2S17D backgrounds where as the destabilizing mutation at 240 
resulted in almost complete loss of ubiquitination.  Slightly more ubiquitination was 
seen in the activating mutation in MDM2WT compared to MDM2S17D which may reflect 
some conformational changes within MDM2 having some effect of the N-terminal 
binding pocket.  These data indicate that the integrity of the acidic domain is required 
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for optimal activating effect of the MDM2S17D protein on p53 degradation. Further, as 
the RING domain is central to the stimulatory effect of MDM2 on p53 protein levels 
(Candeias et al., 2008), these data are consistent with distinct domains of MDM2 being 




A novel model can be developed that incorporates the various biochemical and 
biophysical studies of the flexible N-terminal domain of MDM2 and which supports an 
equilibrium model for pseudo-substrate motif function. As originally suggested (McCoy 
et al., 2003) and later confirmed in the NMR structure of apo-MDM2 (Showalter et al., 
2008; Uhrinova et al., 2005), the N-terminal segment of MDM2 can partially occlude 
the shallow end of the p53-binding cleft; however, this motif is not well structured and 
the remainder of the binding pocket remains empty, at least in the non-phosphorylated 
state. In this conformation, Ile19 occupies much of the space taken up by Pro27 of the p53 
peptide chain (Kussie et al., 1996) and as such excludes the mutual occupancy of the 
pseudo-substrate motif and p53. Interestingly, Ile19 is the only residue in the N-terminal 
region that exhibits any significant interaction with the rest of apo-MDM2 (Uhrinova et 
al., 2005), forming hydrophobic contacts with His96, Arg97 and Tyr100 in the N-terminal 
part of helix 2. In some NMR conformers, Ile19 is displaced from the site occupied by 
Pro27, forming a more intimate association with the N-terminal region of helix 2. 
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Based on this we have proposed that the pseudo-substrate motif exists in dynamic 
equilibrium between states that are incompatible with or compatible with p53 peptide 
binding; p53 can only bind when the pseudo-substrate motif has dissociated from the 
hydrophobic binding site. In favor of this equilibrium, both NMR studies indicated 
several residues within the pseudo-substrate domain and the region surrounding helix 
2 that behaved as though in slow conformational exchange (McCoy et al., 2003) 
(Uhrinova et al., 2005). Furthermore, it is interesting to note that a shorter p53 peptide, 
lacking residues 27-29 which share an overlapping binding site with the pseudo-
substrate motif, bind to MDM2 with a ten fold higher affinity (Schon et al., 2004). 
Thus, in order for p53 to bind to MDM2, the following events need to occur 
possibly in a concerted fashion.  Firstly residues 19-25 forming the pseudo-substrate 
motif must dissociate from one end of the hydrophobic pocket groove and be replaced 
by residues 27-29 of the incoming p53.  Next the two MDM2 sub-domains, the lid and 
the hydrophobic pocket, swing apart from one another by 3-4 Å and during the process 
of p53 binding, strand β3’ is formed, completing the terminal (β1, β2, β3’) sheet that 
caps one end of the groove and helps to hold the two sub-domains in their new more 
rigid conformation. However, deletion of the flexible lid de-stabilizes the N-terminal 
domain of p53, so this motif must have a positive role to play in the MDM2:p53 
interaction.  In addition to these ordered and sequential changes in MDM2-substrate 
binding, evidence has suggested an activating model for the function of the flexible 
pseudo-substrate motif upon phosphorylation.  This is thought to enhance the 
displacement of the pseudo-substrate domain by altering its equilibrium between open 
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and closed states, thus opening the groove to stabilize p53-peptide binding to MDM2. 
This conformational change upon hydrophobic pocket occupation by its ligand then 
appears to be propagated to the central acidic domain of MDM2 resulting in enhanced 
MDM2 interactions with p53.  Figure 5.12 summarizes the above events, firstly upon 
phosphorylation (or phospho-mimetic mutation) the lid is directed away from the 
hydrophobic pocket allowing it to come into contact with a basic region (Fig 5.12A and 
B). Displacement of the lid then permits increased binding to the hydrophobic pocket 
and in turn, increases signaling from the acid domain for ubiquitination of the p53 
protein (Fig 5.12C) 
We have proposed a model here in which MDM2 can adopt a conformation 
which as well as degrading wild type p53 can also degrade mutant forms of p53.  It may 
be the case that this form of MDM2 can even bind phosphorylated forms of p53 which 
are normally unable to bind to MDM2.  This could provide a mechanism in which 
MDM2 could quickly switch off the p53 pathway once cellular stress has passed 
allowing the cell to re-enter the cell cycle.  It might be of benefit to target this basic 


















GENERATION AND CHARACTERIZATION OF PHOSPHO-
MDM2
Ser17





Until relatively recently, the only way to study protein phosphorylation was through the 
use of radiolabelled ATP assays, both by in vivo labelling which looks at global 
phosphorylation states and in vitro kinase assays where a purified kinase phosphorylates 
a purified target protein.  More complicated methods of studying protein 
phosphorylation include phospho-peptide mapping where a protein is purified from cell 
lysate, then digested with trypsin and the fragments are analysed by isoelectric focusing 
(using radiolabelled ATP) or by mass spectrometry.  Methods to study protein 
phosphorylation have come along way since its discovery nearly 55 years ago (Burnett 
and Kennedy, 1954).  Phosphorylation is a reversible process which is achieved by over 
2000 kinases and reversed by considerably less phosphatases.  Phosphorylation 
generally leads to one of two things, either phosphorylation induces conformational 
changes within a protein changing its protein function, or phosphorylation can provide a 
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platform for further protein-protein interactions inducing multi-protein complexes 
(Mandell, 2003).   The importance of phosphorylation is also highlighted in gene 
regulation; many transcription factors are phosphorylated and this can have a direct 
effect on gene expression.  Phosphorylation has also been brought into the field of 
protein degradation through phosphorylation-dependent proteolysis (Willems et al., 
1999).  It was quoted that "the reversible phosphorylation of proteins regulates nearly 
every aspect of cell life" (Cohen, 2002).   Protein phosphorylation controls the decision 
of whether a cell should die, differentiate or divide and is evident in the cell cycle in 
which every step is controlled by the phosphorylation of the cyclin dependent protein 
kinases (Nurse, 2000; Zhou and Elledge, 2000).  Given this fact, it is not surprising that 
studying the phosphorylation states of proteins within a cell at a given point, be it after 
stress or during development, is of major importance in today’s science.  
 One major tool for studying protein phosphorylation is phospho-specific 
antibodies.  These antibodies will only bind to the target epitope within a protein when it 
is phosphorylated and can be used in many techniques including western analysis or by 
immunohistochemistry.  Phospho-specific antibodies were discovered in the 1980’s 
accidently when scientists were trying to generate antibodies towards neurofilament 
fibres (Sternberger and Sternberger, 1983).  The 1980s also witnessed the development 
of  monoclonal and polyclonal antibodies, specific for phosphotyrosine and 
phosphothreonine residues which can identify any protein phosphorylated at either 
amino-acid (Glenney et al., 1988; Heffetz et al., 1989; Ross et al., 1981).  
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 The 1990s saw the beginning of a more targeted approach to development of 
sequence-specific phospho antibodies.  The first site-specific phospho-monoclonal 
antibody was generated against phosphorylated forms of glial fibrillary acidic protein 
(GFAP) by injecting mice with a phosphorylated peptide and subsequently screening the 
serum from hybridomas with phospho and non-phospho peptides (Yano et al., 1991).  
This was followed by the generation of polyclonal antisera from rabbits.  This is a far 
less labor intensive process but does require an additional purification step to rid sera of 
non-phospho specific antibodies (Czernik et al., 1991).  As ‘easy’ as it is to make a 
phospho-specific antibody, it is also possible to make non-phospho specific antibodies.  
This procedure is essentially the same as for phospho-specific antibodies except the 
immunogen is a non-phospho peptide and sera is first passed through a column of 
phospho-peptide to remove all antibodies that can bind the phospho form, thus leaving 
only antibodies specific for non-phospho forms of peptide.  Today hundreds of different 
phospho-specific antibodies are commercially available to study all different kinds of 
pathways.   
The first step in generating a phospho-specific antibody is obtaining a peptide 
containing a specific sequence with a phosphorylated amino-acid.  The peptide is then 
conjugated to keyhole limpet hemocyanin (KLH), a carrier protein that helps stimulate 
the immune response upon injection.  Other carrier proteins can be used such as BSA, 
however KLH elicits a stronger immune response due to its large mass and complexity 
(Moravian biotech).  The conjugated phospho-peptide is then injected into BALB/C 
mice in complete Freund’s adjuvant.  Freund’s adjuvant also helps to stimulate the 
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immune response of the mice.  After 21 days the mice are re-injected with a further dose 
of KLH-coupled peptide in incomplete Freund’s adjuvant and tail bleeds are taken to test 
the serum via dot-blot against phospho-peptide.  The same procedure is repeated after 42 
days prior to two injections of KLH conjugated peptide on days 45 and 46.  On day 47 
the mice were prepared for fusion with myeloma cells.  A summarization of the process 
can be seen in figure 6.1.  
 The spleen cells are recovered from the mice and fused with SP2 myeloma cells.  
Splenocytes are mixed with myeloma cells and grown in media containing Azaserine-
Hypoxanthine which will kill unfused cells, therefore only splenocytes fused with SP2 
cells can grow.  Fifteen 96 well plates are then seeded and grown for 7 days before 
antibody screening begins.  Supernatant is screened for immunoglobulin (Ig) production 
and against BSA-coupled phospho-peptide.  Only those positive for both Ig and 
phospho-peptide are taken forward for large scale production.   
 In this study I describe the generation and characterization of phospho-specific 




6.2.1 Screening Phospho-MDM2Ser17 Antibodies 
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In order to study the phosphorylation state of MDM2 at Ser17, we developed a panel of 
monoclonal antibodies with the help from Moravian Biotechnology in the Czech 
Republic.  The mice were immunised with phospho-peptide coupled to KLH as 
described above before splenocytes were removed and fused with myeloma cells and 
seeded into 96 well plates.  Over a two week period, the fifteen 96 well plates were 
monitored daily and wells in which fusions showed good growth, the media was 
screened for the presence of Ig and phospho-peptide specificity.  Figure 6.2A indicates 
all the supernatants screened on day 3.  The supernatants were scored according to their 
response; a yellow mark indicates a positive Ig blot and a red mark indicates a positive 
phospho-peptide blot.  Those wells which showed good response to both were 
highlighted in green and taken forward for further screening.  From this initial screen, 
5B5 and 9G11 both tested positive for both and were taken forward for further analysis, 
the other positive fusions failed to grow when subcultured.  Figure 6.2B shows the 
screening on day 4 where 3A6 was identified, once again, other positive failed to grow 
when subcultured.   
 The positive hybridomas were grown up in larger plates where higher quantities 
of media could be obtained.  9G11, 5B5 and 3A6 supernatants were then screened 
against phospho-peptide in an ELISA format against phospho and non-phospho peptide 
(Fig 6.3A).  This revealed that all three clones have a higher affinity for phospho-peptide 
than non-phospho peptide and in particular 3A6 seemed to be the best at detecting 
phospho-peptide over non-phospho peptide.  Next the serums were screened against full 
length MDM2 proteins to test their cross-reactivity.  Aspartic acid is a good mimic of 
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phosphorylation, so it was hypothesised that the phospho-specific antibodies would 
preferentially bind to MDM2S17D.  All the antibodies showed good specificity towards 
MDM2S17D but not to MDM2WT.  MDM2∆lid was used as a control which should not be 
detected due to lack of the epitope (Fig 6.3B). To test 9G11 further it was screened 
against protein in an ELISA format and showed MDM2S17D specificity at 1:100 dilution 
(Fig 6.3C).  9G11 showed the most consistent response in all assays performed and was 
therefore purified and used to screen against lysates. 
 In order to further characterise 9G11, we attempted to phosphorylate purified 
recombinant MDM2 with endogenous kinases.  To do this we first fractionated MEFs 
(p53-/-mdm2-/-) via anion exchange chromatography.  The double knockout MEFs were 
chosen as they are MDM2 deficient and so endogenous MDM2 wouldn’t obscure our 
observations.  MDM2 was incubated with fractions obtained from chromatography and 
the reaction products were resolved and transferred and probed for the presence of 
phospho-Ser17 using 9G11.  A clear and distinct peak of phospho-Ser17 was detected in 
the presence of fractions 14-30 suggesting these contain kinases which target the Ser17 
residue.  Interestingly whole cell lysate weakens the signal suggesting phosphatase 
activity which de-phosphorylates Ser17 is also present (Fig 6.4)    
 A375 cell lysates were also analysed for the presence of endogenous phosho-
Ser17 MDM2 (Fig 6.5).  A375 cells were used because they have been shown to contain 
an intact MDM2-p53 regulatory network.  A titration of cell lysate was probed for total 
MDM2 or phospho-Ser17 MDM2.  Comparison of the profile for both antibodies shows 
the 9G11 antibody gave rise to a similar pattern of banding seen by the MDM2 specific 
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antibody 2A10, suggesting that the phospho-specific antibody was detecting MDM2 
(Fig 6.5).  Having previously shown that 9G11 does not bind to recombinant MDM2WT 
by western blotting, this result indicated the 9G11 antibody was detecting phospho-Ser17 
MDM2.  To further characterize the 9G11 antibody, physiological conditions in which 
the phosphorylation state of this site changes need to be identified. 
 Having developed a phospho-MDM2Ser17 antibody and confirming that 
recombinant protein can be phosphorylated at this site and that phospho MDM2 can be 
detected in A375 cell lysates, we went on to characterize the physiological conditions in 
which the phosphorylation state might change. 
 
6.2.2 Characterization of 9G11 In Vivo 
 
In order to define the physiological situations in which the MDM2 lid phosphorylation 
might operate, the response to DNA damage was evaluated.  p53 protein is classically 
stabilized by cellular X-irradiation and this is paralleled by increases in MDM2 protein 
through induction of MDM2 gene expression (Fig 6.6A).  This increase begins at 2 hrs 
and peaks at 5 hrs returning to basal levels by 24 hrs (Fig 6.6A and C). Surprisingly, 
analysis of phospho-Ser17 MDM2 in these lysates after X-irradiation showed basal levels 
of MDM2 lid phosphorylation begin to decrease under conditions where p53 and 
MDM2 protein levels begin to accumulate (Fig 6.6A).  Phospho-Ser17 levels decrease by 
20% after 2 hrs and decrease to a max of 60% at 5 hrs and didn’t fully recover up to 24 
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hrs (Fig 6.6A and B). MDM2 hypo-phosphorylation is reported to occur transiently after 
ionizing radiation, as observed by masking of the 2A10 epitope via ATM 
phosphorylation (Maya et al., 2001) and the loss of this epitope after IR is taken to 
represent phosphorylation at Ser395 of MDM2; indeed this increase in phosphorylation at 
the ATM site occurs under conditions where lid hypo-phosphorylation was observed, as 
seen by the parallel decrease in phospho-Ser17 and 2A10 (Fig 6.7A, quantified in 6.7C). 
At later times after X-irradiation when MDM2 protein is not phosphorylated at the ATM 
site and the 2A10 signal is recovered (Fig 6.7A), lid hypo-phosphorylation appeared to 
be maintained as seen by the decrease in signal vs 0 hr (Fig 6.7A, B and C). These data 
suggest that hypo-phosphorylation of the MDM2 lid occurs when p53 protein is 
activated, which is consistent with the data indicating that phospho-mimetic lid MDM2 
is activated as a p53 inhibitor in cells (Chapter 4, figure 4.6A). 
Another physiological condition in which p53 protein activity is known to be 
attenuated is under conditions of high cell density (Bar et al., 2004).  This stress was 
suggested to represent the microenvironment of tumor cells and could place stress on 
p53 pathway inactivation in human cancers in vivo. Accordingly, the ratio of MDM2 lid-
phosphorylation to p53 protein levels as cells are grown to high density were evaluated. 
When cell monolayers are subconfluent at 24 hrs after seeding, a basal ratio of phospho-
MDM2 lid to total MDM2 and p53 can be defined by high levels of MDM2 and p53 and 
low levels of phospho-Ser17 MDM2 (Fig 6.8A). When cells begin to form highly dense 
monolayers from 48 hrs after seeding, de-stabilization of p53 protein levels is observed 
under conditions where MDM2 lid phosphorylation is elevated (Fig 6.8A, and D vs B).  
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Normalisation of phospho-Ser17 MDM2, MDM2 and p53 to actin levels at various stages 
of confluency clearly demonstrates these differences (Fig 6.8B, C, D, and E).  Total 
MDM2 at 96 hrs was 40% of MDM2 at 24 hrs whilst phospho-Ser17 MDM2 was 
considerably higher than phospho-Ser17 at 24 hr (Fig 6.8A and B).  The ratio of 
phospho-Ser17 MDM2 vs MDM2 total also follows and increasing trend (Fig 6.8E).  De-
stabilization of p53 protein under conditions where elevated levels of lid 
phosphorylation are present is further consistent with our data indicating that phospho-
mimetic lid MDM2 is hyperactive as a p53 inhibitor in cells.   
Our findings show lid-phosphorylation is observed at times when p53 and 
MDM2 protein levels are low (Fig 6.8A, B, C and D) and is repressed when these 
proteins are high (Fig 6.6 and 6.7).  These results are consistent with previous 
transfection data where MDM2S17D de-stabilizes p53 protein in cells (Chapter 4, figure 
4.8A).  The next step to confirm the effect was due to S17D mutation and the support the 
phospho-antibody data was to generate stable inducible cell lines containing MDM2WT 
and MDM2S17D.  A375 cells were co-transfected with vectors expressing the Tet-
repressor and either MDM2WT or MDM2S17D and treated with tetracycline for 48 hours.  
The production of stable inducible cell lines similarly demonstrate that induction of 
MDM2WT protein expression following the treatment with tetracycline can increase 
basal expression of p53, p47 and p21 proteins (Fig 6.9A, B, D and E), whilst the 
induction of MDM2S17D protein results in de-stabilization in the steady-state levels of 
p53, p47, and p21 protein (Fig 6.9A, quantified in C, D and E).    
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We have managed to recapitulate the transfection results seen in chapter 4 and 5 
using a phospho-antibody and inducible cells, in that when phospho-MDM2Ser17 levels 
are high as with transfection of MDM2S17D, p53 and p21 levels are reduced.  However, 
when MDM2 is not phosphorylated at this site as with transfection of MDM2WT, p53 
and p21 levels increased.  
  
6.2.3 Developing a New Phospho-MDM2Ser17 Antibody to an optimized Lid 
Peptide 
 
Although the phospho-lid antibody 9G11 proved successful in detecting phospho-Ser17 
MDM2 in vitro an in vivo, it was not easy to work with.  Once purified we realised the 
9G11 antibody was an IgM class of antibody rather than IgG.  This class of antibody is 
less stable than IgG and also tends to be more ‘sticky’ and non-specific.  They also tend 
to be required to be used at higher concentrations to be effective; we found 1:50 dilution 
worked best.  Due to these problems a new optimized peptide was synthesized and used 
to immunize further mice.  Instead of using the old peptide which contained Ser17 quite 
close to the N-terminus, a new peptide was synthesized which containing Ser17 in a more 
central location in the hope that this will provide a better platform for generating a 
phospho-specific antibody (Fig10A).  The same immunization and screening protocol 
used to generate 9G11 were performed.  An ELISA using phospho and non-phospho 
peptide and MDM2WT and MDM2S17D protein identified a few hybridomas with high 
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specificity for the new phospho-peptide and purified MDM2S17D protein (Fig 6.10B and 
C respectively). This specificity was also confirmed by dot-blot analysis comparing 
phospho or non-phospho peptide coupled to BSA (Fig 6.10D and E).  Figure 6.10B and 
D clearly shows hybridomas 17,18 and 23-26 have high reactivity to the optimized 
phospho-peptide and very little cross-reactivity with the non-phospho peptide.  
Hybridoma supernatants 17 and 18 were analysed further by ELISA and titrations of 
sera revealed the high specificity to phospho peptide compared to non-phospho peptide 
at dilutions as low as 1:128 (Fig 6.10F and G).  Supernatant 17 and 18 originate from the 
same hybridoma and are currently being grown and purified for further characterization.  
 
6.3 Discussion  
 
The development of phospho-specific monoclonal antibodies in the 1980s has made 
research into phosphorylation states at specific amino acids in proteins possible.  
Phosphorylation states at distinct points in cellular pathways after stress or during 
development can now be studied with relative ease without the need for the use of 
radiolabelled ATP.  This chapter has focused on the production of a monoclonal 
antibodies towards phospho-Ser17 MDM2 specific antibody with help from Moravian 
Biotechnology, Brno, Czech Republic.  
9G11 was isolated from a panel of potential Ser17 MDM2 specific antibodies 
using various screening techniques such as peptide ELISA’s, protein ELISA’s, dot-blots, 
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and by western blotting against mutant recombinant protein.  Previous studies have also 
shown that phospho-specific antibodies can recognise the phospho-mimic amino acid 
Aspartic acid.  In this study they show that a phospho-specific antibody for HSP27 at 
Ser78 could also detect a band when the serine was replaced with an aspartic acid 
(Kubisch et al., 2004).  Phospho-Ser17 MDM2 antibody has led to the identification of 
conditions when MDM2Ser17 is phosphorylated and how this correlates with the state of 
p53.  From transfection studies using the mutated form of MDM2, MDM2S17D it was 
found that when MDM2S17D is present at high levels, p53 is destabilized and accordingly 
so is p21.  Agreeing with these findings phospho-Ser17 MDM2 is found at high levels in 
circumstances when p53 and MDM2 are destabilized and conversely, at low levels when 
p53 and MDM2 are stabilized.     
MDM2 can be phosphorylated at multiple sites by a myriad of protein kinases 
and these modifications have very different consequences (Meek and Knippschild, 
2003).  CK1 and CK2, along with other kinases, can phosphorylate MDM2 within the 
acidic domain leading to increased p53 degradation, presumably by increasing binding 
between the acid domain and the p53 ubiquitination signal (Gotz et al., 1999; Winter et 
al., 2004).  This phosphorylation could occur in concert with lid phosphorylation which 
also leads to p53 degradation.  The SQ motif within the lid forms a potential DNA-
PK/ATM phosphorylation site. It was previously shown that this site could potentially 
be phosphorylated by DNA-PK in vitro (Mayo et al., 1997), but has not since been 
shown.   
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During cellular growth, the PI3-K/Akt pathway regulates cell cycle and 
proliferation (Lawlor and Alessi, 2001).  Through a series of kinase cascades, Akt is 
phosphorylated and released from the membrane, allowing it to interact and 
phosphorylate substrates such as IKK, p21 and p27, leading to cell survival.  Akt can 
phosphorylate MDM2 at serines 166 and 186 which reside in close proximity to the 
nuclear localisation sequence (NLS) and stimulates entry into the nucleus (Mayo and 
Donner, 2001).  Phosphorylation at these residues within MDM2 leads to the increased 
ubiquitination of p53 and increased binding to p300 (Ogawara et al., 2002; Zhou et al., 
2001).  The activation of MDM2 by the PI3-K/Akt pathway leads, in turn, to increased 
turn over of p53 and thus reduced intracellular levels of MDM2 (Ogawara et al., 2002; 
Zhou et al., 2001).  Phosphorylation at serines 166 and 186 could also coincide with lid 
phosphorylation as during cell growth and contact inhibition, lid phosphorylation was 
found to increase as p53 and MDM2 protein levels fall.  Full activation of the Akt 
pathway requires amongst others, phosphorylation of Akt by DNA-PK which could also 
phosphorylate the lid in the same conditions in which it phosphorylates Akt (Boehme et 
al., 2008).  
In conclusion, the MDM2 lid, exists in dynamic equilibrium between an open 
and a closed state (Fig 6.12A), during cellular stress, such as contact inhibition, the lid 
becomes phosphorylated opening the hydrophobic pocket of MDM2 and allowing 
binding of p53 which is reversed by x-ray (Fig 6.12B).  This activates the dual-site 
model of MDM2 allowing MDM2 to degrade p53 (Fig 6.12C).  These findings highlight 
the fact that a post translational modification (PTM) occur in the lid domain of MDM2 
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in response to a variety of stresses.  The intra-cellular pathways and kinases which 
control this phosphorylation need to be elucidated.  This will enhance our understanding 


































CONCLUSIONS AND FUTURE PERSPECTIVES 
 
p53 is a tumor suppressor that plays a pivotal role in the regulation of the cell cycle.  It 
activates the cell cycle inhibitor p21, arresting cell growth and also activates genes 
involved in DNA repair and/or apoptosis.  p53 is negatively regulated by the E3 ligase 
MDM2 which targets it for proteasomal degradation by ubiquitination.  The mechanism 
of MDM2 catalysed ubiquitination was largely undefined before this study.  We have 
identified a dual-site model in which ubiquitination of p53 occurs through binding of 
MDM2 and p53 through more central regions.  This binding provides the signal which 
elicits the ubiquitination of p53 (Chapter 3).  Initially binding occurs through the p53 
transactivation domain to the MDM2 hydrophobic pocket and this induces 
conformational changes within MDM2 which allows the acid domain of MDM2 to bind 
to the more central BOX-V region of p53, which encompasses the ubiquitination signal 
(Fig 7.1A). 
 This study has also built on this dual-site model of MDM2 dependent 
ubiquitination of p53 and incorporated the lid domain of MDM2 in p53 ubiquitination, 
to which there was no previous function assigned.  This was accomplished using various 
biochemical, biophysical and cell biological techniques.  We have shown that a 
phospho-mimetic substitution within the lid at Ser17 enhances MDM2s binding to p53 
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compared to MDM2WT using in vitro protein binding assays and also that this mutation 
has an inhibitory effect on p53 protein levels in vivo (Chapter 4).  It is also shown that 
MDM2S17D can degrade mutant forms of p53 which are normally refractory to 
degradation by MDM2 (Chapter 5).  Previous studies have suggested that 
phosphorylation of the MDM2 lid allows it to adopt a conformation which occludes the 
hydrophobic pocket (McCoy et al., 2003).  Using previously published NMR data we 
have predicted that when phosphorylated, it can bind to a region outwith the 
hydrophobic pocket of MDM2, adopting a conformation which is compatible with p53 
binding.  In fact, we propose a model where the MDM2 lid is in dynamic equilibrium 
between an open and closed state, adopting conformations which both occlude the 
pocket and leave the pocket in a more open state (Fig 7.1B).  During this study, a paper 
was published which supported our equilibrium model, suggesting the lid was in 
equilibrium between an “open” and “closed” conformation (Showalter et al., 2008).   We 
built upon this and found a basic region in MDM2 (Arginine (R) 97 and Lysine 98 (K)) 
with the potential to form a docking site for the phosphorylated Ser17 within the lid.  
This basic region is absent from MDM4, which also does not contain the lid, perhaps 




Figure 7.1 The Dual-Site Mechanism for MDM2 Catalyzed Ubiquitination of p53.  (A)  The 
hydrophobic pocket of MDM2 binds to the BOX-I site in p53 triggering a conformational change within 
MDM2 inducing binding of the acid domain of MDM2 to the BOX-V region of p53.  This secondary 
binding triggers a signal which catalyzes the ubiquitination of p53.  (B)  The lid can function within the 
dual-site model by opening or closing MDM2s hydrophobic pocket.  Phosphorylation of the lid at Ser17 
induced p53 binding and subsequent ubiquitination. 
    
Having identified a possible function for the phosphorylation at MDM2 Ser17 in 
negatively regulating p53 levels and identifying a potential mechanism, we also went on 
to develop phospho-specific antibodies to the Ser17 epitope (Chapter 6).  These 
antibodies supported previous transfection data suggesting that in the presence of high 


















































phospho-MDM2Ser17 was high then p53 and p21 levels were low and visa versa (Chapter 
4).   
There is growing evidence in the MDM2:p53 field that MDM2 can regulate the 
translation of p53.  MDM2 has been shown to interact with many ribosomal proteins 
including L5, L11, L23 and S7, primarily through the acid domain of MDM2 (Ofir-
Rosenfeld et al., 2008).  The MDM2 acid domain is central in the ubiquitination of p53 
and thus the binding of these ribosomal proteins to the acid domain of MDM2 inhibits 
the degradation of p53 and stabilizes it.  This association of MDM2 with multiple 
ribosomal proteins has implicated MDM2 in the translation of proteins and is also 
highlighted by the fact that MDM2 can be found in complex with the polysomes 
(Candeias et al., 2008).  These interactions are shown to increase when ribosome 
biogenesis is disrupted, a process called ‘ribosomal biogenesis stress’(Ofir-Rosenfeld et 
al., 2008).   
Our studies have shown that when MDM2 is transfected in a low expression 
vector, or is induced in stable A375 cell lines then p53 levels increase.  This observation 
is not accepted in the wider community, with many peers suggesting this observation 
may be due to the activation of the p53 pathway by the transfection of DNA. However in 
our experiments I routinely control for the impact of transfection by using empty vector, 
and we found the transfection data is corroborated by inducible cell systems which also 
suggests these observations are not due to the effect of transient transfection causing 
cellular stress and instead specific expression levels of MDM2.  The scientific 
community find it difficult to accept that ‘MDM2-the negative regulator of p53’ can in 
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fact stimulate p53s synthesis.  MDM2 clearly has a role in degrading p53 via 
ubiquitination, but coupled to this is its ability to regulate the translation of the protein.  
This is highlighted by the effect of our MDM2S17D phospho-mimetic protein in 
switching the stimulation of p53 by MDM2WT to degradation of the p53 protein.   
A couple of recent papers have bought this regulation of p53 translation by 
MDM2 to the forefront again, although they both differ slightly.  One model proposes 
MDM2 mediates protein translation through binding to ribosomal proteins, specifically 
L26.  L26 can bind to the 5’ untranslated region (5’ UTR) of p53 mRNA and stimulate 
its translation upon exposure to DNA damage, contributing to the stress-induced 
increase in p53 protein levels (Takagi et al., 2005).  L26 is also a target for MDM2 
degradation via the proteasome and thus the degradation of L26 by MDM2 leads to a 
reduction in L26 mediated p53 mRNA translation.  MDM2 can either be inhibited from 
ubiquitinating p53 protein through the direct binding of L26 to the acid domain of 
MDM2 which results in p53 translation or it can degrade L26 via acting as an E3 ligase 
leading to the loss of L26 enhanced translation of p53 mRNA.  Phosphorylation of 
MDM2Ser17 could increase ubiquitination of L26, resulting in loss of L26 enhanced 
translation of p53.  One aspect of this model which does not fit with our data is that we 
observe stimulation of p53 protein levels following transfection of MDM2 and p53 
expression vectors.  The transfected p53 plasmid does not contain the 5’ UTR which is 
required for L26 to bind so its translation cannot be depend of L26.  This does not 
entirely rule out the possibility that L26 does play a role in p53 translation as we also see 
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stimulation of p53 protein levels in inducible cell systems with endogenous p53, but it 
suggests there must be another route in which MDM2 can stimulate p53 translation.   
Another paper highlighting MDM2s role in stimulating p53 synthesis suggests 
that it is the MDM2 protein that binds the p53 mRNA directly at the polysomes and 
enhances its translation (Candeias et al., 2008).  They show that MDM2 binds to p53 
mRNA through a RNA binding site within the RING of MDM2.  This RNA binding 
region within the MDM2 RING binds the p53 mRNA at the site which encodes the 
MDM2 binding domain, termed the MDM2 binding domain encoding sequence (MDM-
ES).  Using quantitative real time PCR, the authors show that mutating the RNA binding 
site or deleting the RING domain reduces p53 mRNA binding to the MDM2 protein 
(Candeias et al., 2008).  In support of this, we used the same assay to show that mutation 
of Ser17 to Asp17 prevents MDM2 binding to the p53 mRNA in a manner similar to 
removing the RING domain of MDM2 (Fig 7.2).  This suggests that perhaps 




Figure 7.2  MDM2
S17D
 is unable to bind p53 mRNA.  Immunoprecipitation was carried out as described 
in materials and methods followed by proteinase K treatment and RNA extraction.  qRT-PCR was 
performed using p53 and control primers (Data courtesy of Magda Maslon). 
 
Phosphorylation of MDM2Ser17 may therefore form the switch which could control 
MDM2s functions towards p53.  Under normal conditions, MDM2 is phosphorylated at 
Ser17 which results in a MDM2 form which does not bind p53 mRNA and favours the 
ubiquitination of p53.  Upon cellular stress MDM2Ser17 becomes dephosphorylated by an 
as yet unknown mechanism, activating MDM2s p53 mRNA binding ability and 
enhancing p53 translation.  Thus phosphorylation of the lid at Ser17, provides a switch 
between the p53 degradation and p53 promoting functions of MDM2. 
 To date, most drugs aimed at inhibiting the MDM2:p53 interaction have been 
modelled to fit within the hydrophobic pocket of MDM2.  We have shown that drugs 
that bind within the hydrophobic pocket do not inhibit the ubiquitination of p53, and can 
in fact stimulate p53 ubiquitination.  Due to this observation it may therefore be of 
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instead of the hydrophobic pocket as these would both stabilize p53 and inhibit p53 
ubiquitination.  As well as targeting the acid domain of MDM2 it might also be an 
advantage to inhibit the flexibility of the lid as this would freeze the MDM2 
conformation and prevent activation.  If drugs could inhibit binding of the lid to the 
basic region formed by Arg97 and Lys98 through Ser17, then it is possible that they 
would prevent MDM2 from adopting an activated conformation and would be unable to 
degrade p53, either through ubiquitination, or through decreased p53 mRNA binding. 
Further in vivo characterization of the phospho-MDM2Ser17 antibodies is required 
in order to enhance our understanding of signals involved in targeting the lid.  The 
identification of additional cellular stress’s which can alter the phosphorylation state of 
Ser17 and even the kinases or phosphatases responsible for phosphorylation or de-
phosphorylation at this site need to be elucidated.  Only then will we fully understand 
the signalling network which operates through this region and understand the complex 
signalling pathways which feed into and control MDM2/p53.  Only then will we be able 
to generate drugs which target the control signals when they are deregulated following 





Figure 7.3 The Dual Function of MDM2.  When MDM2Ser17 is unphosphorylated, MDM2 
functions to regulate p53 mRNA synthesis through mRNA binding and its E3-ligase activities are 
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